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 Abstract 
 
Previously thought to be inert, nitrite is now deemed to be an important endogenous source of 
nitric oxide (NO), particularly during hypoxia and ischaemia. Largely animal and some 
limited human studies propose a role for nitrite in ‘hypoxic vasodilatation’ and ischaemia-
reperfusion injury.  
 
One study explores the effect of systemic nitrite infusion on cardiac and peripheral 
haemodynamic parameters in healthy subjects, during normoxia and hypoxia. Despite a lack 
of observed effects in healthy subjects, a study performed in patients with heart failure during 
normoxia demonstrated favourable haemodynamic effects on cardiac output, albeit at high 
doses of nitrite. In patients undergoing coronary artery bypass surgery, low dose nitrite 
infusion afforded protection against ischaemia-reperfusion injury. Several mechanisms of 
nitrite reduction to NO have been described and remain to be fully elucidated. The role of one 
of these putative mechanisms, namely mitochondrial aldehyde dehydrogenase (ALDH2) was 
explored during normoxia and hypoxia. Ex vivo human vascular ring studies confirmed 
ALDH2 as an important nitrite reductase, in contrast to in vivo observations in the forearm 
vasculature, suggesting that numerous mechanisms are involved in vivo which are harder to 
isolate. Furthermore, this hypoxia vasodilatory role was not replicated in with GTN in the 
human forearm vasculature. 
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Chapter 1: General Introduction 
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1.1 Overview 
A significant breakthrough in Medicine was the finding that the gaseous free radical, nitric 
oxide (NO) is an important bioactive vasodilator and signaling molecule in the cardiovascular 
system. NO is integral to a vast array of functions in vivo which include smooth muscle 
relaxation and vasodilatation; modulation of cardiac contractility; protection against 
ischaemia-reperfusion injury; central nervous system neurotransmission; peripheral nervous 
system neurotransmission affecting gastrointestinal, respiratory and genitourinary function; 
platelet aggregation and host and defence mechanisms (1). In 1980, Furchgott and colleagues 
demonstrated that endothelial cells release an ‘endothelium-derived relaxing factor’ (EDRF) 
which contributes to vascular dilatation (2). Years later, Moncada and Ignarro independently 
reported that this EDRF was NO, a substance more commonly recognised as a toxic pollutant 
and lung irritant (3, 4).  Prior to these discoveries, Murad et al. had established that NO 
relaxes vascular smooth muscle through the activation of soluble guanylyl cyclase (sGC) 
raising the possibility of NO as an endogenous molecule (5). The significance of these 
discoveries was reflected in the award of a Nobel Prize for the key researchers concerned. 
Over the last three decades, a great deal of attention has focused on the mechanisms of NO 
release/production both in vitro and in vivo, and its role in numerous physiological and 
pathophysiological processes.  
 
1.2 Endogenous NO production 
The main mechanisms of in vivo NO production now appears to be well established. These 
are outlined below.  
 
3 
 
1.2.1 Enzymatic production of NO 
The majority of endogenous NO is generated using L-arginine as a substrate, resulting in 
formation of NO and L-citrulline (6). In the vascular endothelium this occurs in response to 
shear stress or a host of vasoactive substances present in the blood stream such as 
acetylcholine (Ach), bradykinin, substance P and adenosine (1), as depicted in figure 1.1. 
 
 
 
Figure 1.1: Simplified summary of NO production in vivo. 
 
 
In addition to the availability of L-arginine, several key components are required for this 
process to occur. Firstly this reaction is catalysed by a group of enzymes called NO synthases 
(NOS) which are found throughout the human body (4, 6).  Three well recognised isoforms 
of this enzyme exist, namely neuronal NOS (nNOS or NOS-1), inducible NOS (iNOS or 
NOS-2) and endothelial NOS (eNOS or NOS-3) (7). They are found in abundance in a 
variety of mammalian tissues and all three are expressed in the heart in myocytes and/or 
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endocardial and coronary artery endothelial cells (8, 9). nNOS and eNOS are constitutive 
enzymes that are activated by intracellular calcium/calmodulin. iNOS is a calcium-
independent, inducible enzyme that is regulated at the level of gene transcription, in response 
to pro-inflammatory cytokines and bacterial endotoxins and is thought to be responsible for 
the vasodilatation seen in septic shock. It is present in low levels normally but is capable of 
generating large quantities of NO when activated (10). A fourth NOS enzyme, mitochondrial 
NOS (mtNOS) has also been discovered, and is thought to be important in modulation of 
mitochondrial respiration (11, 12). However there is some controversy surrounding the 
presence of a separate mtNOS. Whether this is a distinct NOS enzyme or a variant of the 
other NOS enzymes, which has undergone modification within the mitochondria, remains 
uncertain (13, 14). 
 
Although the expression may vary in different tissues and conditions, all NOS enzymes 
ultimately lead to NO production through a series of redox reactions and contribute to the 
majority of in vivo NO generation (15). Endothelium-derived NO production via eNOS, is 
thought to increase basal human blood flow by 25-30%, but when stimulated this effect is 
much greater (16). Secondly, essential co-factors for NOS function (particularly eNOS and 
nNOS) include nicotinamide adenine dinculeotide phosphate (NADPH), tetrahydrobiopterin 
(BH4), flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN) and haem proteins 
(1, 17). A third integral component for adequate function of NOS enzymes is the availability 
of oxygen. The usual L-arginine-NOS pathway is attenuated as oxygen levels decrease with a 
consequent reduction in NO bioavailability (18). A reduction in any of these substrates/co-
factors results in reduced NOS activity and reduced NO generation, leading to endothelial 
dysfunction which has been described in many disease states, e.g. diabetes, atherosclerotic 
disease and most cardiovascular conditions (19). One important such process of NOS 
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dysfunction is NOS uncoupling, whereby NOS is unable to convert L-arginine to L-citrulline. 
In this process, an electron is removed from from NADPH and donated to molecular oxygen 
to generate superoxide (O2
−
) instead of NO. This O2
− 
production ultimately leads to oxidative 
stress which has well recognised, deleterious effects on cardiovascular health (20). Depletion 
of BH4 is thought to be the most essential mediator of NOS uncoupling (21).  
 
1.2.2 Non-enzymatic production of NO 
The requirement of oxygen for the production of NO via the L-arginine-NO pathway has 
raised the question of NO bioavailability when oxygen tension falls – is NO manufactured by 
any other mechanisms? NO is a highly reactive gas and any that does not diffuse into 
surrounding tissue immediately is converted to stable products e.g. nitrite, nitrates, 
nitrosothiols (22-24). In ischaemic/hypoxic conditions, release of NO from these stable 
molecules via a NOS-independent pathway may play an important role in NO bioavailability 
(23, 25-27). Recent evidence suggests that the nitrite anion is not an inert molecule as 
originally thought, and may be recycled to generate NO in hypoxic/ischaemic conditions 
(26). The basis of this thesis is the nitrite anion (NO2
-
) and an investigation into its role in 
biological processes. Nitrite will be discussed in more detail from section 1.5 onwards. 
 
1.3 Fate of NO within the vasculature 
1.3.1 cGMP dependent processes 
As depicted in figure 1.2, following production NO can undergo several processes to effect 
signalling and downstream changes to alter biological function. NO generated by endothelial 
cells through activation of eNOS, diffuses into the vascular smooth muscle where it activates 
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the haem-containing NO receptor, sGC (5). This in turn stimulates production of the second 
messenger cyclic guanosine monophosphate (cGMP) from intracellular guanosine-5'-
triphosphate (GTP). cGMP acts on downstream effectors e.g. protein kinases (PKG), 
initiating a cascade of phosphorylation reactions to facilitate cGMP-dependent relaxation of 
vascular smooth muscle and inhibition of platelet aggregation (28-30). Alternative 
intracellular downstream targets of cGMP include cGMP-gated cation channels and cyclic 
nucleotide phosphodiesterases (30). 
 
 
 
Figure 1.2: The fate of NO within the vasculature.   
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1.3.2 cGMP independent processes 
Within mitochondria, cytochrome c oxidase (CcOx) is a key component of the mitochondrial 
respiratory chain and hence oxidative phosphorylation and ATP generation. At normal 
physiological concentrations, NO competes with oxygen to reversibly bind and inactivate 
CcOx, thus reducing mitochondrial oxygen consumption (31). This process is thought to 
exert beneficial effects by increasing the bioavailability of oxygen and allowing deeper 
penetration of oxygen into tissues (32). Furthermore it is thought that this pathway may be 
important in regulation of hypoxic vasodilatation(33).  
 
NO is a highly reactive molecule and any that remains within the vascular lumen is rapidly 
converted to other, more stable metabolites. Its half life in the vasculature is in the range of 
2milliseconds to less than 2 seconds (34). The majority of NO diffuses into erthyrocytes and 
is scavenged heavily by oxyhaemoglobin (oxyHb) to form methaemoglobin (metHb) and 
nitrate through the following reaction:- 
 
NO + Hb(Fe
2+
)O2 → NO3
-
 + Hb(Fe
3+
) 
           (35)   
 
The small amount of NO that remains within the plasma reacts with thiol (SH) containing 
amino acids, peptides and proteins to form S-nitrosothiols, a process termed S-nitrosylation 
(36, 37). These S-nitrosothiols include S-nitroso-albumin, S-nitroso-haemoglobin, S-nitroso-
L-cysteine and S-nitroso-L-glutathione amongst others and they preserve NO bioactivity 
within blood/tissue (24, 38, 39). They are considered to be stable storage forms of NO, with 
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the ability to release NO in conditions of hypoxia/ischaemia when NOS enzyme activity is 
inhibited (40, 41).  
 
Experimental studies suggest that an alternative method of stabilizing NO stores with the 
vasculature is through the formation of nitrite (NO2
-
), via either auto-oxidation to nitrite or an 
oxidation reaction catalysed by caeruloplasmin (42). Historically, nitrite was considered to be 
an inert biological by-product of NO metabolism, but studies in recent years suggest it is a 
stable endocrine store of NO which is able to release NO in conditions where the classical L-
arginine-NOS pathway is inhibited, i.e. during hypoxia/ischaemia (26, 43-46).  
 
Both the ‘S-nitrosylation’ and ‘nitrite’ theories of NO formation and release, particularly in 
conditions of low oxygen concentration are the subject of intense debate and the evidence to 
date is unclear as to which predominates. These theories are discussed in section 1.7.1 on 
hypoxic vasodilatation.  
 
Unscavenged superoxide radicals (O2
-
) react with great affinity with NO to form the harmful 
peroxynitrite (ONOO
-
):- 
 
NO + O2
- → ONOO- 
         (47)  
 
Peroxynitrite is a harmful substance which oxidizes the NOS co-factor BH4, resulting in 
eNOS uncoupling and reduced NO synthesis, which in turn leads to further production of 
superoxide radicals (48). Generation of superoxide radicals and peroxynitrite has been 
implicated in a variety of pathological disorders, namely atherosclerosis, myocardial 
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infarction, myocarditis, heart failure, shock, diabetic complications and neurodegenerative 
and inflammatory disorders (49). 
 
1.4 Biological functions of NO within the cardiovascular system 
NO is a ubiquitous molecule involved in a variety of biological functions including regulation 
of vascular tone and smooth muscle cell proliferation, inhibition of platelet aggregation, anti-
inflammatory effects and signalling within neural networks (50). NO derived from the 
endothelium accounts for a vast proportion of the biological functions exhibited by NO and 
some of these pertaining to the cardiovascular system are described herein. 
 
1.4.1 Regulation of vascular tone 
NO is critical in the regulation of vascular relaxation and tone, and hence blood flow. Shear 
stress, produced by blood flowing past the endothelium is the predominant stimulus for 
release of NO from the endothelium, which in turn alters vascular tone to meet the body’s 
demands (50-52). Other stimuli include agonists such as acetylcholine or bradykinin which 
can also effect a change in vascular tone through release of NO from the endothelium (53). 
Endothelial NO diffuses into adjacent vascular smooth muscle cells and functions as a 
paracrine signalling molecule, where it activates sGC and through a cGMP-dependent 
mechanism results in the relaxation of vascular smooth muscle. As described in section 1.3.1, 
activation of cGMP results in activation of protein kinases. Protein kinase G (PKG) activates 
myosin light chain phosphatase, the enzyme that dephosphorylates myosin light chains, 
leading to smooth muscle relaxation. There are two main types of PKG – PKG I and PKG II. 
PKG I is primarily implicated in smooth muscle relaxation and platelet aggregation (54). 
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PKG I also causes a decrease in intracellular Ca
2+
 due to inhibition of Ca
2+
 entry into the cells 
(51). 
 
Several animal and human studies have demonstrated the importance of NO generation from 
eNOS in vascular relaxation and tone (52, 55, 56). Lack of NO bioavailability either due to 
attenuated production or accelerated breakdown, is considered a hallmark of endothelial 
dysfunction. Endothelial dysfunction is an independent predictor of cardiovascular mortality 
and morbidity and, is associated with a range of cardiovascular conditions including 
atherosclerosis, hypertension and coronary artery disease (57). 
 
NO is also important in the control of smooth cell proliferation, and studies have shown that 
endogenously produced NO limits proliferation in numerous cell types, not just vascular 
smooth muscle cells (58).  
 
1.4.2 Inhibition of platelet aggregation 
Platelets serve as another target of NO-mediated activity. Endothelial cells release NO which 
can diffuse into platelets to prevent platelet adhesion and aggregation (59, 60). Additionally, 
NO produced by eNOS can act in an autocrine manner to regulate platelet function and 
inhibit platelet aggregation (61-63). This process is effected through the activation of sGC 
and cGMP to release PKG. Several mechanisms of PKG have been identified as the route via 
which platelet aggregation is inhibited by NO, and these include recruitment of sarcoplasmic 
reticlulum, ATPase – dependent refilling of intra-platelet Ca2+ stores, phosphorylation of 
thromboxane A2 receptors, direct cGMP activation of cyclic adenosine monophosphate 
(cAMP) and inhibition of phosphatidylinositide 3-kinase  (PI3-K) activation (64). Further 
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evidence suggests that NO can regulate platelet function via cGMP independent methods 
(65). Although the exact mechanisms still remain to be fully decribed, it is well established 
that NO serves a critical function in inhibiting platelet aggregation and controlling platelet 
function in vivo. 
 
1.4.3 Modulation of myocardial function 
A wealth of studies with differing results exist, regarding the role of NO in regulation of 
myocardial function, some of which are covered very briefly here (66). The mammalian heart 
expresses all three forms of NO synthases and NO can be derived from the endothelium of 
the coronary blood vessels, cardiomyocytes and nerve terminals (54). nNos and eNOS are 
constitutively expressed whereas iNOS is expressed primarily during pathological states such 
as in heart failure (67) or particularly following septic shock with its associated cardio-
depression (66). Contractility can be affected by NO indirectly through regulation of 
coronary vascular tone or directly through NO release from cardiomyocytes (68). Animal 
models have demonstrated that NO can, at low concentration (<0.05µM) causes an increase 
in myocardial contractility and at high concentration (>10µM) can exert a negatively 
inotropic effect (69, 70). These effects can be mediated through both cGMP-dependent and 
independent pathways (68). The heart rate can also be affected by NO. In a canine model, 
inhibition of NO was shown to reduce heart rate independently of an increase in baroreceptor 
stimulation (71). A direct effect on cardiac contraction was observed particularly from 
nNOS-derived NO (72). Deleterious effects of NO have been observed, whereby in a canine 
model of pacing-induced heart failure, Chen and colleagues noted an increase in NO 
synthesis in the failing heart primarily from iNOS. iNOS inhibition resulted in an increase in 
cardiac contractility (67). However, Shinke et al. reported that release of endogenous NO was 
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associated with a reduction in oxygen consumption through attenuation of the myocardial 
contractile response (73). In contrast, Recchia et al. noted a fall in basal cardiac NO 
production in heart failure (74). Other studies have demonstrated a role for the NO-sGC-
cGMP cascade in the prevention of adverse remodeling post-myocardial infarct (75-77). 
These studies compromise a small number of experimental studies investigating NO and 
merely reflect the vast array of interactions/processes involving NO within biological 
systems, many of which remain to be fully discovered. 
 
1.4.4 Modulation of mitochondrial biogenesis and function 
Some studies suggests that NO plays an essential role in mitochondrial biogenesis and 
modulation of mitochondrial function. NO-mediated mitochondrial biogenesis is to some 
extent contributed to by eNOS-related regulation of blood flow to and therefore, oxygen 
supply to mitochondria (41) Other data suggest that NO generated by eNOS plays a role in 
mitochondrial biogenesis in a cGMP-dependent manner. Nissoli and colleagues observed an 
increase in mitochondrial DNA in a variety of cell types such as brown adipocytes. They 
demonstrated a reduction in mitochondrial biogenesis in the brown fat of eNOS knock-out 
mice. Moreover, these mice had a reduced metabolic rate and accelerated weight gain as 
compared to wild-type mice (78). The same group later reported that this effect is not 
restricted to specific cell/tissue types (79).  
 
The role of NO in modulating mitochondrial function is more complex. Mitochondria are 
considered the ‘workhouse’ of cells in terms of energy production and respiration. NO has an 
impact on cell physiology and cell death through its effects on the mitochondria. This NO 
may be produced within the mitochondria or be transported into the organelle from outside 
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(80). Briefly, within mitochondria, the electron transport system and the oxidative 
phosphorylation system comprise ‘the mitochondrial respiratory chain.’ This respiratory 
chain is located on the inner mitochondrial membrane and consist of 5 protein complexes (I 
to V) and two electron carriers (coenzyme Q and cytochrome c oxidase) which generate 
energy in the form of adenosine triphosphate (ATP) (81-83). NO at physiological 
concentrations, can inhibit mitochondrial respiration by competing with oxygen and 
reversibly binding to CcOx. This has first demonstrated in in vitro studies with isolated 
mitochondria by adding NO donors to mitochondrial preparations (84), and later in vivo in 
animal models (85, 86). However, CcOx has to be severely inhibited for this to translate into 
a significant reduction in total body oxygen consumption. This is thought to be a protective 
mechanism to prevent severe inhibition of CcOx by NO under normal physiological 
conditions (87). The interaction between NO and CcOx also results in generation of 
particularly high levels of reactive oxygen species (ROS), regulation of mitochondrial 
membrane potential, activation of AMP-kinase, regulation of glycolysis, modulation of 
mitochondrial Ca
2+
 release, modulation of transcription factor activity and induction of 
cytoprotection (88).  
 
Furthermore, it is well recognised that NO inhibits autophagy through several mechanisms 
including S-nitrosylation (89). NO causes irreversible inhibition of several mitochondrial 
enzymes, either directly or indirectly. NO-mediated nitrosation of thiol residues on creatinine 
phosphokinase irreversibly disrupt ATP production (90). Peroxynitrite (which diffuses into 
the mitochondria from the cytosol or that generated through the reaction of NO with reactive 
oxygen species) can react with NO to irreversibly damage enzymes involved in the citric acid 
cycle and inhibit glycolysis, leading to irreversible mitochondrial damage (91).  
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Paradoxically, NO can both protect against ischaemia-reperfusion injury as well as causing 
cell apoptosis and/or necrosis, through its actions on the mitochondria. (88), (92, 93). The 
effect of NO on the membrane permeability transition pore (MPTP) and its role in 
cytoprotection is discussed in further details in section 1.7.2.2. 
 
1.4.5 Role of NO in myocardial ischaemia-reperfusion injury  
1.4.5.1 Ischaemia-reperfusion injury 
Ischaemia is a pathophysiological process which occurs in a variety of clinical conditions 
such as acute myocardial infarction, stroke, cardiac surgery and peripheral vascular disease. 
If left untreated, an ischaemic insult will lead to irreversible cellular injury and ultimately cell 
death. The obvious treatment is well-timed reperfusion (restoration of blood flow) to the 
affected organ/tissue. However reperfusion in itself can add further to the ischaemic injury 
that has occurred. This phenomenon is known as ‘ischaemia-reperfusion injury’ (IRI) and can 
limit the benefits seen from restoration of blood flow, enhancing end-organ damage. It was 
first described in 1960 by Jennings and colleagues (94). The authors described the 
histological features of canine myocardium, which had undergone temporary ischaemia, 
followed by reperfusion. These features included cellular swelling, myofibril contracture, and 
disruption of the sarcolemma and intra-mitochondrial calcium phosphate particles. Although 
the majority of cellular necrosis occurs during ischaemia and/or early after reperfusion, the 
process of injury can be seen days after reperfusion (95). These mechanisms are described in 
detail in section 1.7.7.2. 
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1.4.5.2 NO and myocardial protection 
Numerous studies have implied a protective role for NO in limiting the damage caused by 
IRI. Whereas other studies have raised controversy by failing to identify a clear protective 
role of NO and suggest that NO in the setting of IRI may actually be harmful (96). One 
theory to account for these contradictory findings is that cytoprotection afforded by NO may 
be a function of NO concentration. Low, nanomolar, levels of NO may stimulate 
cytoprotection whereas pharmacological (micromolar and millimolar) levels may mediate 
cell death (97).  
 
Current opinion attributes NO-mediated protection against IRI to occur via both eNOS and/or 
non-enzymatic-mediated NO production. Inhibition of bradykinin (and therefore NO release) 
was associated with diminished myocardial protection (98). Administration of adenosine 
(through activation of eNOS and subsequent NO release) has also been shown to be 
cardioprotective against IRI (99). Opening of mitochondrial-ATP potassium channels (100), 
inhibition of MPTP (101) and activation of the reperfusion-injury salvage kinase pathway 
(102) are important mechanisms in protection against IRI. NO release has been shown to be 
an important step in these processes (103, 104). NO-mediated myocardial protection against 
IRI has been demonstrated to occur in both cardiac pre- and post-conditioning (68). 
 
1.5 Nitrite 
As described previously, NO is a highly reactive molecule which is readily scavenged in 
plasma to form alternative, more stable stores of NO (34). One such stable storage product is 
nitrite. Nitrite was originally thought to be an inert by-product of NO metabolism however, it 
is now regarded as a significant source of endogenous NO under certain conditions (26). 
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Nitrite can be generated in humans either endogenously or obtained exogenously from dietary 
sources or the environment. 
 
1.5.1 Endogenous nitrite production 
In the human body, nitrite is generated endogenously by two main methods:- 
 
(1) Endogenous L-arginine-NO-pathway 
 NO is readily oxidised to NO2
-
 and nitrate (NO3) in blood and tissue, and accounts for the 
majority of nitrite production (105, 106). Approximately 70% of nitrite in mammals is 
considered to be derived from oxidation of NO (43, 107). Historically, NO auto-oxidation 
was thought to be the main method of nitrite generation from NO (108). However, an integral 
discovery regarding nitrite production was that caeruloplasmin (a multi copper oxidase) 
converted NO to NO
+
 with further hydration to nitrite (109). Shiva and colleagues 
demonstrated substantially lower plasma nitrite levels in caeruloplasmin knockout mice and 
in humans with congenital acaeruloplasminaemia. This process is proposed to offer an 
alternative to auto-oxidation of NO, especially in view of the rapid scavenging properties of 
oxyhaemoglobin which compete with auto-oxidation. During pathological states, such as 
sepsis where iNOS expression increases, plasma nitrite and nitrate concentrations are 
markedly elevated also (110, 111).  
 
(2) Endogenous entero-salivary circulation of nitrates  
An alternative source in humans is dietary nitrate which is recycled to nitrite via the entero-
salivary circulation, as depicted in figure 1.3. Firstly, dietary nitrates are absorbed into the 
blood stream, with up to 25% being taken up and concentrated in the salivary glands (112). 
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This uptake into the salivary glands is thought to be facilitated by the anion exchange 
channel, Sialin (113). Thereafter, these salivary nitrates are reduced to nitrite by salivary 
reductase enzymes in the oral cavity, with NO2
-
 reduction to NO occurring within the 
stomach. The remaining nitrite is absorbed by the stomach to be converted to NO in blood 
and tissue (114-117). It is estimated that about two-thirds of nitrite, of dietary origin is 
produced in this way with one-third being obtained from the ingestion of cured meat products 
(117).  
 
The concentration of nitrite found to occur in human plasma is reported to be between 100 – 
600nM (43, 118, 119). Furthermore, endogenous nitrite is found primarily within tissue rather 
than in plasma (38, 120). 
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Figure 1.3: The entero-salivary circulation of nitrates in humans  
(117) 
 
1.5.2 Exogenous sources of nitrite 
Dietary sources account for the majority of exogenous nitrate and to a lesser degree nitrite 
(116). Nitrate-rich foods (particularly leafy green vegetables) are associated with an increase 
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in plasma levels of both nitrates and nitrite (121). Nitrite has been used for centuries as a food 
preservative, and cured meat products represent a direct source of nitrite (122). 
Environmental sources of nitrite also include pollutant nitrogen oxides from cigarette smoke 
and car exhaust fumes, contaminated groundwater commonly due to fertilizers, livestock, and 
human excreta (123). 
 
1.6 NO production from nitrite 
The generation of NO from nitrite has been the subject of intense debate and research over 
the last two decades. Oxygen is crucial for the synthesis of NO via the conventional arginine-
NOS-NO pathway (1). In conditions where there is a lack of oxygen e.g. during hypoxia 
and/or ischaemia, the ability of NOS to generate NO is thus limited. Nitrite has emerged as a 
source of NO in these situations (117). Numerous mechanisms for nitrite-mediated NO 
reduction, independent of the oxygen-dependent eNOS pathway have been investigated.  
 
1.6.1 Acidification of nitrite 
Acidification (or acid disproportionation) of nitrite has been shown to generate NO from 
nitrite independent of enzymes, as follows:- 
 
NO2
-
 + H+ → HNO2 
2HNO2 → 2N2O + H20 
N203 → NO + NO2 
      (124)  
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This reaction occurs primarily in the acidic stomach. In the presence of ascorbic acid or 
polyphenols (sourced from the diet), there is greater NO production with less generation of 
other nitrogen oxides such as nitrous oxide and di-nitrogen trioxide (125, 126). The resultant 
NO is thought to play a role in gastric defence mechanisms against microbial organisms and 
in regulation of gastric blood flow (124, 127). In theory, this mechanism can occur in any 
tissue where pH has been significantly reduced. Zweier and co-workers demonstrated this in 
cardiac ischaemic cardiac tissue where NO production significantly increased following 
administration of nitrite (25). The pH of ischaemic cardiac tissue can decrease below 6 and it 
was proposed that in this environment there is nitrite-mediated reduction to NO via acid 
disproportionation of nitrite (128). This mechanism has also been demonstrated in vascular 
tissue preparations and ischaemic cardiac tissue, in vitro (129-133). 
 
1.6.2 Haemoglobin and deoxyhaemoglobin 
The interaction between nitrite and haemoglobin was noted over 100 years ago when Haldane 
proposed that, in salted meat products nitrate was first reduced to nitrite which then 
underwent deoxyhaemoglobin-mediated reduction to NO (134). In 1937, Brooks expanded on 
this reaction further and suggested that nitrous acid reacts with deoxyhaemoglobin to 
generate NO and methaemoglobin (equation 1). The NO then binds a second 
deoxyhaemoglobin to produce iron−nitrosyl-haemoglobin (equation 2):- 
 
NO
2-
 + HbFe
2+
 + H
+
  →  NO + HbFe3+ + OH-                 (equation 1) 
 
NO + HbFe
2+
  →  HbFe2+-NO               (equation 2) 
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(135) 
 
In 1981, Doyle and colleagues, delineated the exact biochemistry of this reaction and 
reinforced that nitrite reacts with deoxyhemoglobin (in the presence of protons) to produce 
methaemoglobin and NO (136).  
 
Haemoglobin-mediated nitrite-dependent NO synthesis has been proposed as an explanation 
for hypoxic vasodilation, but the evidence that haemoglobin (especially oxyhaemoglobin) 
acts as a potent NO scavenger has rendered this hypothesis the subject of intense controversy 
(45, 137-139). Haemoglobin de-oxygenation is closely associated with the physiological 
oxygen gradient, with the greatest rate of de-oxyhameoglobin-mediated nitrite reduction 
occurring when haemoglobin is 50% saturated with oxygen (Hb P50) (140). This was reported 
by Cosby and co-workers who observed that the vasodilatory effects of nitrite at near 
physiological and supra-physiological concentrations correlated with an increase in NO 
production. NO prodyction was measured by the rate of formation of iron-nitrosylated 
haemoglobin, which increases as haemoglobin oxygen saturation decreases (26). Some of the 
controversy surrounding haem-protein mediated nitrite reduction concerns the mechanism of 
NO-escape (produced by nitrite reduction) from the scavenging properties of these haem 
proteins both within and outside of the red blood cells (RBC). It remains to be fully 
determined whether NO formed from the reaction of nitrite with deoxyhaemoglobin is 
directly exported from the red blood cell or is transformed into another NO adduct (RXNO) 
to mediate nitrite-induced vasodilation elsewhere (123). Grubina et al. proposed that at low 
oxygen saturations the reductive deoxyhaemoglobin-nitrite reaction dominates whereas at 
high oxygen saturations the oxidative oxyhaemoglobin-nitrite reaction dominates. The two 
reactions are deemed to occur to a similar degree at Hb P50 (138). At physiologically low 
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haemoglobin oxygen saturations, nitrite will thus preferentially react with deoxyhaemoglobin 
to produce NO, rather than be incapacitated by oxyhaemoglobin to the physiologically 
inactive nitrate. An alternative theory suggests that the NO is converted to more stable 
substances such as S-nitrosothiols which then effect NO-mediated signaling/processes (41). 
This will be discussed further in section 1.7.1 on hypoxic vasodilatation.  
 
1.6.3 Myoglobin 
With a wealth of studies investigating the role of haemoglobin as a nitrite reductase, the role 
of myoglobin has been explored also (141). High concentration of myoglobin is found in 
erythrocytes (20 mM) and cardiac/skeletal muscle (300–900 μM) respectively (142, 143) 
Oxymyoglobin has been shown to catalyse the conversion of nitrite to NO 60 times faster 
than deoxyhaemglobin (144), 144, 145). The levels of nitrite (0.5 - 10µM) in tissue e.g. heart, 
liver, brain, are greater than in blood (120, 145). In these tissues myoglobin may function as a 
hypoxia-specific NO donor. Myoglobin has been found to serve as a nitrite reductase at a 
very low oxygen tension because of its high oxygen affinity (139). Two recent studies have 
demonstrated the presence of myoglobin in the murine vascular wall where it contributes to 
nitrite-mediated vascular relaxation, particularly under hypoxic conditions (146, 147). 
 
1.6.4 Neuroglobin  
Neuroglobin is a haem protein that is of uncertain physiological significance, and may 
promote survival of neurones under hypoxic conditions (148). One recent in vitro study by 
Tiso and co-workers has postulated that neuroglobin serves as an important nitrite reductase 
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in conditions of oxidative stress (149). Further pre-clinical studies are required to investigate 
this mechanism.  
 
1.6.5 Cytoglobin 
In comparison to other haem proteins, cytoglobin is relatively newly discovered ubiquitous 
molecule, with the first literature report of its existence published in 2002 (150). Recently, Li 
and colleagues demonstrated cytoglobin-mediated NO generation from nitrite and sGC 
activation under hypoxic conditions in isolated smooth muscle cell preparations (151). Again, 
further studies are required to investigate its properties as a significant nitrite reductase. 
 
1.6.6 Enzymatic reduction  
Several enzymes are implicated in nitrite reduction to NO, which include xanthine 
oxidoreductase, aldehyde oxidase, eNOS and mitochondrial aldehyde dehydrogenase 
(ALDH2).  
 
1) Xanthine oxidoreductase (XOR) is an enzyme involved in purine metabolism and 
catalyses the conversion of hypoxanthine to xanthine which is further converted to 
uric acid. XOR has been found in endothelial, epithelial and connective tissue cells 
(152). The role of XOR in the conversion of nitrate to nitrite has been described 
previously (153-155). Following on from this, published data has established its role 
in the reduction of nitrite to nitric oxide also (156-158). This conversion has been 
subsequently demonstrated in rat and human hearts and in rat kidney (27, 159). 
Recently, Webb and colleagues demonstrated that human blood vessels and red blood 
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cells reduce nitrite to NO through the enzymatic conversion of XOR (160). One 
commonality to these observations is that nitrite reduction to nitric oxide occurs 
preferentially in very hypoxic/anoxic and/or ischaemic conditions. Dejam and 
colleagues did not observe any diminution of nitrite-mediated forearm vascular 
response following inhibition of XOR during normoxia in humans (161). Recently, 
Ghosh et al. demonstrated a nitrite-mediated reduction in blood pressure in humans. 
This was attributed largely to the nitrite reductase activity of erythrocyte-XOR (162). 
 
2) Aldehyde oxidase is a cytosolic enzyme, similar in morphology to XOR (163). A 
study performed in rat cardiac and hepatic tissue under anaerobic conditions measured 
NO generation in the presence of aldehyde oxidase (164). The investigators reported 
that inhibition of aldehyde oxidase in tissue resulted in attenuated NO production, but 
not in blood, with oxygen tension, and pH levels being reported as important 
regulators of aldehyde oxidase-mediated NO production. These findings were 
confirmed in a later study by the same group which sought to characterise aldehyde 
oxidase-mediated nitrite reduction further. (165). 
 
3) eNOS was shown to catalyse the reduction of nitrite to NO during anoxia in a recent 
study using cultured endothelial cells (166). Webb and colleagues have provided 
further in vitro support of this mechanism when they demonstrated that during 
hypoxia alone (without acidosis) eNOS facilitates the conversion of nitrite to NO in 
red blood cell supernatants obtained from human blood samples and rat blood vessels 
(160). In a study of renal IRI utilising eNOS-knockout mice, the benefits of nitrite-
mediated protection against renal IRI was attenuated/absent in eNOS-knockout mice 
compared to wild-type animals (167). These are interesting observations as eNOS has 
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conventionally been thought to be an oxygen-dependent NO generator from L-
arginine with nitrite as a by-product of this conversion.  
 
4) Mitochondrial aldehyde dehydrogenase (ALDH2) was identified by Chen and 
colleagues as an important enzyme involved in the bioconversion of GTN to 1,2-GDN 
in animals (168). They suggested that nitrate tolerance may be caused by ALDH2 
inhibition. Furthermore, they proposed that nitrite may undergo reduction to NO via 
ALDH2. The role of ALDH2 in the bio-activation of organic nitrates has been 
confirmed in subsequent in vitro and in vivo animal studies (168-170). This was 
corroborated in healthy volunteers when it was shown that the forearm vascular 
response to GTN was attenuated when the ALDH2 enzyme was inhibited by 
disulfiram (171). Evidence suggests that nitrite is a major product of GTN bio-
activation (172). Additionally, other experimental studies suggest that mitochondria 
may be involved in the reduction of NO2
- 
to NO (173, 174). Therefore, it is feasible to 
hypothesise that ALDH2 may be important in nitrtite reduction to NO. Contrary to 
these studies, Philpott and colleagues demonstrated that administration of GTN in 
patients undergoing coronary artery bypass grafting surgery, rapidly inactivates 
vascular ALDH, and that this inactivation occurs prior to the development of 
significant nitrate tolerance, and prior to detectable impairment of GTN 
bioconversion, arguing against this as the central mechanism responsible for tolerance 
of organic nitrates (175). Perlman and colleagues recently reported a dose-response 
relationship for the cardio-protective effect of nitrite in a rat model (176). Using a 
proteomic approach they showed that the phosphorylation of ALDH2 consistently 
correlated with cardio-protection. As NO2
-
 has been discovered to be an important 
source of NO during hypoxia and/or ischaemia, ALDH2 may be an important nitrite 
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reductase during these conditions and whether ALDH2 is of prime importance in 
nitrite-mediated vasodilatation also remains unknown. This mechanism needs 
elucidating further and how this translates into physiological effects is as yet 
unknown, and will provide the basis of some of the experiments for the purposes of 
this thesis. 
 
1.6.7 Mitcohondrial enzymes 
Some components of the mitochondrial respiratory chain have been identified as possessing 
nitrite reductase activity e.g. complex III (177) and Complex IV (178). These studies have 
demonstrated that under conditions of hypoxia or even anoxia and reduced pH, nitrite is 
reduced to NO at a cellular level in vitro. These findings have yet to be confirmed in vivo.  
 
1.7 Downstream effects of nitrite 
The role of nitrite in modulating biological function has concentrated predominantly on two 
focal concepts – (1) hypoxic vasodilatation and (2) protection against IRI.  
 
1.7.1 Nitrite and hypoxic vasodilatation 
It is well recognised that as haemoglobin oxygen concentrations drop, there is an increase in 
local blood flow to tissues to try and restore oxygen supply to meet metabolic demand (179). 
This occurs in the local vasculature of organs and is termed ‘hypoxic vasodilatation.’ 
Important steps of hypoxic vasodilatation, as for most physiological mechanisms include a 
stimulus, a sensor, a signal and an effector. In hypoxic vasodilatation, the stimulus is hypoxia 
and the effector is vascular smooth muscle (41). To date, the underlying hypoxic sensing and 
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effector signaling mechanisms remain to be fully elucidated. NO has been proposed as an 
effector of hypoxic vasodilatation (180, 181). However, a considerable amount of 
controversy surrounds the role of NO (and therefore nitrite-derived NO) in effecting hypoxic 
vasodilatation. It has been demonstrated that haemoglobin within erythrocytes play an 
important role in hypoxic vasodilatation by acting as the sensor that transduces the hypoxic 
stimulus into a signal via allosteric transformation from the R-state (relaxed) to the T-state 
(tense), with the formation of NO (144, 182, 183). The resulting interactions of and 
mechanisms of departure of NO from the red blood cell (RBC) into the vasculature, to effect 
hypoxic vasodilatation without being scavenged by haemoglobin first, remain unclear. It has 
therefore, been suggested that nitrite-derived NO cannot contribute significantly to hypoxic 
vasodilatation. The resulting NO, particularly in erythrocytes, would be heavily scavenged by 
haemoglobin before it can exert its vasodilatory effect (184).  
 
An alternative theory proposes that NO reacts with nitrosyl-adducts (e.g. thiols or albumin) to 
form more stable, products such as nitroso-haemoglobin (Hb-SNO) which can then effect 
hypoxic vasodilatation (41, 182). How this Hb-SNO exerts its effect remains to be fully 
determined. One theory is that the SNO-Hb is facilitated by Anion Exchanger 1, a protein 
found in abundance in the RBC membrane where it facilitates anion exchange (185). SNO-
Hb may exit the RBC using other transporters such as ATP-binding cassette protein or Km 
transporters (186). However, conflicting studies have failed to show sufficient circulating 
SNO-Hb concentrations to effect hypoxic vasodilatation (187-189). Other substances 
including ATP, adenosine, vasoactive peptides, carbon dioxide, protons and potassium ions 
have also been proposed as effectors of hypoxic vasodilatation (190).  
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Despite this controversy, the hypoxic vasodilatory effect of nitrite itself has been observed in 
several studies. Interestingly, this was demonstrated as far back as the 19
th
 Century when 
Brunton reported in the Lancet that amyl nitrite reduced both angina and blood pressure 
(191). This was reported again in 1937 and subsequently confirmed in 1953 (192, 193). 
However, high concentrations of nitrite (100 - 1000µmol/L) were required to induce vaso-
relaxation in isolated aortic rings (193). Some interest was re-ignited when arterio-venous 
gradients of nitrite were observed in the human forearm vasculature with an augmentation of 
these gradients during exercise and regional NOS inhibition (194). However, others 
demonstrated nitrite to be a relatively ineffective in vivo vasodilator in the forearms of 
healthy volunteers even with concentrations of up to 200µmol/L (195). This discrepancy 
between the micromolar concentrations required to demonstrate an effect in vitro and the 
nanomolar concentrations present in vivo led to the conclusion that nitrite was an 
insignificant physiological vasodilator. Later studies challenged Lauer and colleagues’ 
findings signifying that nitrite may be important in physiological regulation of blood flow. 
Nagababu and colleagues observed that nitrite reduction at reduced oxygen pressures is a 
major source of erythrocyte NO (196). Cosby and co-workers observed nitrite-mediated 
vasodilatation in the human forearm vasculature at near physiological concentrations and 
relaxation of rat aorta with nitrite during hypoxia (26). A further study in isolated rodent 
aortic rings demonstrated attenuation of nitrite-dependent vasodilation at high haemoglobin 
oxygen saturation, with stimulation of vasodilation as haemoglobin oxygen saturation 
decreased to 50% (197). In a separate study using isolated rabbit vascular rings, Ingram and 
co-workers reported a greater dilatation of pulmonary artery as compared to aorta, with an 
enhanced hypoxic vasodilatation in all vessels (198). Maher and colleagues demonstrated 
exogenous intra-arterial nitrite administration only modestly dilates forearm resistance 
vessels, but potently dilates capacitance vessels under normoxic conditions (46). 
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Additionally, under hypoxic conditions, nitrite markedly dilated forearm resistance vessels. 
In a separate study, Ingram and colleagues demonstrated nitrite-mediated arterial and 
pulmonary vasodilatation following administration of systemic nitrite infusion in healthy 
volunteers(199). The clinical potential of these and further studies are reviewed in section 
1.8. 
 
There are limited explanations as to how nitrite causes hypoxic vasodilatation. One potential 
theory is that nitrite-reacted haemoglobin has a high affinity for the RBC membrane and that 
this high affinity contributes to RBC-induced vasodilatation by two pathways. Firstly the 
increased membrane binding activates glycolysis and the synthesis of ATP. This newly 
synthesized ATP is released from the RBC under hypoxic conditions. The released ATP 
interacts with purinergic receptors on the endothelium that stimulate the synthesis of NO by 
endothelial NO synthase. This reaction will induce vasodilation without requiring that NO be 
released from the RBC. Secondly, the interaction with the membrane, of intermediates 
formed during the reaction of nitrite with deoxygenated haemoglobin, stimulates the release 
of NO from these intermediates. NO released on the membrane can escape the large pool of 
intracellular haemoglobin and be released into the vasculature resulting in vasodilatation 
(200). Other theories of how nitrite exits the RBC, propose the use of transporters such as the 
Anion Exchanger 1 or through protonation to nitrous acid (201, 202). With the paucity of 
data in this area, the role of nitrite in hypoxic vasodilatation therefore remains controversial. 
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1.7.2 Nitrite and ischaemia-reperfusion injury 
Several molecular processes are implicated in the development of ischaemia and IRI. An 
appreciation of these allows better understanding of methods of protection against IRI and, 
therefore are summarised herein.  
 
1.7.2.1 Ischaemia 
Ischaemia itself results in a cascade of changes which ultimately lead to cellular 
necrosis/death. The myocardium in particular is a highly efficient ATP generating organ, 
which is achieved through an abundance of mitochondria and largely aerobic metabolism. An 
ischaemic insult results in a reduction in rapid ATP depletion and high-energy intracellular 
phosphate due to lack of myocardial anaerobic metabolic pathways (203). A 90% reduction 
in myocardial ATP is thought to result in irreversible cellular damage (204, 205). Ischaemia 
is also associated with a decrease in intra-cellular pH, which is counteracted by proton (H
+
) 
efflux through the sodium/proton (Na
+
/H
+
) exchanger but at the expense of intra-cellular Na
+
 
accumulation (206, 207). This coupled with an inactivation of ATPases, e.g. ATP-dependent 
Ca
2+
 re-uptake results in calcium overload. In combination with an initiation of the apoptotic 
cascade through various intra-celluar proteases and opening of the MPTP, cellular and 
ultimately tissue/organ death occurs (208).  
 
1.7.2.2 Mechanisms of IRI 
Timely reperfusion and hence re-oxygenation is known to prevent irreversible ischaemia-
related cellular damage. However, it is well recognised that despite prompt restoration of 
blood flow to ischaemic tissue/organs, reperfusion itself can cause further injury (94). This 
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paradox is termed ‘ischaemia-reperfusion injury’ (IRI). Methods to inhibit the deleterious 
effect of IRI has been the ‘holy grail’ of many a research study due to its potential to improve 
clinical outcomes in several circumstances e.g. following an acute myocardial infarction 
(AMI), in cardiac surgery with cardio-pulmonary bypass, following organ transplantation and 
following cardiac arrest and have been extensively reviewed by others (209-211). 
 
Several inter-related mechanisms are thought to be implicated in the development of IRI, and 
are summarised as follows:-  
 
(1) Re-oxygenation and oxygen free radicals  
During reperfusion, re-oxygenation of the ischaemic myocardium, although providing 
essential oxygen to the affected area, also adds to the injury through release of further oxygen 
free radicals (212, 213). Hearse and colleagues first reported this in an animal model, where 
they observed that severe myocardial injury developed with the onset of re-oxygenation in 
rats (214). During reperfusion, oxygen undergoes reduction leading to the formation of ROS 
such as superoxide anion (O2
−
), hydroxyl radical (OH
·
) and reactive nitrogen species such as 
peroxynitrite (ONOO
−
) (215). Other sources of ROS include xanthine oxidase and NADPH 
oxidase (216). ROS are highly reactive molecules which are generated in both the endothelial 
cells and the myocytes and interact with the cell membrane resulting in oxidative stress and 
myocardial cell damage/necrosis (217). It has been postulated that ROS-mediated damage in 
the setting of IR involves the MPTP (218). 
 
The contribution of oxygen free radicals to IRI has been reported in a variety of clinical 
settings of myocardial IRI (219, 220). In addition to the direct effects of oxygen free radicals, 
they also reduce the availability of NO and therefore the cardio-protective effects that arise 
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from it (216). The role of these oxygen free radicals, however, has been debated in the 
literature with inconclusive evidence in both animal and clinical studies protection afforded 
by antioxidant therapy (215).  
 
(2) Changes in intracellular pH 
As described, during ischaemia, intracellular and interstitial pH decreases as a result of 
anaerobic metabolism with lactate accumulation and ATP breakdown, resulting in excessive 
levels of protons (206, 207). Upon reperfusion, interstitial H
+
 are washed out creating a 
proton gradient across the cellular membrane and resulting in activation of the Na
+
/H
+
 
exchanger. This leads to extrusion of H
+
 at the expense of an increase in intracellular Na
+
 
(75). This reduces intracellular acidosis, a protective element against hyper-contracture of the 
myofibrils, and loss of its protective abilities (221, 222). Additionally, consequent rise in Na
+
 
leads to activation of the Na
+
/Ca
2+
 exchanger, further increasing the intracellular levels of 
Ca
2+
 (223). 
 
(3)  Calcium overload and hypercontracture 
Elevated levels of intracellular Ca
2+
 are observed during reperfusion, which is significant in 
IRI (224). This is partly thought to be due to a sequence of downstream effects of rapid 
normalisation of extra-cellular pH following reperfusion, followed by activation of the 
Na
+
/H
+
 exchanger, resulting in stimulation of the Na
+
/Ca
2+
 exchanger with the end result 
being substantial intracellular Ca
2+
 overload (225). Furthermore, it is suggested that 
ischaemia induces defects in the cell's viability to regulate Ca
2+
 such that upon reperfusion 
the cell accumulates toxic levels of Ca
2+
. This leads to myocyte death by hyper-contraction of 
the myocardial cells, which may also result in cellular disruption and necrosis of adjacent 
cells (226-228). Development of hyper-contracture causes mechanical stiffness and tissue 
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necrosis. The contracture can affect the entire heart as may occur after global ischemia, e.g. 
during prolonged cardiac surgery (226).  
 
(4)  Mitochondrial Permeability Transition Pore  
The Mitochondrial Permeability Transition Pore (MPTP) is a non-selective channel located 
on the inner mitochondrial membrane (229). Normally, the inner mitochondrial membrane is 
impermeable to the majority of metabolites/substances. Opening of the MPTP depletes the 
mitochondrial energy stores and initiates a cascade leading to cell apoptosis and necrosis 
(230). During the ischaemic phase of the insult, the MPTP remains closed and opens within 
the first few minutes of the reperfusion phase (231). Factors which promote MPTP opening 
include Ca
2+
 overload, raised phosphate concentration, restoration of pH and oxidative stress 
(with production of 02
-
), all of which are critical mediators of IRI (232-234). It has been 
postulated that the MPTP opens within minutes after onset of reperfusion, when pH has 
started to recover (234). Opening of the MPTP is thought to signify the onset of irreversible 
cellular necrosis. The significance of this structure as a possible target in providing protection 
against IRI has been demonstrated in numerous pre-clinical studies, where inhibition of the 
MPTP confers protection against IRI (235, 236).  
 
(5) Other mechanisms  
Other important contributory factors in myocardial IRI include neutrophil activation and 
accumulation, platelet-mediated injury, augmentation of the complement and of the renin-
angiotensin systems. Excessive neutrophils can produce oxygen free radicals, proteases and 
pro-inflammatory mediators and can contribute to leucocyte entrapment in the capillaries, 
leading to micro-vascular plugging (237, 238). Platelets also contribute to micro-vascular 
dysfunction and complement activation results in myocardial necrosis through direct cell 
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injury by increasing cell permeability and release of histamine and platelet activating factor 
and stimulation of neutrophil adherence and superoxide production (239, 240). Stimulation of 
the renin-angiotensin system has been associated with myocardial necrosis particularly 
following AMI (241). Blockade of the renin-angiotensin system is readily achieved through 
the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers which 
are widely available for treatment of cardiovascular disease. The use of these agents in 
studies, has demonstrated a reduction in reperfusion arrhythmias and myocardial infarct size 
with improved functional recovery following myocardial IRI (242).  
 
1.7.2.3 Clinical manifestations of myocardial IRI 
The clinical manifestations of the molecular processes which underpin myocardial IRI 
include myocardial stunning, reperfusion arrhythmias, endothelial dysfunction, myocyte 
necrosis and microvascular dysfunction including the ‘no re-flow’ phenomenon (226). These 
have been noted in several settings e.g. following an AMI treated by thrombolysis 
therapy/primary percutaneous coronary intervention (PCI), during cardiac surgery with the 
use of cardio-pulmonary bypass (CPB), during heart transplantation and following a cardiac 
arrest (209-211).  
 
(1) Myocardial stunning 
Myocardial stunning is a commonly encountered manifestation of IRI. It is defined as 
‘prolonged post-ischaemic mechanical dysfunction that persists after reperfusion of 
previously ischaemic tissue in the absence of irreversible damage, including myocardial 
necrosis’ (243). This suggests that it is transient and reversible. Myocardial stunning is 
encountered in a variety of clinical scenarios where ischaemia and reperfusion are present - 
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restoration of blood flow following AMI through thrombolysis or PCI, in unstable or 
exercise-induced angina, following cardiac transplantation/ ‘on-pump’ cardiac surgery and 
following cardiopulmonary resuscitation (244-248). In the setting of cardiac surgery, the 
incidence of stunning has been reported to be as high as 60% and usually manifests as a low 
cardiac output state and a requirement for inotropic support (249). Length of complete 
recovery can be variable, ranging from a few days to upto 6 months (247, 250-252). 
Myocardial stunning is deemed a marker of poor prognosis, particularly after cardiac 
ischaemic events (253). Additionally, there is some evidence to suggest that myocardial 
stunning may lead to heart failure due to repeated episodes of myocardial ischaemia and 
reperfusion (254).  
 
(2) Reperfusion arrhythmias 
Reperfusion arrhythmias such as accelerated idio-ventricular arrhythmias, ventricular 
tachycardia or ventricular fibrillation typically occur after AMI and although easily treated if 
recognised, can be lethal (255). They often occur following the onset of reperfusion (256). It 
has been suggested that these arrhythmias are related to the sudden ionic changes or 
generation of oxygen free radicals (257, 258).  
 
(3) Endothelial dysfunction 
The first evidence of coronary endothelial dysfunction following IRI originated from Ku and 
colleagues who measured coronary vascular reactivity following 90 minutes of myocardial 
ischaemia and up to 120 minutes after onset of reperfusion(259). They observed that coronary 
endothelial dysfunction was a prominent feature of myocardial IRI. In a recent study, remote 
endothelial dysfunction has also been observed in rat mesenteric arteries following 60 
minutes of myocardial ischaemia followed by 120 minutes of reperfusion (260). Interestingly, 
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there is some data which states that ischaemia alone is not associated with significant 
endothelial dysfunction (261, 262). It is during reperfusion that this injury predominantly 
occurs and is mediated through NO-dependent mechanisms, while endothelium-independent 
responses and smooth muscle responsiveness are maintained (263). Oxygen-derived free 
radicals appear to also play a significant role in IRI-associated coronary endothelial 
dysfunction (264, 265). Response to vasoconstrictors such as endothelin I, is enhanced and 
this coupled with the response to oxygen-derived free radicals leads to coronary 
vasoconstriction and reduced coronary blood flow (266). This endothelial dysfunction 
intensifies platelet and neutrophil activation further compounding IRI (267). In a canine 
study, coronary endothelial dysfunction was still present 12 weeks after the ischaemic event 
(268). In a further human study, coronary endothelial dysfunction was evident 6 months after 
AMI treated by early reperfusion (269). 
 
(4) Myocyte necrosis and death 
The myocardium can tolerate up to 15 minutes of severe and even global myocardial 
ischaemia without cardiomyocyte necrosis and death (270). Prolonged ischaemia resulting in 
irreversible injury followed by reperfusion leads to the development of ‘contraction band 
necrosis’ whereby the affected tissue swells and develops contraction bands (271). This 
signifies lethal irreversible injury which cannot be undone. In animal models, contraction 
band necrosis has been associated with sudden death (272).  
 
(5) Micro-vascular dysfunction and the ‘no re-flow’ phenomenon 
Micro-vascular dysfunction encompasses several processes including endothelial 
dysfunction, micro-vascular obstruction (downstream micro-embolism of platelets), de novo 
thrombosis, and neutrophil capillary plugging, oedema and oxidative stress (226, 273). It can 
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cause the ‘no-reflow’ phenomenon whereby restoration of blood flow to an ischaemic organ 
is often not fully restored after release of a vascular occlusion – a situation commonly 
encountered by Cardiologists in patients undergoing PCI (273). It can be associated with 
AMI, myocardial rupture and death (274, 275). No-reflow has been shown to be associated 
with a poor prognosis in several clinical trials and correlates with micro-vascular obstruction 
on cardiac magnetic resonance imaging (276-280).  
 
1.7.2.4 Protection against IRI 
(1) Ischaemic Conditioning 
The clinical importance of IRI has resulted in decades of research investigating methods to 
protect against it. This is termed ‘conditioning’. Anecdotal evidence for this came from 
reports of reduced myocardial injury following AMI in patients with pre-infarct angina (281). 
In 1986, Murry et al. demonstrated that a period of sub-lethal ischaemia prior to an AMI 
reduced subsequent myocardial injury by 75% (282). This was termed ‘ischaemic pre-
conditioning’ whereby the heart was primed for a lethal ischaemic insult with brief periods of 
preceding sub-lethal ischaemia. Two discrete time windows of ischaemic pre-conditioning 
(IPC) have been reported. The first (‘immediate’ or ‘early’) window of protection is seen 
immediately after the protective stimulus is administered and can last 2-3 hours (282). The 
the second (or ‘late’) window of conditioning occurs 12-24 hours following the first window 
of protection (283-285). This delayed protection although less powerful, appears to last 2-3 
days (286). This biphasic response has been observed in human studies also (287, 288). Since 
Murry’s seminal paper describing this ‘classical’ method of IPC, subsequent experimental 
studies have investigated a variety of both pharmacological and non-pharmacological 
interventions which can effect conditioning. Furthermore, differences have been discovered 
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in the molecular processes underlying these two time windows of protection. Early IPC is 
achieved through rapid reactions which are complete in a short period of time e.g. activation 
of existing ion channels, receptors, existing enzymes etc. (289). Late IPC is dependent on 
changes in gene expression and new protein synthesis e.g. NOS, heat shock proteins and anti-
oxidant enzymes (290, 291). Some of these reactions will be discussed in section (2) 
‘Mechanisms underlying ischaemic conditioning, below.  
 
Protection has also been observed when the conditioning stimulus is delivered following 
onset of reperfusion. This was first identified by Na and colleagues in felines whereby 
delivering a pre-lethal ischaemic insult prior to AMI reduced subsequent arrhythmias (292). 
In a subsequent canine study, a 44% reduction in myocardial infarct size was noted with 
improvement of post-ischaemic endothelial dysfunction following delivery of sub-lethal 
ischaemia in early reperfusion (293). The protective stimulus needs to be delivered early in 
reperfusion. Post-conditioning offers an attractive therapeutic option in the setting of 
conditions such as an acute AMI, where the timing of index ischaemia is unpredictable. 
Several animal and small-sized human studies have demonstrated significant reductions in 
AMI-related myocardial injury leading to publication of a Position Paper from the Working 
Group of Cellular Biology of the Heart of the European Society of Cardiology (294). 
Although, this paper does not advocate the widespread use of post-conditioning stimuli in 
clinical practice, it recognises its potential as an important adjunct to current AMI therapy 
and recommends further large-scale clinical trials to determine prognostic benefit.   
  
(2) Mechanisms underlying myocardial ischaemic conditioning 
In their entirety, both IRI and myocardial conditioning encompass a highly complex set of 
molecular and biochemical processes. Intense research into this area in recent years has 
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yielded an abundance of reactions and mechanisms integral to myocardial protection, in a 
variety of species and preparations. It is now accepted that myocardial conditioning 
comprises 3 broad components – triggers, mediator cascades and effectors. Crucial 
ingredients of this complex process include NO, protein kinase activation and mitochondria 
(295). Moreover, activation of these protective pathways appears to occur immediately after 
onset of reperfusion (296).  
 
 
 
 
Figure 1.4: Molecular mechanisms involved in cyto-protection against IRI. The SAFE, RISK 
and PKC_NO pathways. 
 
Firstly, triggers of conditioning include substances such as adenosine, bradykinin, or opioids 
(297-299). These are released during ischaemia and act on cell-surface receptors such as Gi 
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protein-coupled receptors (GiPCR), initiating a cascade of signaling (mediator) pathways 
which include the ‘Reperfusion Injury Salvage Kinase’ (RISK) pathway and the ‘Survivor 
Activating Factor Enhancement (SAFE) pathway, as depicted in figure 1.4 (296, 300, 301). 
These in turn converge on a final common effector - the MPTP. The MPTP opens 
approximately 3 minutes after onset of reperfusion and is thought to signify the onset of 
irreversible cellular necrosis (231). Stimulation of cardio-protective mechanisms abrogate 
opening of the MPTP, with consequent reduction in IRI during ischaemic pre- and post-
conditioning (235, 236, 302). 
 
(3) Reperfusion Injury Salvage Kinases (RISK) Pathway 
The RISK pathway was first described by Hausenloy and colleagues in 2004 (102). Research 
performed by this group provided two important insights into ischaemic conditioning -(1) 
classification of the RISK pathway and (2) the onset of reperfusion as the crucial phase of 
ischaemic conditioning via the RISK pathway (296). The salient components of this pathway 
are depicted in figure 1.4. Stimulation of receptors e.g. GiCPR, leads to activation of the 
prosurvival kinases - phosphatidylinositol-3-OH kinase (P13K–Akt) and extra-cellular signal-
regulated kinases (Erk 1/2). The role of these substances in ischaemic protection had been 
investigated prior to classification of the RISK pathway. Early in vitro experiments first 
demonstrated P13K–Akt-mediated protection against IRI (303, 304). Tong and colleagues 
confirmed these findings in an Langendorff rodent heart model, when they observed that 
inhibition of P13K–Akt abrogated the protective effect of IPC through a decrease in recovery 
of left ventricular developed pressure (305). Similarly, both in vitro and in vivo experimental 
studies have confirmed a role of Erk1/2 in cardioprotection (306-308).  
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A variety of studies reveal these pro-survival kinases confer cardio-protection through 
phosphorylation of downstream effectors which include eNOS (309), p70S6K (310), Bcl-2-
associated death promoter or BAD (311), protein kinase C (312) and Glycogen Synthase 
Kinase-3β or GSK-3β (313). Inhibitory phosphorylation of GSK-3β occurs during the lethal 
ischaemic period (305). It is recognised that inhibitory phosphorylation of GSK-3β increases 
the threshold and therefore prevents MPTP opening during reperfusion, thus promoting 
protection against IRI (302, 314).  
 
(4) Survivor Activating Factor Enhancement (SAFE) Pathway 
In 2009, Lecour described the SAFE pathway (figure 1.4) as an alternative cardio-protective 
signaling (mediator) process (301). The cytokine tumour necrosis factor-alpha (TNF-α) has 
been implicated in affording protection in several models of IRI (315, 316). It is postulated 
that TNF- α binds to its cell surface receptors, found in abundance on cardiomyocytes, which 
in turn stimulate ‘janus kinase’ (JAK) and the ‘signal transducer and activator of 
transcription’ (STAT) pathways (300). Inhibition of JAK-STAT was shown to increase 
apoptosis in rat cardiomyocytes (317). Activation of this pathway has been observed in both 
immediate and delayed IPC and post conditioning. Xuan and colleagues demonstrated a 
protective role due to up-regulation of the JAK-STAT pathway in a mouse model of 
myocardial IRI (318). A recent human study demonstrated enhanced activation of STAT-5 
during early reperfusion in myocardial cells of pre-conditioned patients compared to controls 
(319). One of the downstream effects of JAK-STAT stimulation is inhibitory phosphorylation 
of GSK3-β (320). Most studies have evaluated the role of the SAFE pathway in IPC. TNF- α 
and STAT-3 have been implicated in ischaemic post-conditioning also (321, 322). 
Increasingly, inhibition of MPTP opening is recognised to be the final common effector of 
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cardiac conditioning pathways. As yet, a direct association between the SAFE pathway and 
MPTP opening has yet to be established.  
 
(5) PKC_NO mediated ischaemic protection 
A further important cardio-protective pathway involves both NO and PKC as crucial 
ingredients for mediating ischaemic conditioning. PKC is activated by 2 main mechanisms – 
(1) directly by cell surface receptors, e.g. GiCPR or (2) indirectly by P13-Akt via 
upregulation of eNOS with consequent NO production. This NO in turn activates PKC via 
PKG. The process is completed by activation of mitochondrial ATP-dependent potassium 
channels (KATP) and formation of ROS (323, 324). High levels of ROS are known to be 
detrimental to cardiomyocytes, whereas in low levels they effect cardio-protective signaling 
which can occur through stimulation of mitogen-activated kinase (MAPK) and inhibition of 
opening of MPTP (217, 323).  
 
(6) Mitochondrial  - the final common effector  
IRI protective pathways are believed to converge on the mitochondria. The MPTP is 
proposed to be the final common effector of the cardio-protective signaling cascades 
described. The MPTP is a non-selective channel located on the inner mitochondrial 
membrane. It was first described in 1976 (325) with further work in the 1980s signifying its 
role in cardio-protection (232). Griffith and colleagues first observed that the MPTP remains 
closed during ischaemia and opens following onset of reperfusion (231). In 2002, Hausenloy 
and co-workers reported that ischaemic pre-conditioning was effected through inhibition of 
the MPTP following onset of reperfusion. Administration of cyclosporine A (an inhibitor of 
MPTP opening) reduced infarct size in an isolated rat heart model of IRI by 24% (235). In 
2005, Argaud et al demonstrated that post-conditioning in rabbits subjected to cardiac IRI, is 
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afforded through inhibition of MPTP (236). These earlier animal studies paved the way for 
further human studies investigating the role of the MPTP in IRI. Piot et al undertook a small, 
pilot study investigating inhibition of MPTP opening during reperfusion in patients with AMI 
undergoing PCI. They observed a reduction in myocardial infarct size as assessed by plasma 
creatinine kinase levels and on cardiac magnetic resonance (CMR) studies (326). Inhibition 
of MPTP opening was conferred through administration of intravenous cyclosporine A. 
Currently, a double-blind randomised-control trial called the MITOCARE Study is underway 
(327). Patient with an AMI undergoing PCI will receive placebo or TRO40303 (inhibitor of 
MPTP opening). The primary outcome measure will be reduction in infarct size (assessed as 
plasma creatinine kinase and troponin I area under the curve over 3 days). The main 
secondary endpoint will be infarct size normalized to the myocardium at risk (expressed by 
the myocardial salvage index assessed by cardiac magnetic resonance). Hausenloy’s initial 
study in 2002 prompted extensive further research into the role of the MPTP as the end-
effector of IRI (235). However much still remains to be elucidated about this channel and its 
exact role in the complex pathophysiology of IRI.  
 
1.7.2.5 Evidence for nitrite in protection against IRI 
Decades of research has explored the role of both pharmacological and non-pharmacological 
methods of cardiac protection against IRI. As described previously, NO has a well-
established role in cardio-protective pathways. More recently, nitrite has emerged as an 
important in vivo NO donor, principally in acidotic and hypoxic conditions (117). Mounting 
evidence suggests that nitrite may have an important role to play in protection against 
myocardial IRI (328). Interestingly, the cardioprotective effect of nitrite through release of 
NO, was observed as far back as 1990 in a feline model of myocardial IRI, before the 
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bioactivity of nitrite was fully appreciated (329). Additionally, an association between 
ischaemic pre-conditioning and increases in cardiac/tissue nitrite and nitrate levels has been 
observed previously (330, 331). Years later, following renewed interest in nitrite as a 
bioactive source of endogenous NO, Webb and colleagues, using a Lagendorff rat heart 
model of IRI demonstrated nitrite-mediated cardio-protection. A 60% reduction in 
myocardial infarct size was recorded following nitrite (both 10 and 100 µM), with no 
abrogation of myocardial injury following administration of a NO scavenger (27). This 
cardio-protection was thought to be mediated through nitrite reduction to NO via XOR, 
promoted by the hypoxic and acidotic environment that occurs during ischaemia. Similar 
findings were noted in murine models of IRI by Duranski et al (332)and Shiva et al (333). In 
vivo studies corroborated these findings by demonstrating reduction in myocardial injury in 
rat, murine and canine models of IRI (334, 335). Gonzalez and colleagues explored the effect 
of low-dose nitrite infusion administered to dogs during myocardial ischaemia (336). Two 
differing nitrite administration protocols were utilised (1) a 60-minute infusion of 
0.20µmol/min/kg (20 minutes) followed by 0.17µmol/min/kg (40 minutes); (2) a 5-minute 
infusion of 0.20µmol/min/kg immediately prior to reperfusion. The primary endpoint of 
infarct as a proportion of area at risk (assessed using CMR) was significantly reduced with 
both the 60-minute and 5-minute infusions from 70±10% in the placebo group compared with 
23±5% (p<0.001) and 36±8% (p<0.05) in the nitrite-treated animals, respectively. In a recent 
rat study, cardio-protection observed following administration of inhaled NO was associated 
with an increase in plasma nitrite levels. Furthermore, intravenous nitrite produced a similar 
cardio-protective effect to inhaled NO, suggesting that nitrite is a potential biocarrier of NO 
activity (337). In a human study, the role of nitrite-mediated protection in a forearm model of 
IRI was explored. Administration of dietary nitrate in the form of beetroot juice (with a 
resultant increase in plasma nitrite) to 10 healthy subjects was associated with diminution of 
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ischaemia-induced endothelial dysfunction (338). In a murine cardiac arrest model, 
intravenous nitrite therapy improved cardiac function, survival and neurological outcomes 
(339). This study also provided important mechanistic data regarding nitrite molecular 
activity e.g. nitrite treatment restored intra-cardiac nitrite (depleted as a result of cardiac 
arrest), increased S-nitrosothiol levels, and positively modulated mitochondrial function. 
Recently, the same group have published preliminary data from an on-going phase I human 
trial of intravenous nitrite therapy in human cardiac arrest survivors exploring the safety and 
tolerability of intravenous nitrite administration, suggesting nitrite is safe to administer to 
humans in doses that confer cardio-protection in animals (340).  
 
1.7.2.5 Mechanisms of nitrite-mediated cyto-protection 
Despite an increasing number of studies detailing nitrite-mediated protection against IRI, 
there is a relative paucity of data outlining the exact mechanisms of this protection. The 
likelihood is that nitrite-mediated cardio-protection occurs primarily via generation of NO in 
the ischaemic tissue. NO-mediated cyto-protection occurs as described in section 1.4.5. 
However, NO-independent protective activity may also occur. Mitochondria are established 
to be important in IRI protection (295). It has been previously shown that nitrite is cardio-
protective though modulation of mitochondrial function (333). A recent study demonstrated 
that mitochondrial biogenesis also occurs, independent of an NO-mediated pathway (341). 
Perlman and colleagues provided some further important insights into this field (176). Their 
experiments demonstrated that nitrite exhibits a dose-response relationship in affording 
cardio-protection. Low (0.1mg/kg) and high (10mg/kg) doses of nitrite were cardio-protective 
whereas intermediate (1.0mg/kg) doses had no effect. Furthermore, nitrite directly and 
through NO-release alters tissue redox status, alters transcription factor signaling, protein 
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expression and cardiac metabolism. Perlman’s experiments also provided a greater 
understanding into the mechanisms of NO release from nitrite. Singh and colleagues 
demonstrated an abrogation of oxidative stress in rat myocardium subject to hypobaric 
hypoxia following supplementation of dietary water with nitrite (342). They observed an 
increase in transcription factors, anti-oxidant genes and cardio-protective molecules. 
Dezfulian’s study, although investigating mechanisms of neuro-protection, have again 
demonstrated protection via modulation of mitochondrial function, and S-nitrosation 
independent of sGC-signaling pathways (340). Other examples lend support to NO-
independent nitrite-mediated cyto-protection, e.g. nitrated lipids (which can form through a 
reaction between unsaturated fatty acids and nitrite) have been demonstrated to confer cardio-
protection (343, 344).  
 
To date, there is extremely limited data on mechanisms of protection against IRI in the 
human myocardium undergoing cardiac surgery, with no studies investigating the 
mechanisms of nitrite-mediated cardio-protection specifically. There is one human study of 
remote ischaemic preconditioning demonstrating STAT-5 activation in the left ventricular 
myocardium at early reperfusion after cardioplegic ischaemic arrest (319). This deficit in 
knowledge within this subject forms the basis of some of the experiments outlined herein. 
 
1.8 Potential clinical applications of nitrite in man 
1.8.1 Protection against ischaemia-reperfusion injury 
As described in the previous section, one of the main therapeutic applications of nitrite 
includes protection of the myocardium against IRI. Clinical situations where this may be 
important includes in the settings of AMI (336), cardiac surgery (no in vivo animal human 
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studies), cardiac transplantation (no in vivo animal or human studies) and cardiac arrest (339). 
Nitrite-mediated tissue/organ protection has been demonstrated in other clinical conditions 
such as cerebrovascular accidents and sub-arachnoid haemorrhage (345, 346). There are 
several on-going clinical trials investigating nitrite-mediated protection in humans 
(www.clinicaltrials.gov).  
 
1.8.2 Pulmonary arterial hypertension 
Pulmonary artery hypertension (PAH) is associated with a poor prognosis with limited 
treatment options demonstrating a mortality benefit. Treatment is largely aimed at improving 
morbidity. Lack of NO bioavailability appears to be an important feature in the development 
of PAH (347). The majority of available therapeutic options enhance NO bioavailability e.g. 
phosphodiesterase-5 inhibitors (348, 349). The pulmonary vasculature is relatively hypoxic 
compared to the systemic vasculature, with an oxygen saturation of between 60-80% (350). 
The ability of nitrite, either directly or through release of NO, to induce vascular relaxation 
during hypoxic conditions can potentially be exploited in treating PAH.   
 
Hunter et al induced PAH in new-born lambs by rendering them hypoxic or inducing 
vasoconstriction with thromboxane (351). They noted a 60-70% reduction in pulmonary 
artery blood pressure following administration of nebulised sodium nitrite. No significant 
change in systemic blood pressure was observed. Comparable findings were noted in an 
analogous rat model of hypoxia and thromboxane-induced PAH with intravenous sodium 
nitrite (352). In humans, Ingram and colleagues noted vasodilatation of the hypoxic 
pulmonary vasculature following administration of intravenous sodium nitrite (199). 
Interestingly, this vasodilatory effect persisted even after plasma nitrite concentrations had 
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returned to baseline levels. Furthermore, increased NO bioavailability may result in alteration 
of the adverse structural changes seen in the pulmonary vasculature in PAH as demonstrated 
in several animal models (353-355). Further human data is required to determine the potential 
clinical benefit of nitrite therapy in PAH. 
 
1.8.3 Heart failure  
Heart failure (HF) poses a significant health burden in the Western World and it is therefore 
not unsurprising that it comprises a significant proportion of the workload for Physicians and 
Cardiologists (356, 357). Studies have demonstrated nitrite to be a selective vasodilator in the 
human vasculature (46, 199). Nossaman et al studied the cardiovascular and pulmonary 
haemodynamic effects of nitrite and nitrates (glyceryl trinitrate, GTN) in rats (358) They 
demonstrated a significant reduction in pulmonary and systemic arterial blood pressure, 
although GTN was 1000-fold more potent than nitrite. 
 
With its profile of relatively selective dilatation of systemic capacitance and pulmonary 
resistance vessels, nitrite is a potentially attractive treatment for decompensated HF. It would 
likely increase cardiac output, and decrease ventricular diastolic pressures with less reduction 
in blood pressure than would be seen with a potent arterial vasodilator such as GTN (359). To 
date, no human studies investigating the role of nitrite in heart failure exist.   
 
1.8.4 Systemic arterial hypertension 
Hypertension remains a leading cause of cardiovascular morbidity and mortality (360). 
Although, several pharmacological options exist to treat hypertension, dietary methods of 
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arterial blood pressure reduction have been intensely studied. Diets rich in fruit and leafy 
vegetables have been shown to lower blood pressure and provide beneficial cardiovascular 
effects (361). Some vegetables such as spinach, beetroot and lettuce, contain high levels of 
nitrate (121), some of which is converted to nitrite when ingested, as described in section 
1.5.1. Therefore, it would seem intuitive that nitrite with its vasodilatory properties is a 
reasonable candidate to lower blood pressure.  
 
In 2005, Larsen and colleagues demonstrated the blood pressure lowering effects of oral 
nitrate supplementation in healthy volunteers (362). 72 hour administration of oral sodium 
nitrate resulted in a significant reduction in mean and diastolic blood pressure associated with 
an increase in plasma nitrite levels. Webb and colleagues provided oral nitrate 
supplementation via the ingestion of 500mL of beetroot juice to healthy subjects, and 
compared it to placebo (water). They noted a significant reduction (p<0.01 for all) in systolic 
(10.4±3.0mmHg), diastolic (8.1±2.1mmHg) and mean (8.0±2.1mmHg) arterial blood 
pressure 2-3 hours after ingestion. This was attributable to increased nitrite levels because 
interruption of the entero-salivary circulation resulted in an abrogation of the plasma nitrite 
increase and blood pressure lowering effects. Kapil and co-workers investigated this one-step 
further by demonstrating a dose-dependent increase in plasma nitrite levels and associated 
blood pressure lowering effects, following oral administration of beetroot juice and inorganic 
nitrate supplementation (in the form of potassium nitrate) in healthy volunteers (363). 
Additional studies have reported a significant reduction in blood pressure in hypertensive 
patients with no previous pharmacological therapy receiving oral nitrate supplementation 
(162). Interestingly, the rise in plasma nitrite observed in these hypertensive subjects had 
previously been shown to have no effect on lowering blood pressure in healthy volunteers. 
However, a recent study by the same group utilised this ‘beetroot juice’ model of nitrite 
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supplementation in patients with diabetes with conflicting results (364). Following a 2-week 
intervention period, there was no significant change in blood pressure, endothelial function or 
insulin sensitivity, despite an increase in plasma nitrate and nitrite levels. These contradictory 
effects between health and disease-states require further exploration.  
 
1.8.5 Other clinical applications 
NO plays a key role in vascular function and remodelling, and therefore nitrite as a NO-donor 
may have the potential to induce angiogenesis and promote recovery in chronic ischaemic 
conditions such as peripheral vascular disease (PVD) (365). Kumar and colleagues 
demonstrated that administration of intravenous sodium nitrite improves ischaemic hind-limb 
blood flow, stimulates endothelial cell proliferation and stimulates angiogenesis in an NO-
dependent manner (366). Other studies have observed differences in plasma nitrite levels in 
different groups of patients with PVD suggesting that altered NO bioavailability is important 
in the disease process (367-369). Again, no human data exists as to the role of nitrite in 
angiogenesis.  
 
Revascularisation in the form of coronary or peripheral angioplasty/stent insertion can be 
complicated by an exaggerated healing process, namely intimal hyperplasia resulting in re-
stenosis of the affected artery (370). Alef and colleagues have demonstrated an abrogation of 
intimal hyperplasia seen in isolated rodent and murine vessels, when sodium nitrite is 
administered prior to balloon injury (371). Whether this can be translated into human models 
of percutaneous coronary/peripheral arterial revascularisation with balloon 
angioplasty/stenting remains to be seen. 
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Septic shock is a life-threatening condition, with evidence suggesting that failure of the 
micro-circulation with resulting vasoconstriction may be an important pathophysiological 
manifestation (372). Pre-clinical studies suggest that NO donors may improve 
microcirculatory blood flow and tissue oxygenation with favourable mortality outcomes, 
despite the concurrent macro-vascular hypotension (373). As such, nitrite with its limited 
effect on arterial responsiveness could confer a potential benefit in patients with septic shock 
by improving micro-vascular blood flow especially in acidotic/ischaemic tissues. 
 
Platelet inhibition is an important adjunct to coronary artery stenting to reduce the risk of 
stent thrombosis and other athero-thrombotic events (374). NO is well known to attenuate 
platelet activity in vivo (59, 60). A recent study demonstrated an abrogation (although not 
statistically significant) of platelet activity in healthy, human subjects following oral 
administration of nitrate/nitrite via reduction to NO (375). This requires further exploration in 
humans and disease states to confirm the role of nitrite as an adjunct to anti-platelet therapy. 
 
1.9 Objectives 
Despite great advances in our understanding of nitrite biology, much remains to be elucidated 
about the importance of nitrite in health and disease states, at both a mechanistic and clinical 
level. The research presented herein aims to expand on the workings of nitrite further and to 
add to the relative paucity of existing data in humans.  Several, small scale studies have 
formed the experimental procedures undertaken and are summarised below.  
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(1) Following on from studies undertaken by Maher and Colleagues (46), we sought to 
determine the systemic effect of nitrite in healthy volunteers, to establish dose-
response relationships during normoxia and hypoxia, and its effect on peripheral and 
cardiovascular haemodynamics (CHAPTER 2).  We sought to investigate the effect 
of intravenous sodium nitrite on acute hemodynamic parameters in healthy 
volunteers, during both normoxia and hypoxia. We hypothesised the following:- 
 
i. While subjects are breathing room air, there would be no significant 
vasodilatation of the resistance vessels as verified by an unchanged 
arterial blood pressure and systemic vascular resistance;  
ii. When subjects inspire 12% oxygen, rendering arterial blood relatively 
hypoxic, a significant reduction in arterial blood pressure and systemic 
vascular resistance would be observed.   
 
(2) A profile of relatively selective dilatation of systemic capacitance and pulmonary 
resistance vessels would be potentially attractive in the treatment of decompensated 
heart failure (HF) since it would likely increase cardiac output (CO), and decrease 
ventricular diastolic pressures with less reduction in blood pressure than would be 
seen with an arterial vasodilator (359). Therefore, the second series of experiments 
explored the effect of systemic nitrite administration in patients with advanced heart 
failure undergoing assessment for cardiac transplantation (CHAPTER 3). We 
hypothesised that in patients with advanced HF, intravenous sodium nitrite 
infusion would reduce pre-load (as measured by a reduction in mean right atrial 
pressure), which would be associated with an increase in cardiac output, but 
without a change in arterial blood pressure or systemic vascular resistance. 
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(3) Nitrite as a NO donor with its relative venoselectivity and attribute of specific 
hypoxic vasodilatation, could potentially offer an alternative therapy to the well-
established inorganic nitrates (e.g. GTN) which are widely used in clinical practice. 
Whether this characteristic is truly unique to nitrite or inorganic nitrates exhibits a 
similar hypoxic vasodilatation remains unknown. A small experiment performed in 
healthy volunteers aimed to establish whether GTN exhibits hypoxia-specific 
vasodilatation in the forearm vasculature (CHAPTER 4). We hypothesised that 
hypoxia would not augment GTN-mediated increase in forearm blood flow (as 
measured by venous occlusion plethysmography) as compared to normoxia.  
 
(4) With a wealth of pre-clinical data suggesting a role for nitrite in protection against 
ischaemia-reperfusion injury, we carried out a ‘proof of principle’ study in patients 
undergoing coronary artery bypass grafting (CABG) surgery investigating molecular 
mechanisms of nitrite-mediated cardioprotection (CHAPTER 5). We sought to 
determine:- 
 
i. The optimal timing of nitrite-mediated cardioprotection against IRI e.g. 
early window and late window. 
ii. The optimal dose of nitrite required, for cardioprotection. 
iii. We hypothesised that nitrite-mediated cardioprotection will occur via 
activation of the RISK pathway, as evidenced by an upregulation of 
signalling molecules involved in this pathway i.e. pAKT and eNOS. 
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(5) ALDH2 is one enzyme that has been implicated in nitrite-mediated nitrite reduction 
to NO (CHAPTER 6). Its role in nitre-mediated reduction to NO in humans has not 
been fully explored. We hypothesised that:- 
 
i. In patients with HF, nitrite-mediated increase in forearm blood flow 
would be attenuated by ALDH2 inhibition. 
ii. This attenuation of nitrite-mediated vascular relaxation would occur 
preferentially during hypoxia, as compared to normoxia.   
 
These experiments are discussed in further detail, in their respective chapters.  
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Chapter 2: Systemic Nitrite Infusion in Healthy Volunteers during 
Normoxia and Hypoxia 
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2.1 Introduction 
During the last decade, the importance of nitrite in biological processes has been increasingly 
appreciated. Nitrite can undergo reduction to NO by various potential mechanisms especially 
under hypoxic and/or acidotic conditions (45, 144, 146, 158, 160, 176, 328). Furthermore, 
nitrite has been shown to elicit NO-dependent vasodilatation (26, 161), angiogenesis (366) 
and cardioprotection (376). Nitrite itself may also potentially exert biological effects on the 
heart and vasculature directly via S – nitrosylation of proteins (377).  
 
Interestingly, nitrite was shown to have vasodilatory properties as far back as 1937 and 
subsequently in 1953 (192, 193). In Furchgott and co-workers’s experiments, high 
concentrations of nitrite (100 - 1000µmol/L) were required to induce vasorelaxation in 
isolated rabbit aortic rings. Decades later it was shown to be a relatively weak vasodilator in 
the forearms of healthy volunteers even with concentrations of up to 200µmol/L (195). This 
discrepancy between the micromolar doses required to see an effect in vitro and the 
nanomolar concentrations present in vivo rendered nitrite an insignificant physiological 
vasodilator. However, later studies challenged Lauer’s conclusions, indicating that nitrite 
may be important in physiological regulation of blood flow, cell signalling and cytoprotection 
following ischaemia-reperfusion injury. In some of these studies, the vasodilatory properties 
of nitrite were observed at pharmacological concentrations including those not greatly above 
physiological concentrations. (26, 46, 131, 161, 328, 338, 351, 378, 379).  
 
The observation that during intra-arterial infusion of nitrite, forearm vasodilation was 
enhanced following exercise raised the possibility that nitrite bioactivity was enhanced by 
hypoxia (26, 161). Findings consistent with this hypoxic vasodilatory effect have been 
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reported by others. Studies in animal models have demonstrated that nitrite administration 
augments pulmonary vasodilatation during hypoxia (351, 352, 380). Although the pulmonary 
vasculature is fundamentally different to the systemic vasculature, hypoxic augmentation of 
the pulmonary vasculature is a commonality to these studies. 
 
Hypoxic vasodilatation has been observed in humans also. In the intact forearm vasculature 
of healthy subjects, intra-arterial sodium nitrite infusion only modestly dilates forearm 
resistance vessels, but potently dilates capacitance vessels (that are exposed to substantially 
lower ambient oxygen tension) under normoxic conditions (46). Moreover, under hypoxic 
conditions, nitrite markedly dilated forearm resistance vessels. Studies undertaken by Ingram 
and colleagues reported that systemic nitrite infusion abrogated the increase in pulmonary 
artery pressure induced by hypoxia in healthy volunteers and that this effect was not 
dependent on an increase in plasma nitrite levels (199). Recently, Pluta et al. explored the 
safety and toxicity of intravenous sodium nitrite which provided further insight into the 
potential of sodium nitrite as a clinical therapy (381). They infused healthy volunteers with 
escalating doses of sodium nitrite (from 0.07µg/kg/min up to a maximal dose 8.9µg/kg/min) 
and were able to ascertain that the maximal tolerated dose was 4.5µg/kg/min and that dose 
limited toxicity occurred at 7.4µg/kg/min. The results of these recent studies have been 
published after the study presented herein was undertaken. However, limited data still exist 
on the effects of systemic nitrite infusions on the cardiovascular system in man, particularly 
during hypoxia and this requires further exploration.  
 
One of the potential side-effects of sodium nitrite administration is methaemoglobin 
accumulation.   This side-effect is exploited in the treatment of cyanide poisoning with 
300mg intravenous sodium nitrite. Cyanide ions combine with nitrite-generated 
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methaemoglobin to produce cyanmethaemoglobin, thus protecting cytochrome oxidase from 
the cyanide ions. In cyanide poisoning, levels of 30-40% are tolerated safely, with symptoms 
occurring above levels of 10-20%. Symptoms of methaemoglobinemia include dyspnoea, 
lethargy, tachycardia, cyanosis and decreasing sonsciousness as methemoglobin levels rise 
above 55%, with eventual death with levels > 70% (382). In one study, the highest dose of 
nitrite used (110µg/kg/min) in healthy adults induced methaemoglobinaemia of 3.2% (161). 
Furthermore, Pluta et al. who reported a modest increases in metHb (approx. 5%) during 
sustained infusion of the highest infusion rate of nitrite (>500 µg/kg/hour which translates 
into ~ 9µg/kg/min) used in their study (381). This is an important safety aspect of sodium 
nitrite administration that requires addressing in studies investigating the role of nitrite in 
humans, particularly with sustained infusions.    
 
2.2 Objectives 
This study sought to determine a dose of intravenous sodium nitrite in healthy volunteers that 
was safe, tolerable and efficacious. This was to be achieved by administering brief infusions 
of sodium nitrite at escalating doses and during prolonged infusions (several hours). In order 
to better understand the vascular and cardiac effects of systemic nitrite infusion we evaluated 
the haemodynamic effects of systemic nitrite infusion in healthy subjects (during both 
normoxia and hypoxia), evaluating the dose -response relationship for these effects during 
both brief and prolonged infusions. We hypothesised that:- 
 
 (1) Intravenous infusions of sodium nitrite would be efficacious, safe and well tolerated in 
man. 
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 (2) Systemic nitrite infusion would have little effect on blood pressure or systemic vascular 
resistance in healthy subjects during normoxia, but would reduce both when subjects were 
made hypoxaemic.  
 
2.3 Power calculation 
This is a 20 subject study, with participants acting as their own control (measurements during 
normoxia and hypoxia). We anticipated a 10% reduction in MABP during hypoxia, with α = 
0.05 and 1-β = 0.85 this required 16 subjects. 20 subjects in total were recruited to allow for 
subject drop-out. 
 
2.4 Methods 
2.4.1 Participants 
Subjects were recruited from the University of Birmingham. The studies were granted full 
ethical approval (University of Birmingham ERN_10-0247). The investigation conforms to 
the principles outlined in the Declaration of Helsinki. All of the subjects gave written, 
informed consent after satisfying the inclusion and exclusion criteria (see below). The study 
was performed at the University of Birmingham Clinical Research Block in a quiet vascular 
laboratory that was temperature-controlled at 22 - 24ºC. All subjects were requested to 
abstain from alcohol and follow a low nitrate/nitrite diet for 24 hours (table 2.1) and to 
abstain from caffeine-containing drinks for 24 hours before the study.  
 
Inclusion criteria included age over 18 years, history of no-smoking and no regular 
medication (except the oral contraceptive pill). All subjects underwent a cardiovascular 
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examination and had a normal electrocardiogram (ECG). Pregnant women or nursing 
mothers, those with BMI≥30kg/m2 and migraine sufferers were excluded from the study. 20 
subjects were recruited into this study. 
 
 
Leafy vegetables e.g. Cured meat Pickled vegetables 
Lettuce Cured fish Pickled meat 
Beetroot  Pickled fish 
Celery   
Radish   
Rhubarb   
Turnip   
Spinach   
 
Table 2.1: List of food items subjects were asked to abstain from, as part of a nitrate/nitrite 
poor diet. 
 
2.4.2 Pilot study - effects of sodium nitrite infusion on methaemoglobin 
At the time of this study being conducted, no human data existed on systemic sodium nitrite 
infusion in humans. Therefore, prior to the main study being conducted, a pilot safety study 
on 7 healthy volunteers was conducted to ascertain the safety/tolerability of intravenous (i.v.) 
sodium nitrite and to quantify the increase in methaemoglobin (metHb) associated with 
systemic sodium nitrite administration. Subjects received 10, 30 or 60µg/kg/min of 
intravenous sodium nitrite for up to 6 hours or until metHb levels reached 10% of total 
haemoglobin. A cut-off of 10% was chosen to allow a wide safety margin as symptoms are 
noted to occur above 10-20% (382). 
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Subjects rested in a semi recumbent position on a hospital bed and an intravenous cannula 
(Venflon, 20 Gauge) was placed in each antecubital fossa. One intravenous cannula was used 
to administer the infusion, with blood obtained from the contra-lateral arm cannula. 
Continuous cardiac monitoring and peripheral haemodynamic variables were measured using 
the Taskforce® Monitor (CN Systems, Graz, Austria) and oxygen saturations using pulse 
oximetry (Nellcor N-180, Nellcor, Pleasanton, California). Heart rate (HR) and blood 
pressure (BP) were recorded at baseline and every 30 minutes for 6 hours or until the infusion 
was terminated. Venous blood samples were taken at baseline at 30 minute intervals, and 
analysed using a blood gas analyser (Bayer Rapidlab 865, Siemens, Tarrytown, NY) for 
metHb levels. This pilot data allowed the determination of the sodium nitrite doses for this 
study in healthy volunteers and for a further study in heart failure patients (Chapter 3).  
 
2.4.3 Haemodynamic effects of short term incremental infusion of sodium nitrite 
20 healthy volunteers were recruited into a single-blind placebo-controlled study to evaluate 
the dose-response relationship of systemic sodium nitrite infusion during normoxia and 
during hypoxia. Each subject attended on two separate occasions a week apart, with random 
order allocation to hypoxia and normoxia. The study design (study A) is depicted in figure 
2.1A. At each visit, subjects were studied twice (60 minutes apart) with systemic infusions of 
escalating doses of sodium nitrite 20minutes each or placebo, also in random order. 
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Figure 2.1: Study protocol. (A): Participants received escalating infusions of intravenous 0.9% saline and sodium nitrite for 20minutes 
each during both normoxia and hypoxia, in random order allocation; (B) Participants received a 6-hour infusion of intravenous sodium 
nitrite (10mcg/kg/min) over 6 hours.
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Figure 2.2: Photograph depicting typical experimental set-up with administration of hypoxia. 
 
 
Subjects rested in a semi-recumbent position on a hospital bed. Intravenous cannulae 
(Venflon, 20 Gauge) were inserted into a vein in each ante-cubital fossa. Each subject 
underwent placement of a finger cuff for continuous blood pressure recording, an upper arm 
cuff for blood pressure measurement and electrocardiogram and band electrodes on the trunk 
for impedance cardiography (TaskForce Monitor
®
, CN Systems, Graz, Austria).  
 
Following 10 minutes of rest, an i.v. infusion of either 0.9% sodium chloride (placebo) or 
sodium nitrite was administered for 60 minutes, in a single-blind randomised order. Nitrite 
infusion consisted of 3 escalating infusion rates of sodium nitrite: 1, 10 and 50µg/kg/min for 
20minutes each. All infusions were administered at a rate of 1ml/min. Cardiac (cardiac 
output, CO; stroke volume, SV; systemic vascular resistance, SVR) and peripheral (HR and 
BP) haemodynamic variables were measured non-invasively by transthoracic electrical bio-
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impedance (Taskforce
® 
Monitor
, 
CN Systems, Graz, Austria), as used previously (383). BP 
and HR were measured continuously. Changes in SV, CO and SVR were calculated and 
recorded using the Taskforce
®
 monitoring system. Although absolute values of these 
parameters measured by the bio-impedance technique differ significantly from those 
measured using the invasive thermo-dilution technique it has been shown to be a valid way of 
assessing changes in these parameters (384). Haemodynamic variables were recorded at 
15minutes, 35minutes and 55minutes into each infusion over a 5-minute period, to coincide 
with the final 5minutes of each nitrite infusion dose. Arterial oxygen saturation levels were 
monitored continuously using pulse oximetry (Nellcor N-180, Nellcor, Pleasanton, 
California). At the end of each recording period, venous blood samples were obtained (from 
the non-infused arm) and analysed as described later in section 2.3.5. After the 60-minute 
infusion, subjects were allowed a 60 minute rest following which they received a further 60 
minute infusion of the opposite treatment allocation (i.e. sodium nitrite or placebo) as 
described above. Following the second infusion of each visit, an arterial blood sample was 
obtained from the right radial artery for immediate blood gas analysis using a blood gas 
analyser (Bayer Rapidlab 865, Siemens, Tarrytown, NY). The experimental set-up is depicted 
in figure 2.2. 
 
During the hypoxia visit, hypoxia was induced by subjects inspiring 12% oxygen via a 
facemask connected to a two-way valve. The target oxygen saturation as measured by pulse 
oximetry was in the range 83% - 88%, aiming for an approximate pO2 6.32–7.32 KPa based 
on Severinghaus’s calculations (385). Attainment of target oxygen saturation was followed 
by a 10minute stabilisation period, after which the study proceeded (as described above) with 
subjects receiving sodium nitrite and placebo infusions in a cross-over method.  
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2.4.4 Haemodynamic effects of sustained infusion of sodium nitrite  
Following on from the main limb of the study as described above, 6 additional healthy 
volunteers (study B) were allocated to receive a 6-hour infusion of 10µg/kg/min of i.v. 
sodium nitrite (at a rate of 1ml/min) during normoxia to assess the sustained haemodynamic 
effects and metHb accumulation of this infusion rate (as depicted in figure 2.1B).  
 
Subjects rested in a semi recumbent position on a hospital bed and an intravenous cannula 
(Venflon, 20 Gauge) was placed in each antecubital fossa. Peripheral haemodynamic 
variables (HR and MABP) were measured using the Taskforce
® 
Monitor and oxygen 
saturations using pulse oximetry as described above, at baseline and every 30 minutes for 6 
hours. Venous blood samples were taken, from the contra-lateral arm at baseline at 30 minute 
intervals, and analysed as described in section 2.3.5.  
 
2.4.5 Blood sampling 
Venous blood samples were obtained at the time points indicated in figure 2.1. 8mL of blood 
was transferred into two EDTA collection tubes (K3 EDTA, BD Vacutainers). 400µL of the 
thiol alkylator N-ethylmaleimide (Merck, Germany) was added to one of the tubes (1mM 
final concentration) and centrifuged at 2000rpm at 4ºC. Plasma samples were immediately 
snap-frozen in liquid nitrogen and stored at -80ºC for subsequent analysis of plasma 
nitrite/nitrates and protein-bound NO (RXNO). A further 2ml of venous blood was analysed 
immediately using a blood gas analyser (Bayer Rapidlab 865, Siemens, Tarrytown, NY) for 
pH, lactate and metHb quantification. In study A (figure 2.1A), an arterial blood sample was 
obtained from the subjects at the end of each visit to ascertain change in arterial oxygen 
content following administration of 12% oxygen.  
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Plasma nitrite/nitrate and RXNO analysis 
Briefly, at the time of analysis, the NEM-treated samples were thawed and added to a 
solution containing potassium ferricyanide (NO-haem species) for nitrite/nitrate measurement 
and a tri-iodide-containing reaction mixture (for the release of RXNO species), which was 
continually washed with nitrogen. Group-specific reductive denitrosation by iodine–iodide 
was used to measure plasma nitrite and nitrate and RXNO concentrations (386). Subsequent 
detection of liberated NO was undertaken using by gas-phase chemiluminescence using a gas 
phase chemiluminescence detector (CLD 77am sp, EcoPhysics) under reduced light 
conditions, to avoid photolytic decomposition of NO and NO-species (387).  
 
Plasma cGMP assay 
Plasma cGMP was determined using an enzyme immunoassay (cGMP EIA Biotrak System, 
GE Healthcare UK Ltd) according to the manufacturer’s instructions. Briefly, plasma was 
diluted 1:10 with assay buffer (0.05M sodium acetate, pH 6.0 containing 0.002% (w/v) 
bovine serum albumin and 0.01% (w/v) preservative). 50μL aliquots of sample per well were 
added to a 96-well plate in triplicate, containing 100μL of rabbit anti-cGMP antibody. The 
plate was covered and allowed to incubate at 4ºC for 2 hours. 100 μL of cGMP-peroxidase 
conjugate was added with further incubation of the plates at 4ºC for 1 hour. All wells were 
washed four times, followed by the addition of 200μL of peroxidase substrate. The plates 
were covered and gently agitated for 30minutes at room temperature using a micro-plate 
shaker. 100 μL of 1M Sulphuric acid was added each well to terminate the reaction. A 
spectrophotometric microplate reader (450nm) was used to measure the absorbance of each 
well. For study A, these analyses were performed at baseline and peak nitrite infusion rate of 
50µg/kg/min only. 
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2.4.6 Study medication 
Sodium nitrite was obtained from Martindale Pharmaceuticals UK (Brentwood, United 
Kingdom) and 0.9% sodium chloride from Baxter, UK.  Sodium nitrite was diluted to the 
required concentration using 0.9% sodium chloride solution.  
 
2.4.7 Statistical analysis 
The data were analysed using SPSS version 21.0 software (SPSS Inc., Chicago, USA). The 
data are expressed as mean ± standard error of mean (mean±SEM), unless otherwise stated. 
Probability values of <0.05 were considered statistically significant. One-way repeated 
measures ANOVA with consecutive Bonferroni post-hoc test was used to test for changes 
from baseline in haemodynamic parameters, during study A. Non-normally distributed data 
(study B) was analysed with Friedman repeated measures test with the Wilcoxon signed-rank 
test for post-hoc analysis. Paired data were analysed using a paired Student’s t-test.  
 
2.5 Results 
2.5.1 Preliminary studies 
7 healthy subjects (mean age 25±4 years, 5 male) were recruited into the supplemental pilot 
study. A dose-dependent increase in metHb during sustained i.v. infusion of 10, 30 or 
60µg/kg/min of sodium nitrite was observed (figure 2.3A). 60µg/kg/min of sodium nitrite 
induced a rapid increase in venous metHb up to 10%, 2.5hours into the infusion and the 
infusion was terminated at this point as pre-specified. The two subjects receiving 
68 
 
30µg/kg/min of i.v. nitrite also achieved metHb levels of 10% but this occurred over a longer 
time period (4.5 and 6 hours). 10µg/kg/min was well tolerated with a maximal metHb rise of 
2.1%. All infusion rates were well tolerated with no adverse symptoms reported. The HR and 
mean arterial blood pressure (MABP) profile from these participants are shown in figure 
2.3B and figure 2.3C.  
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Figure 2.3: Individual subject data from the pilot study. (A) Venous metHb; (B) Heart rate 
profile; (C) Mean arterial blood pressure (MABP) during sustained infusions of 10, 30 or 
60µg/kg/min of i.v. sodium nitrite. N=7. 
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2.5.2 Baseline characteristics of subjects  
The table below (table 2.2) outlines the baseline characteristics of the subjects.  
 
 Study A 
n=19 
Study B 
n=6 
 
Age, years (mean±SD) 
 
23±3 
 
25±5 
Gender, m 16 3 
Body mass index (kg/m
2
, mean±SD) 23±3 24±2 
HR (bpm) 66±2 69±6 
MABP (mmHg) 83±3 93±4 
HR, heart rate; MABP, mean arterial blood pressure. 
 
Table 2.2: Baseline characteristics of study subjects 
 
One subject who was recruited into study A was excluded from subsequent analysis as he did 
not tolerate hypoxia, therefore no data was acquired. As he withdrew from the whole study, 
no normoxia data was obtained on this participant either.  
 
2.5.3 Haemodynamic effects of short term incremental nitrite infusion (study A) 
during normoxia and hypoxia in healthy volunteers 
During the hypoxia phase, mean arterial oxygen saturations were significantly lower than 
during normoxia (p<0.0001 normoxia vs hypoxia readings) and remained consistently so 
throughout the study period (table 2.3). This was mirrored by changes in arterial oxygen 
content obtained from the arterial blood sample, as depicted in figure 2.4 (15.1±0.9KPa 
during normoxia vs 6.5±0.2KPa during hypoxia, p<0.0001, n=12).  
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Table 2.3: Arterial oxygen saturations during study A, as measured by pulse oximetry. 
 
 
 Arterial O2 saturations 
(%) 
 Saline 
Time (minutes) Normoxia Hypoxia 
 0 (baseline) 98.1±0.2  85.8±0.8**** 
 20 98.3±0.2 86.0±0.9**** 
 40 98.5±0.2 85.8±1.0**** 
 60 
 
98.5±0.2 86.5±0.9**** 
 Nitrite 
Nitrite dose (µg/kg/min) Normoxia Hypoxia 
 0 (baseline) 98.4±0.3  85.1±0.9**** 
 1 98.6±0.3 85.2±0.8**** 
 10 98.9±0.2 85.6±0.8**** 
 50 
 
98.4±0.2 85.9±0.8**** 
*p-value <0.0001 compared to pre-infusion values at the corresponding time-point in the 
normoxia arm of the study. N=19, p<0.05 is statistically significant. 
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Figure 2.4: Arterial oxygen content obtained via an arterial blood sample at the end of the 
normoxia and the hypoxia protocols in study A. *p<0.0001; n=12.  
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As shown in figure 2.5A, HR increased following nitrite infusion during normoxia (from 
64±2bpm at baseline to 71±2bpm at peak nitrite infusion rate, p<0.001) but during hypoxia 
the change in HR from baseline was not significant (77±3bpm to 81±3 respectively, p>0.05). 
Baseline HR was significantly higher during hypoxia (74±3bpm prior to saline infusion and 
77±3bpm prior to nitrite infusion) compared to normoxia (66±3bpm prior to saline infusion 
and 64±2bpm prior to nitrite infusion, p<0.001). No change from baseline in HR was 
observed during saline infusion under either normoxic or hypoxic conditions.  
 
MABP (figure 2.5B) did not alter with either infusion during both normoxia and hypoxia 
(normoxia: 84±2mmHg at baseline vs 83±2mmHg during peak nitrite infusion rate, p>0.05; 
hypoxia: 86±3mmHg at baseline vs 85±3mmHg during peak nitrite infusion rate, p>0.05). 
During both normoxic and hypoxic conditions, SVR (figure 2.5C) did not change 
significantly with nitrite administration (normoxia: 1217±46 dyne*s/cm^5 at baseline vs 
1150±41 dyne*s/cm^5 at peak nitrite infusion rate, p>0.05; hypoxia: 1128±72 at baseline vs 
1061±49 dyne*s/cm^5 at peak nitrite infusion rate, p>0.05). 
 
Baseline CO (figure 2.6A) was marginally higher during hypoxia vs normoxia, 
(5.6±0.1L/min vs 5.4±0.1L/min p=0.05). Under normoxic conditions there was a significant 
increase in CO from baseline to peak nitrite infusion rate (from 5.4±0.2 L/min to 
5.7±0.2L/min, p<0.05) but not under hypoxic conditions (6.2±0.3 L/min to 6.4±0.2L/min, 
p>0.05). However, the effect of nitrite infusion on CO did not significantly differ between 
normoxic vs hypoxic conditions (p>0.05). SV (figure 2.6B) did not alter with either infusion 
during both normoxia and hypoxia (normoxia: 86.6±3.4ml at baseline vs 81.6±3.1ml during 
peak nitrite infusion rate, p>0.05; hypoxia: 81.6±3.0ml at baseline vs 80.1±2.9ml during peak 
nitrite infusion rate, p>0.05).  
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Figure 2.5: Peripheral haemodynamic parameters from subjects in study A during i.v. saline 
and 20minute escalating doses of i.v. sodium nitrite, during normoxia and hypoxia. (A) HR; 
(B) MABP and (C) SVR. ***p<0.001, n=19. 0, 20, 40 and 60minutes into nitrite infusion 
correspond to 0, 1, 10 and 50µg/kg/min of i.v. sodium nitrite, respectively. 
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Figure 2.6: (A) SV and (B) CO from subjects in study A during i.v. saline and 20minute 
escalating doses of i.v. sodium nitrite, during normoxia and hypoxia. *p<0.05; n=19. 0, 20, 
40 and 60minutes into nitrite infusion parallel 0, 1, 10 and 50µg/kg/min of i.v. sodium nitrite, 
respectively. 
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2.5.4 Effect of oxygen tension on venous acid-base balance 
Table 2.4 shows venous pH and lactate data with placebo and nitrite infusion, during 
normoxia and hypoxia.  
 
Venous pH remained steady during normoxia or hypoxia, without any significant change. 
Overall venous lactate was higher during hypoxia as compared to normoxia (p<0.05 
normoxia vs hypoxia, n=19). Pre-infusion normoxia lactate concentration was 
1.32±0.10mmol/L and 1.47±0.08mmol/L with saline and nitrite infusion, respectively. 
During hypoxia, baseline lactate was 1.57±0.08mmol/L and 1.89±0.22mmol/L
*
 with saline 
and nitrite infusion, respectively (n=19, *p<0.05 compared to baseline normoxia levels).   
 
Arterial blood gas analysis obtained at the end of the normoxia and hypoxia limbs of the 
study demonstrated no difference in arterial lactate between the two groups (1.03±0.06 
mmol/L during normoxia and 0.98±0.05mmol/L during hypoxia, p>0.05, n=8)  
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pH 
 
 
Lactate 
(mmol/L) 
   
 
Normoxia saline 
  
 Baseline 7.366±0.004 1.32±0.10 
 
 
20mins 7.364±0.004 1.28 ±0.09 
 40mins 7.362±0.004 1.25± 0.08 
 60mins 
 
7.362±0.004 1.26± 0.07 
 
Normoxia nitrite 
  
 Baseline 7.359±0.005 1.47±0.08 
 1µg/kg/min 7.352±0.005 1.43±0.07 
 10µg/kg/min 7.356±0.005 1.19±0.28 
 50µg/kg/min 
 
7.353±0.006 1.45±0.17 
 
Hypoxia saline 
  
 Baseline 7.379±0.006 1.57±0.08 
 20mins 7.370±0.006 1.59±0.15 
 40mins 7.378±0.006 1.57±0.11 
 60mins 
 
7.377±0.008 1.60±0.19 
 
Hypoxia nitrite 
  
 Baseline 7.379±0.006 1.89±0.22
*
 
 1µg/kg/min 7.382±0.006 1.91±0.20 
 10µg/kg/min 7.378±0.006 1.64±0.15 
 50µg/kg/min 
 
7.385±0.006 1.46±0.10 
 
Table 2.4: Venous pH and lactate data from subjects in study 1 during normoxia and 
hypoxia. 
*
p-value versus baseline normoxia is <0.05, n=19.  
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2.5.5 Haemodynamic effects of sustained infusion of sodium nitrite in healthy 
volunteers (study B) 
Prolonged infusion (up to 6 hours) of 10µg/kg/min of sodium nitrite in healthy volunteers did 
not result in a significant change in either HR or MABP. HR was 64(58 - 86)bpm at baseline 
and remained at a similar level throughout the infusion (figure 2.7A; n=6, p>0.05). MABP 
(figure 2.7B) was 92(86 - 103)mmHg  at baseline and 95(93 - 97)mmHg  after 6 hours (n=6, 
p>0.05). Data is expressed as median (inter-quartile ranges).  
 
2.5.6 Effect of nitrite on metHb accumulation in healthy volunteers  
Venous metHb increased in a dose-dependent manner during the incremental short term 
nitrite infusion (study A) during both the normoxia and hypoxia interventions (figure 2.8A). 
Venous metHb increased from 0.3±0.03% at baseline to 0.7±0.08% at peak nitrite infusion 
rate during normoxia (n=19, p<0.001) and from 0.3±0.04% at baseline to 1.6±0.06% at peak 
nitrite infusion rate (n=19, p<0.001) during hypoxia.  
 
During the 6-hour infusion of 10µg/kg/min of sodium nitrite in healthy volunteers, venous 
metHb increased in a dose-dependent manner from a median of 0.3(0.05 - 0.5)% at baseline 
to 2.1(1.3 - 2.5)% at 3 hours (p<0.05 compared to baseline, figure 2.8B). For the latter 3 
hours, the metHb level appeared to plateau reaching a median of 1.9(1.5 - 2.4)% at 6 hours 
(p<0.05 compared to baseline). Data are expressed as median (inter-quartile ranges).   
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Figure 2.7: Median (inter-quartile) ranges showing (A) HR and (B) MABP during 6-hour 
infusion of i.v. sodium nitrite in healthy volunteers. No significant change was observed in 
either parameter. N=6. P>0.05 compared to baseline at all time-points for both HR and 
MABP.  
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Figure 2.8: Venous metHb increase in healthy volunteers during (A) short incremental 
infusions of i.v. saline and nitrite during normoxia and hypoxia (n=19); data is expressed as 
mean±SEM; (B) prolonged (6-hour) infusion of i.v. sodium nitrite at 10µg/kg/min (n=6); data 
is expressed as median (inter-quartile ranges). *p<0.05 and ***p<0.001. 
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2.5.7 Effect of systemic nitrite on plasma nitrite, nitrate, RXNO and cGMP levels 
In study A, plasma nitrite, nitrate and RXNO concentrations increased from baseline to peak 
(50µg/kg/min) nitrite infusion rate (figure 2.9). Plasma nitrite levels (figure 2.9A) also 
increased dose dependently from baseline values of 1.3±0.1µM and 1.3±0.1µM to 
13.6±1.1µM and 12.9±1.4µM following 50µg/kg/min of i.v. sodium nitrite during normoxia 
and hypoxia, respectively (p<0.001, comparing baseline and post nitrite infusion). During 
normoxia, nitrate levels (figure 2.9B) increased from 19.8±3.4µM at baseline to 31.3±3.2µM 
following 50µg/kg/min of i.v. sodium nitrite (p<0.01). However, during hypoxia there was a 
smaller increase in nitrate levels from 18.3±1.9µM at baseline to 25.2±2.2µM following peak 
nitrite infusion rate which was not statistically significant (p>0.05). Plasma RXNO (figure 
2.9C) increased from baseline values of 16.3±1.6nM and 14.1±0.9nM to 33.8±2.8nM and 
27.9±1.7nM following 50µg/kg/min of i.v. sodium nitrite during normoxia and hypoxia, 
respectively (p<0.001, respectively). 
 
During the sustained infusions of intravenous sodium nitrite (10µg/kg/min) in healthy 
volunteers, there was an increase in plasma nitrite (figure 2.10A) increased from 1.1(1.06 – 
2.0)µM to a peak level at 3 hours of 9.8(7.2 – 10.1)µM (p<0.05, n=6).  Plasma nitrate (figure 
2.10B) continued to increases steadily throughout the duration of the infusion, from 20.6(17.2 
– 29.0)µM at baseline to 78.4(72.6 – 92.0)µM after 6 hours (p<0.05, n=6). Plasma RXNO 
and nitrite which appeared to plateau after 120minutes. Plasma RXNO (figure 2.10C) 
increased from 12.8(10.8 – 19.3)nM at baseline to a peak of 32.5(21.3 – 33.0)nM at 6hours 
(p<0.05, n=6). Data are expressed as median (inter-quartile ranges). 
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Plasma cGMP levels were measured at baseline and following peak nitrite infusion rate 
(50µg/kg/min) in healthy volunteers during study A only (figure 2.11). There was no 
significant change from baseline in cGMP levels, during both normoxia and hypoxia. 
Baseline cGMP levels were 0.84±0.12fmol/well at baseline during normoxia and 
0.78±0.06fmol/well at baseline during hypoxia. Following 50µ/kg/min of i.v. sodium nitrite, 
cGMP levels were 0.93±0.12fmol/well and 0.77±0.06fmol/well during normoxia and 
hypoxia, respectively (p>0.05 compared to baseline, n=10).  
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Figure 2.9: Plasma (A) Nitrite; (B) Nitrate and (C) RXNO concentrations from subjects in 
study A at baseline and following peak nitrite infusion rate of 50µg/kg/min. *p<0.05 and 
***p<0.001 compared to baseline during the same oxygenation condition, n=10. 
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Figure 2.10: (A) Nitrite; (B) Nitrate and (C) RXNO concentrations from subjects in study B 
during a 6-hour infusion of 10µg/kg/min of i.v. sodium nitrite. *p<0.05, n=6. Data is 
expressed as median (inter-quartile ranges) 
 
85 
 
 
Figure 2.11: cGMP data from subjects in study A at baseline and following peak nitrite 
infusion rate of 50µg/kg/min, during normoxia and hypoxia. There was no significant 
difference in cGMP levels between baseline and peak nitrite infusion rate or oxygen states. 
P>0.05, n=10.  
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2.6 Discussion 
This study followed-on from previous work undertaken by Maher et al. investigating the role 
of nitrite on forearm vasculature in healthy volunteers (46). Limited data is available on the 
systemic effects of nitrite. To date only two studies in the published literature (published after 
commencement of the study herein) have evaluated the role of systemic cardiovascular and 
peripheral haemodynamic effects of sodium nitrite in healthy volunteers (199, 381). Herein, 
the effects of nitrite were evaluated under both normoxic and hypoxic conditions, given the 
previously reported hypoxic augmentation of vascular effects during intra-arterial 
administration (46). Furthermore the current study utilised a ‘placebo infusion’ during both 
normoxia and hypoxia as a comparator against which to assess the haemodynamic effects of 
sodium nitrite infusion. 
 
The preliminary study investigating the effects of up to 10, 30 or 60µg/kg/min in 7 healthy 
volunteers revealed no significant alteration in HR or MABP in any individual, although 
formal statistical analysis is unable to be performed due n≤ 3 at each infusion rate (figure 
2.3). This pilot data allowed quantification of metHb accumulation and high infusion rates of 
60µg/kg/min resulted in rapid accumulation of venous methHb up to 10% after 2.5hours. 
This informed the dosing for the main study discussed herein and a further study in heart 
failure patients (detailed in chapter 3). A lower starting infusion rate of 1µg/kg/min was 
utilised in case of significant hypoxic augmentation of nitrite. 
 
In healthy subjects, there was no significant change in MABP or SVR under normoxic 
conditions at doses of up to 50µg/kg/min, but there was a modest increase in CO (figure 2.6), 
which was due to an increase in HR (figure 2.5). SV remained unchanged. At infusion rates 
of slightly less than just under 10µg/kg/min, Pluta et al. previously reported a transient, 
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modest fall in blood pressure in healthy subjects (381). Importantly unlike the current study, 
there was no placebo comparator against which to judge the effects of the nitrite infusion. 
Nossaman et al. recently showed that, in healthy open-chest rats, systemic sodium nitrite had 
an effect on blood pressure only at very high infusion rates, with a potency approximately 3 
log orders lower than that of glyceryl trinitrate (GTN) (358). Contrary to our hypothesis that 
we would observe hypoxic augmentation of the vasodilator effects of sodium nitrite, which 
was based on previous evidence of hypoxic augmentation of the effects of intra-arterial nitrite 
infusion (46), there were no significant haemodynamic effects even at the highest infusion 
rate of sodium nitrite under hypoxic conditions. Furthermore, Pluta et al. reported modest 
increases in metHb (approx. 5%) during sustained infusion of the highest infusion rate of 
nitrite used in their study (>500µg/kg/hour which is approximately 9µg/kg/min) (381). In this 
study, short term infusion of even the highest infusion rate of sodium nitrite (50µg/kg/min) 
resulted in only modest increases in methHb. Consistent with the observations of Pluta et al. 
sustained infusion of 10µg/kg/min caused only modest increases in metHb (<2%) but we 
found that sustained infusion of 30µg/min and 60µg/min resulted in very marked increases in 
metHb (approximately 8% at 6 hours with 30µg/kg/min and abandoned at 2.5 hours with 
60µg/kg/min because metHb increased above 10% in both subjects). This data suggests great 
caution should be applied (with regular metHb monitoring) if sustained infusion of more than 
10µg/kg/min is to be administered.  
 
The increase in HR observed with nitrite during normoxia (figure 2.5) was not observed 
during normoxia saline infusion or during either infusion in hypoxia. This effect cannot be 
attributed to arterial blood pressure or SVR as these parameters remained unchanged with 
nitrite infusion. Whether nitrite has a direct effect on baroreceptor responsiveness or directly 
on the myocardium itself was not investigated in this study. In a previous human study, NO 
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has been reported to modulate autonomic control, possibly through augmentation of cardiac 
vagal tone (388). A wealth of animal data exists suggessing a role for NO in autonomic 
control of heart rate and effect on  cardiac autonomic efferents at the level of the heart (389). 
Alternatively NO may have a direct effect on cardiac autonomnic ganglia resulting causing a 
rise in heart rate. Systemic administration of NO donors has been shown to induce 
tachycardia, independent of baro-reflec activation. (390, 391). This may be a direct effect on 
the pacemaking current (If) found within myocytes, which are intrinsic for controlling 
activation of the sinoatrial node and therefore heart rate (392, 393). Potentially, either through 
release of NO or directly, nitrite may modulate autonomic control of heart rate or through 
direct effects on the heart. No study exists investigating this phenomenon. This would be an 
important question to address in future studies administering systemic infusions of nitrite to 
humans.    
 
 
Plasma cGMP did not alter significantly in the healthy subjects and this would be in keeping 
with the lack of haemodynamic effects observed in this group, since cGMP is an index of 
soluble guanylate cyclase (sGC) activation. Plasma nitrite and nitrate increased in a dose 
dependent manner both healthy volunteers during the short-term infusions (figure 2.9). There 
was no significant difference in baseline values of plasma nitrite during normoxia and 
hypoxia in contrast to findings by others (199). This could be due to the shorter period of 
hypoxia in the current study, whereas Ingram and colleagues allowed a 3hour equilibration 
period during hypoxia, prior to commencement of nitrite infusion.  
 
In addition to oxygen tension, acid-base status is well recognised to affect nitrite reduction to 
NO (117). In this study, pH was unaffected by hypoxia (table 2.4). Overall lactate levels 
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were higher during hypoxia compared to normoxia, as described previously (394). Despite 
these changes in lactate and a substantial increase in plasma nitrite concentration from 
baseline to peak nitrite dose of 50µg/kg/min, there was a lack of haemodynamic effect, in 
contrast to observations in the forearm vasculature with intra-arterial nitrite infusion, during 
normoxia and hypoxia (26, 46, 199). In these studies, increases in plasma nitrite 
concentration of between 2 to 10-fold resulted in localised vasodilatation especially during 
hypoxia. In the current study, plasma nitrite concentration increased 10-fold following both 
short, incremental infusions of nitrite and sustained infusion of nitrite at 10µg/kg/min, 
without any change in haemodynamic parameters. In contrast, studies exploring the role of 
dietary nitrate/nitrite intake observed a significant reduction in blood pressure following 
ingestion of 3.5mmol of oral nitrate resulting in a modest 1.5 fold increase in plasma nitrite 
(162). Despite attempts to standardise the study protocol, differences in dietary nitrate intake 
and nitrite metabolism between individuals may be a possible explanation for this lack of 
observed changes. Moreover, delivery of nitrite orally may result in a differing 
pharmacokinetic profile compared to intravenous nitrite, resulting in a sustained or larger, 
total nitrite exposure of the whole body over a given period of time. Furthermore, Ingram and 
colleagues reported that infusion of sodium nitrite prevented hypoxia-induced 
vasoconstriction in healthy subjects an hour after cessation of the infusion at a time when 
plasma nitrite had returned to baseline (199). This may provide a rationale to investigate 
pulsed high dose sodium nitrite therapy in heart failure that may potentially have sustained 
favourable haemodynamic effects with only modest associated methaemogobinaemia.  
 
Study limitations 
For greater accuracy and reliability, invasive methods of measuring cardiac haemodynamic 
parameters would ideally have been used in the healthy volunteers. Pulmonary vascular and 
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cardiac haemodynamic measurements can only be reliably obtained by invasive 
measurements. However, the use of such investigative tools in these healthy, subjects was 
deemed unjustified for the purpose of research alone. Hypoxia was administered via a face 
mask as previously employed by Maher et al (46). This did not allow a period of equilibrium 
as employed by others (199) and therefore may not have allowed for the physiological effects 
of hypoxia to stabilise.  
 
Conclusions 
In healthy subjects only minor haemodynamic effects were observed under both normoxic 
and hypoxic conditions, despite substantial increases in plasma nitrite concentrations. This is 
in contrast to what was expected from previous findings in the literature. However, this study 
provided important insight into the safety of tolerability of sodium nitrite infusion in human 
subjects to assess this further in patients with heart failure.  
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Chapter 3: Systemic Nitrite Infusion in Heart Failure 
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3.1 Introduction 
Heart failure is a common cause of admission to hospital, intensive care and of death (356, 
357). It is thought to affect approximately 900, 000 people in the UK (395). Most treatment 
of heart failure consists of chronic management of patients over the long-term to alleviate 
fluid overload, prevent acute decompensation and reduce mortality (396). In acute 
decompensation, patients with heart failure can become extremely unwell with acute 
pulmonary oedema requiring emergency treatment. In these patients, intensive therapy often 
includes diuretics and vasodilators. In some circumstances, inotropic agents may also be 
required to help improve cardiac function, albeit at the expense of increased myocardial lactic 
acidosis and with no improvement in mortality (397). For the majority of heart failure 
patients, whom are generally elderly with multiple co-morbidities, medical (drug) therapy 
remains the mainstay of treatment. In the Western world, this population is predicted to 
increase, predominantly due to an ageing population with coronary artery disease (398). With 
the degree of health burden that heart failure poses, novel therapeutic agents are continually 
being sought to treat this chronic condition. 
 
In acutely decompensated or worsening chronic congestive cardiac failure, vasodilating drugs 
are commonly used to reduce both preload and afterload on the congested myocardium, 
decrease myocardial oxygen demand and increase coronary blood flow (399). One such 
vasodilator includes organic nitrate such as glyceryl trinitrate (GTN) which have formed the 
mainstay of treatment for many years, particularly in acutely decompensated heart failure. 
Trials investigating the role of intravenous nitrate in acute heart failure have demonstrated 
improvement in clinical condition and prevention of adverse consequences such as 
myocardial infarction and need for mechanical ventilation, when compared to other therapies 
for acute heart failure such as furosemide and non-invasive ventilation (400-402). However, 
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organic nitrates suffer from several shortcomings which limit their efficacy. Firstly, they 
markedly dilate resistance as well as capacitance vessels, resulting in hypotension which 
often constrains dose escalation. Secondly, patients can suffer from a significant headache 
which occasionally necessitates withdrawal of treatment with nitrates. Thirdly, resistance and 
the development of tolerance are significant clinical issues, which limit the efficacy and 
duration of treatment (403, 404). Furthermore, there is no evidence to suggest nitrates 
improve mortality in acute heart failure. Despite these drawbacks, GTN use is associated with 
long-standing clinical experience and remains an important drug of choice in acutely 
decompensated heart failure with no worthy alternative.  
 
It is well recognised that venodilation decreases right-sided filling pressures and increases 
stroke volume (SV), probably via diminution of diastolic ventricular interaction (DVI). DVI 
is the term given to the situation in which the filling of the left ventricle is reduced by 
external constriction from the raised right ventricular diastolic pressure (RVEDP) which, 
confined within the relatively non-distensible pericardium, impedes left ventricular (LV) 
filling and reduces SV. In heart failure, DVI is often significant. Paradoxically, decrease of 
right ventricular (RV) volume and pressure (e.g. by venodilation) reduces this interaction and 
augments LV filling, resulting in an increased in SV (359, 405). Therefore, a profile of 
relatively selective dilatation of systemic capacitance and pulmonary resistance vessels would 
be potentially attractive in the treatment of decompensated heart failure (HF) since it would 
likely increase cardiac output (CO), and decrease ventricular diastolic pressures with less 
reduction in blood pressure than would be seen with an arterial vasodilator. In this regard, 
nitrite could potentially have a role in heart failure treatment.  
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A vasodilatory role for nitrite is well established. Nebulised nitrite resulted in a 65% 
reduction in hypoxia-induced pulmonary hypertension in newborn lambs (351). This effect 
was closely associated with the degree of pH reduction and deoxyhaemoglobin content. In an 
intact rat chest model, 100µmol/kg of i.v. nitrite resulted in a significant reduction in 
systemic arterial and pulmonary arterial pressures (358). These changes were attenuated by 
inhibition of soluble guanylate cyclase (sGC), suggesting that nitrite-mediated vaso-
relaxation occurs via release of NO. In humans, following intra-brachial infusions of nitrite, 
Maher and colleagues, observed only modest effects on resistance vessel tone in normoxia. In 
contrast, there was potent dilatation of the forearm capacitance bed (presumably due to the 
lower ambient oxygen tension in venous blood). In contrast, under hypoxic conditions nitrite 
profoundly vasodilated the forearm resistance bed (46). In healthy subjects, Ingram and 
colleagues demonstrated significant reductions in systemic arterial and pulmonary artery 
pressure with low dose (1µmol/min over 30minutes) of i.v. nitrite, during hypoxia but not 
normoxia (199). These effects were associated with a no more than a 2-fold increase in 
plasma nitrite concentration. No changes in stroke volume (SV) or cardiac output (CO) were 
observed. In contrast, our work (presented in Chapter 2) did not demonstrate significant 
changes in haemodynamic parameters in healthy volunteers, during normoxia or hypoxia.  
 
Since pulmonary arteriolar blood has a low oxygen tension, particularly in low output states it 
is also likely that nitrite reduction to NO will occur in the pulmonary vasculature causing 
pulmonary vasorelaxation. Through selective venodilation and pulmonary vasorelaxation, 
without systemic arteriolar vasodilation, sodium nitrite has the potential to relieve DVI in 
heart failure, increasing stroke volume without excessive hypotension. Furthermore, in 
primates nitrite did not induce tolerance unlike organic nitrates (406). However, a study in 
which nitrite was administered in the Langendorff rat heart demonstrated eNOS-independent 
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NO mediated negative inotropic and lusitropic effects that might be expected to reduce CO if 
these were replicated in vivo in man (407). A further study in the Langendorff rat heart 
demonstrated the converse (162). Angelone and co-workers reported that exogenous nitrite 
improved cardiac contractility through enhancement of the Frank-Starling mechanism. This 
improvement was accomplished primarily through intra-cardiac NO production via activation 
of the sGC/cGMP/PKG pathway, although S-nitrosylation may play a role in nitrite-mediated 
cardiac modulation also. These contrasting and variable findings necessitate further 
investigation of nitrite in humans and in disease states. This early study, presented herein 
investigates the acute haemodynamic effects of sodium nitrite in patients with severe, but 
stable heart failure.  
 
3.2 Objectives 
We sought to better understand the vascular and cardiac effects of systemic nitrite infusion in 
patients with severe heart failure (HF), evaluating the dose-response relationship for these 
effects during both brief and more prolonged infusions. We hypothesised that systemic nitrite 
infusion would increase CO and reduce right atrial pressure (RAP) and pulmonary vascular 
resistance (PVR) with relatively modest reductions in systemic vascular resistance (SVR) and 
mean arterial blood pressure (MABP) in patients with severe HF.  
 
3.3 Power calculation 
19 patients were recruited into this ‘proof of principle’ pilot study, with participants acting as 
their own control (baseline measures compared to three different doses of nitrite infusion), 
thus increasing the statistical power. This number was chosen to give a representative sample, 
based on our experience of physiological studies with nitrite and the typical patient groups 
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undergoing transplant assessment. The intended group size in the heart failure study was 
guided by the calculation that 19 participants would give a statistical power of 80% to detect 
a 0.9 L/min difference in cardiac output at a standard deviation of 0.9 L/min. 
 
3.4 Methods 
3.4.1 Participants 
The study was granted full ethical approval (South Birmingham Local Research Ethics 
Committee 08/H1207/67). The investigation conforms to the principles outlined in the 
Declaration of Helsinki. HF patients, undergoing elective right heart cardiac catheterisation to 
assess suitability for cardiac transplantation were recruited from the Queen Elizabeth 
Hospital Birmingham NHS Trust. All of the subjects gave written, informed consent after 
satisfying the inclusion and exclusion criteria (table 3.1). The study was performed in a 
temperature-controlled, cardiac catheterisation laboratory at the Queen Elizabeth Hospital 
Birmingham NHS Trust. All subjects had a light breakfast and were requested to abstain from 
alcohol and caffeine-containing drinks and nitrite/nitrate rich food for 24 hours before the 
study (foods to avoid as part of nitrite/nitrate poor diet outlined in table 2.1).  
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Table 3.1: Inclusion and exclusion criteria for study A and B. 
 
 
  
 
Inclusion criteria 
 Systolic heart failure of any cause 
 Aged 18 years or over 
 Admission to hospital for pulmonary artery catheterisation, under the transplant 
assessment protocol 
 
 
Exclusion criteria 
 Pregnant women or nursing mothers 
 Pre-existing inotrope therapy 
 Recent acute coronary syndrome 
 G6PD Deficiency or high risk of G6PD deficiency 
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3.4.2 Haemodynamic effects of short term incremental infusion of sodium nitrite in 
heart failure patients (study A) 
19 patients with advanced HF (NYHA class III - IV), who were undergoing right heart 
catheterisation as part of planned haemodynamic assessment for cardiac transplantation, were 
recruited and underwent evaluation of the dose-response relation to short systemic infusions 
of sodium nitrite (as depicted in figure 3.1A). Subjects were placed in a supine position to 
allow insertion of a 7.5French, quadruple-lumen Swan-Ganz pulmonary artery catheter 
(Edwards Lifesciences, California, USA) by the Clinician (independent of the study) 
performing the cardiac catheterisation . This was introduced via an 8French introducer sheath 
into the right internal jugular vein (under local anaesthesia, 1% lidocaine). Positioning was 
confirmed by fluoroscopy and pressure waveform monitoring. The position of the patient 
remained unchanged for the duration of the study. Placement of the Swan-Ganz catheter 
allowed invasive cardiac measurements, as described in more detail in section 3.4.3.  
 
Following placement of the Swan-Ganz catheter each subject was allowed to rest for 5 
minutes following which baseline measurements were obtained. Heart rate (HR), Mean 
arterial blood pressure (MABP), right atrial pressure (RAP), right ventricular end-diastolic 
pressure (RVEDP), pulmonary artery pressure (PAP), pulmonary capillary wedge pressure 
(PCWP) and CO (thermodilution) were recorded. 10ml of venous blood was obtained from 
the pulmonary artery, via the distal port of the Swan Ganz catheter for immediate blood gas 
analysis and later analysis of plasma RXNO, nitrite, nitrate and cGMP, as described in 
section 3.4.5. Thereafter, subjects received three 5-minute infusions of sodium nitrite at 
incremental rates (1, 10 and 50µg/kg/min) into the right internal jugular vein sheath.  
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On completion of each infusion rate, HR, MABP, PAP, PCWP and CO (thermodilution) were 
recorded again. Estimation of CO by the Fick principle and changes in estimated trans–septal 
pressure gradient (TSG, left ventricular end-diastolic pressure – right ventricular end-
diastolic pressure) were calculated at baseline and following peak nitrite infusion rate, as 
described in section 3.4.3. MABP was measured non-invasively using an automated 
sphygmomanometer and all subjects had continuous electrocardiogram and arterial oxygen 
saturation monitoring for the duration of the study (Phillips Intellivue MP70, Surrey, UK). As 
shown in figure 3.1A, venous blood samples were taken at baseline and following each 
infusion rate of sodium nitrite. 
 
3.4.3 Cardiac and peripheral haemodynamic measurements 
Placement of the Swanz-Ganz catheter allowed direct measurement of the following 
haemodynamic parameters:- 
 Right atrial pressure (RAP) 
 Right ventricular end-diastolic pressure (RVEDP) 
 Pulmonary artery pressure (PAP)  
 Pulmonary capillary wedge pressure (PCWP)  
 CO (Thermodilution method) 
 
Other haemodynamic parameters which were calculated include the following:- 
 CO by the Fick principle 
 End-diastolic trans-septal pressure gradient (TSG)  
 Pulmonary vascular resistance (PVR)  
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 Systemic vascular resistance (SVR) 
 
These are described in more detail below. 
 
CO was calculated using both the Thermodilution Method and the Fick Principle. The Fick 
Principle of measuring CO was used because of the frequent presence of tricuspid 
regurgitation in these patients which leads to inaccuracy of thermodilution-measured CO and 
due to the tendency of thermodilution to overestimate CO in severe HF (163, 408). To avoid 
multiple insertions of the catheter into the pulmonary artery, RAP, RVEDP and other 
measures derived thereof (systemic vascular resistance and end-diastolic trans-septal 
gradient), were only available at baseline and at peak nitrite infusion rate.  
 
The Fick principle states that the uptake or release of a substance (e.g. oxygen) by an organ 
(e.g. lungs) is the product of blood flow through that organ and the difference between the 
arterial and venous values of the same substance. This therefore allows calculation of CO by 
measuring oxygen uptake and the difference in oxygen consumption across the pulmonary 
bed using the equation below (409):- 
 
VO2  
                                                 CO =  ------------------------ 
(CaO2 – CvO2) 
 
(VO2= oxygen consumption/uptake; CaO2 = oxygen content of arterial blood; CvO2 = oxygen 
content of pulmonary venous blood).  
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For the purposes of this study due to the inherent difficulty in measuring oxygen consumption 
directly, CO was measured using the following equation:- 
 
                                  135 (ml O2/min/m
2
) x BSA (m
2
) 
CO (L/min) =           -------------------------------------------                        
                                         13 x Hb x (SaO2-CvO2) 
(BSA = body surface area)    
 
Venous blood from the pulmonary artery was obtained for CvO2 measurement. Peripheral 
arterial oxygen saturation (SaO2) were used as a measure of CaO2 (410).  
 
TSG is the difference between left ventricular end-diastolic pressure (LVEDP) and RVEDP. 
TSG determines the end-diastolic position of the inter-ventricular septum (411). In the 
presence of pulmonary hypertension or congestive HF, volume loading of the right ventricle 
(RV) can result in flattening or leftward displacement of the inter-ventricular septum, with a 
decrease in or reversal of end-diastolic TSG (411). With the putative selective venodilatation 
and pulmonary vasorelaxation conferred by nitrite in patients with HF, end-diastolic TSG is 
expected to increase. End-diastolic TSG was derived at baseline and following peak nitrite 
infusion using the following equation:- 
TSG = PCWP – RVEDP 
PCWP was used as surrogate of LVEDP.  
 
Pulmonary vascular resistance (PVR) and systemic vascular resistance (SVR) were calculated 
using the following equations:- 
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PVR = mean PCWP  –  mean PAP 
             CO 
 
 
SVR = MABP  –  RAP 
      CO 
CO = cardiac index  
 
3.4.4 Haemodynamic effects of sustained infusion of sodium nitrite (study B) 
8 additional heart failure patients received a 3 hour infusion of 10µg/kg/min of intravenous 
sodium nitrite to evaluate the sustained haemodynamic effects of sodium nitrite in this patient 
group (as depicted in figure 3.1B). This infusion rate was established to be safe in healthy 
volunteers, as outlined in Chapter 2.  
 
Subjects were prepared and a Swanz-Ganz catheter inserted as described previously. 
Following baseline measurements, subjects received i.v. sodium nitrite with haemodynamic 
measurements at 5, 15, 30, 60 minutes and every 30 minutes thereafter. Each measurement 
was followed by venous blood sampling (as depicted in figure 3.1B) and analysed as 
described in section 3.4.5. 
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Figure 3.1: Study protocol. (A) HF subjects received 3 incremental doses of i.v. sodium 
nitrite at 1, 10 and 50µg/kg/min over 5 minutes each; (B) 8 HF subjects received a sustained 
infusion of 10µg/kg/min of i.v. sodium nitrite over 3 hours.  
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3.4.5 Blood sampling 
Blood samples were obtained, from the distal port of the pulmonary artery catheter at the time 
points indicated in figure 3.1. 4mL of blood was transferred into an EDTA collection tubes 
(K3 EDTA, BD Vacutainers) containing 400µL of the thiol alkylator N-ethylmaleimide 
(Merck, Germany; 1mM final concentration) and centrifuged at 2000rpm at 4ºC, as described 
elsewhere (386). Plasma samples were immediately snap-frozen in liquid nitrogen and stored 
at -80ºC for subsequent analysis of plasma nitrite/nitrates and protein-bound NO (RXNO), as 
described in Chapter 2, section 2.4.5. 
 
4mL of blood was transferred into an EDTA collection tube without any additive (K3 EDTA, 
BD Vacutainers) and centrifuged at 2000rpm at 4ºC. Plasma samples were immediately snap-
frozen in liquid nitrogen and stored at -80ºC for subsequent analysis of cGMP, as described 
in Chapter 2, section 2.4.5. For study A, these analyses were performed at baseline and peak 
nitrite infusion rate of 50µg/kg/min only. 
 
A further 2ml of blood was analysed immediately using a blood gas analyser (Bayer Rapidlab 
865, Siemens, Tarrytown, NY) for metHb quantification.  
 
3.4.6 Statistical analysis 
The data were analysed using SPSS version 21.0 software (SPSS Inc., Chicago, USA). The 
data are expressed as mean ± standard error of mean (mean±SEM), unless otherwise stated. 
Probability values of <0.05 were considered statistically significant. One-way repeated 
measures ANOVA with consecutive Bonferroni post-hoc was used to test for changes from 
baseline in haemodynamic parameters during the short infusions of incremental sodium 
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nitrite in subjects who received all 3 doses of i.v. sodium nitrite (study A). A paired t-test was 
used for non-repeated data. Non-parametric data (during the sustained infusion of sodium 
nitrite, study B) was analysed using a Friedman’s test with Wilcoxon signed-rank test for 
post-hoc analyses (study B). Changes in TSG were correlated with changes in stroke volume, 
CO and PCWP using Pearson’s correlation.  
 
3.5 Results 
The patients had a diagnosis of HF of various aetiologies and all patients were on optimal 
standard heart failure therapy (table 3.2). 
 
In study A, administration of all three nitrite infusion rates of 1, 10 and 50µg/kg/min was 
achieved in 9 out of 19 HF patients.  
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 Study A 
 
Study B 
 
 n=19 n=9 n=8 
 
Age, years (mean±SD) 
47±14 47±15  
50±12 
Gender, m 13 5 7 
Body mass index (kg/m
2
, mean±SD) 26±4 28±4 26±4 
HR (bpm) 78±4 79±5 67±3 
MABP (mmHg) 73±2 74±3 78±4 
Baseline mean RAP (mmHg) 11.0±1.8 13.7±3.1 11.5(6.3 - 23) 
Baseline mPAP (mmHg) 29± 2 31± 3 30(20 - 37) 
Baseline mPCWP (mmHg) 20± 2 22±3 - 
Baseline CO (L/min) 3.6±0.3 3.7±0.3 3.1(2.8 – 4.2) 
Aetiology of heart failure    
      Dilated cardiomyopathy 9 6 6 
 Ischaemic cardiomyopathy 5 1 2 
 Valvular heart disease 1 - - 
 Other 4 1 - 
Medication    
 ACEI/AT2 receptor blocker 19 9 8 
 Beta blocker 13 7 6 
 Loop diuretic 19 9 6 
 Other diuretic 12 5 2 
 Aspirin/Warfarin 15 4 6 
 
Table 3.2: Baseline characteristics of the HF patients.  
 
3.5.1 Haemodynamic effects of short, incremental infusions of nitrite in heart failure 
patients (study A) 
During short term incremental infusion rates of nitrite in HF patients, HR (figure 3.2A) 
decreased marginally from 79±5bpm at baseline to 76±5bpm following 50µg/kg/min of 
nitrite (n=9, p<0.05). HR remain unchanged following 1, 10 and 50µg/kg/min of nitrite (n=9, 
p>0.05). MABP remained unaltered throughout the duration of the study in 9 HF patients 
who received all 3 doses of i.v. sodium nitrite (figure 3.2B). However, in the 19 HF patients 
who received 50µg/kg/min of i.v. sodium nitrite only, there was a modest but statistically 
107 
 
significant reduction in MABP from 73±1.6mmHg at baseline to 70±1.3mmHg at peak nitrite 
infusion rate (figure 3.2C, n=19, p<0.05).  
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Figure 3.2: (A) HR decreased marginally from baseline following administration of 
50µg/kg/min i.v. sodium nitrite to HF patients (p<0.05, n=9); (B) MABP remained unaltered 
at each dose in the 9 HF subjects who received 1, 10 and 50µg/kg/min i.v. sodium nitrite 
(p>0.05, n=9); (C) MABP decreased significantly at peak nitrite infusion rate, in HF patients 
following peak nitrite infusion rate of 50µg/kg/min (n=19, p<0.05). *p<0.05 compared to 
baseline. 
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At the highest infusion rate only, nitrite infusion significantly decreased PVR (figure 3.3A) 
by 30% from 184±23dyne*s/cm^5 to 129±15dyne*s/cm^5 (n=18, p<0.05) whereas SVR fell 
by 11% from 1356±82dyne*s/cm^5 to 1203±64dyne*s/cm^5 (figure 3.3B; n=18, p<0.05). 
These changes were associated with a significant reduction in mean PAP from 29± 2mmHg 
at baseline to 26± 2mmHg during 50µg/kg/min of i.v. sodium nitrite (n=19, p<0.05). Mean 
PCWP did not change (20± 2mmHg at baseline to 19± 2mmHg following peak nitrite 
infusion, n=19 and p>0.05). Escalating doses of i.v. sodium nitrite in 9 subjects demonstrated 
non-significant decreases in both PVR and SVR.  
 
At peak infusion rate there was a significant (36%) reduction in mean RAP (figure 3.4A) 
from 11.0±1.8mmHg to 7.0±1.5mmHg following peak nitrite infusion rate (n=19, p<0.01). 
CO (Fick) increased by 10% from 3.8±0.2L/min to 4.3±0.2L/min from baseline to peak 
nitrite infusion rate (figure 3.4B, n=18; p<0.001). There was a trend towards an increase in 
CO (thermodilution) from baseline in 9 HF subjects at all doses with escalating i.v. nitrite 
infusion (figure 3.4C, n=9, p>0.05 compared to baseline). 
 
Estimated TSG increased significantly from 9.1±1.9mmHg to 14.8±1.8mmHg at peak nitrite 
infusion rate (n=18, p<0.01). Change in TSG correlated positively with change in CO (figure 
3.5, r=0.70, p=0.002) and change in stroke volume (r=0.73, p=0.001). Change in PCWP did 
not significantly correlate with change in CO (r=0.04, p>0.05). 
 
All subjects were normoxic. Arterial oxygen saturations remained steady during nitrite 
infusion. Baseline saturations were 96.0±1.0% and did not vary with escalating doses of 
nitrite infusion (96.0±0.8%, p>0.05, n=9) or in patients only receiving the highest nitrite dose 
(97±0.2%, p>0.05, n=19). 
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Figure 3.3: Both (A) PVR and (B) SVR decreased significantly from baseline at peak nitrite 
infusion rate in HF patients. PVR decreased to a greater degree than SVR. N=18, *p<0.05 
compared to baseline. 
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Figure 3.4: (A) RAP increased significantly from baseline at peak nitrite infusion rate 
(50µg/kg/min) in HF patients (n=19); (B) CO (Fick) increased significantly from baseline at 
peak nitrite infusion rate (50µg/kg/min) in HF patients (n=18); (C) CO (thermodilution) 
showed a trend towards increase from baseline with escalating nitrite (n=9, p>0.05).  
**p<0.01 and ***p<0.001 compared to baseline. 
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Figure 3.5: Change in TSG (baseline to peak nitrite infusion rate of 50µg/kg/min) correlated 
positively with change in CO (R=0.70, p=0.002, n=16). 
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3.5.2 Haemodynamic effects of sustained nitrite infusion of 10µg/kg/min in heart 
failure patients (study B) 
 
Following prolonged infusion of 10µg/kg/min of i.v. sodium nitrite over 3 hours, HR and 
MABP did not alter. HR was 68(58 - 74)bpm at baseline and remain unchanged throughout 
the duration of the nitrite infusion (p>0.05, n=8, figure 3.6A). Similarly, MABP was 79(65 - 
88)mmHg at baseline and remain unchanged throughout the duration of the nitrite infusion  
(p>0.05, n=8, figure 3.6B). Arterial oxygen saturations remained steady during nitrite 
infusion. Baseline saturations were 96.0±0.1% and did not vary throughout the infusion 
(p>0.05, n=8). 
 
Mean PAP (mPAP) was 30(20 - 37)mmHg at baseline and decreased significantly from 
baseline after 30minutes to 23(15 - 34)mmHg (p<0.05, n=8). Thereafter it remain unchanged 
and was 22(16 - 42)mmHg after 180 minutes (p>0.05 from baseline, n=8).  There was a trend 
towards a reduction in both SVR and PVR, but these changes were not significant. SVR 
(figure 3.7A) decreased non-significantly by 20% from 1711(1382 - 1778)dyne*s/cm^5 at 
baseline to 1369(1189 - 1682)dyne*s/cm^5 after 30minutes (p>0.05) and to 1375(1007 - 
1902)dyne*s/cm^5 after 180 minutes (p>0.05, n=8). PVR decreased non-significantly from 
144(68 - 261)dyne*s/cm^5 at baseline to 110(83 - 120)dyne*s/cm^5 after 30minutes (p>0.05) 
and thereafter increased to near baseline values of 16 (107 - 252)dyne*s/cm^5 after 180 
minutes (figure 3.7B; n=8).  
 
Figure 3.8A shows the change in RAP observed with sustained nitrite infusion. There was 
again a non-significant trend towards a reduction in RAP with nitrite infusion.  Baseline RAP 
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decreased from 11.5(6.3 - 23)mmHg to 9(4.5 - 21.5)mmHg after 30minutes (p>0.05) and to 
8.5(6.3 - 24)mmHg after 180 minutes (p>0.05, n=8). Congruently, there was a small, non-
significant increase in CO (figure 3.8B). CO was 3.1(2.8 - 4.2)L/min at baseline and 
increased to 3.6(2.9 - 5.8)L/min/m2 after 180 minutes (p>0.05, n=8). 
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Figure 3.6: Both (A) HR and (B) MABP remained unchanged throughout the 3-hour i.v. 
nitrite infusion in HF patients (n=8, p>0.05, respectively). Data is expressed as median 
(interquartile ranges).  
  
116 
 
 
 
Figure 3.7: There were non-significant reductions in both (A) PVR and (B) SVR during 3-
hour i.v. nitrite infusion in HF patients (n=8, p>0.05, respectively). Data is expressed as 
median (interquartile ranges). To avoid multiple insertions of the Swanz-Ganz catheter, SVR 
data is only available for the 3 time-points specified. 
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Figure 3.8: (A) There was a non-significant reduction in mean RAP following i.v. nitrite 
infusion in HF patients; (B) CO remained unaltered over the 3 hours (n=8, p>0.05). Data is 
expressed as median (interquartile ranges). To avoid multiple insertions of the Swanz-Ganz 
catheter, RAP data is only available for the 3 time-points specified. 
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3.5.3 Effects of nitrite infusion on venous metHb in heart failure patients 
As expected, venous metHb levels rose in a dose-dependent and time-dependent manner with 
short, incremental infusions of nitrite (figure 3.9A) and following sustained nitrite infusion of 
10µg/kg/min over 3 hours (figure 3.9B). 
 
MetHb levels increased significantly following peak nitrite dose from 0.33±0.03% at baseline 
to 1.01±0.013% following 50µg/kg/min of i.v. sodium nitrite (p<0.001, n=9). Following 
sustained nitrite infusion, metHb increased significantly from baseline in a time-dependent 
manner (figure 3.9B). Baseline metHb increased from 0.5(0.3 - 0.5)% to a maximum of 
1.5(0.8 - 2.0)% (p<0.05, n=8). After 60 minutes, the metHb level appeared to plateau. 
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Figure 3.9: (A) Venous metHb increased in a dose-dependent manner with short, incremental 
infusions of nitrite in HF patients (n=9, **p<0.001, data is expressed as mean±SEM); (B) 
Similarly, there was a time-dependent increase in venous metHb with prolonged nitrite 
infusion, in HF patients (n=8, *p<0.05, data is expressed as median (interquartile ranges)).  
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3.5.3 Plasma nitrate, nitrite and RXNO levels in heart failure patients following 
nitrite infusion 
Plasma RXNO, nitrite and nitrates all increased significantly from baseline to peak nitrite 
dose of 50µg/kg/min following a short (5-minute infusion) in HF patients (figure 3.10). 
Plasma RXNO levels were 12.2±1.3nM and increased to 37.7±5.9nM after administration of 
50µg/kg/min i.v. sodium nitrite (figure 3.10A; n=18, p<0.0001). Baseline nitrite 
concentrations increased from 1.6±0.7µM to 16.0±2.8µM following the peak nitrite infusion 
rate (figure 3.10B; n=18, p<0.0001). Nitrate levels increased from 26.1±2.8µM to 
37.1±3.6µM, respectively (figure 3.10C; n=18, p<0.0001).  
 
Following prolonged (3-hour) infusion of 10µg/kg/min of i.v. sodium nitrite in HF patients, 
plasma RXNO concentration did not change significantly (figure 3.11A; n=7, p>0.05 
compared to baseline). Plasma nitrites increased significantly from baseline values of 1.9(1.4 
– 5.0)µM to a peak concentration of 9.6(6.3 – 14.8)µM after 120minutes (figure 3.11B; 
p<0.05 compared to baseline, n=7). After this time, plasma nitrite levels appeared to plateau 
and remained significantly above baseline levels. After 3 hours plasma nitrite concentration 
was 8.9(5.3 – 10.9)µM (n=7, p<0.05 compared to baseline). Plasma nitrate levels rose in a 
similar manner to nitrite (figure 3.11C). Baselines nitrate concentration increased from 
24.7(18.93 – 52.0)µM to 54.3(31.7 – 59.7)µM after 120minutes and plateaued thereafter 
(n=7, p<0.05 compared to baseline). 
 
In study A, baseline cGMP levels were 2.7±0.6fmol/well and after a 5-minute infusion of 
50µg/kg/min of i.v. nitrite were 2.3±0.4fmol/well (n=11, p>0.05). 
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Figure 3.10: Plasma (A) RXNO, (B) Nitrite and (C) Nitrate increased in a dose-dependent 
manner from baseline (n=10). N=18, ***p<0.0001. 
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Figure 3.11: (A) Plasma RXNO concentrations remained stable throughout the 3hour 
(10µg/kg/min) nitrite infusion; (B) Plasma nitrite levels increased significantly from baseline 
after 30minutes and appeared to plateau after 120minutes; (C) Plasma nitrate levels increased 
from baseline after 120minutes and plateaued thereafter. N=7, *p<0.05. Data is expressed as 
median (inter-quartile range). 
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3.6 Discussion 
 
To date this study is the first to assess the haemodynamic effects of systemic intravenous 
sodium nitrite infusion in patients with heart failure. In contrast to the findings in healthy 
subjects (as presented in Chapter 2), in patients with HF i.v.sodium nitrite demonstrated a 
highly favourable haemodynamic profile during short term administration, with an increase in 
CO in these patients though this was only significant at an infusion rate of 50µg/kg/min. 
There was a substantial reduction in PVR (30%) but only a modest reduction in SVR (11%) 
at this dose. Since CO increased and SVR fell only modestly, the fall in blood pressure was 
very small. This would be a very attractive haemodynamic effect for the treatment of 
decompensated heart failure. The use of current vasodilators such as GTN in these patients is 
often limited by the development of hypotension (403).  
 
The observed substantial reduction in PVR in heart failure patients is consistent with a recent 
report of a substantial reduction in PVR with chronic administration of sodium nitrite in the 
rat monocrotaline model of pulmonary hypertension (412) and with the observation in man 
that a low infusion rate of sodium nitrite substantially reduced pulmonary artery pressure in 
acute hypoxia–induced pulmonary hypertension (199). Ventilation-perfusion mismatch is 
increased in patients with heart failure (413). Since nitrite is a hypoxia dependent vasodilator 
it might be expected to preferentially dilate arterioles supplying relatively under–ventilated 
alveoli and this could worsen ventilation–perfusion mismatching resulting in arterial 
desaturation. However, despite a substantial fall in PVR there was no observed reduction in 
systemic arterial oxygen saturation. 
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This study provides important mechanistic insights into how nitrite increased CO in patients 
with heart failure. RAP was markedly reduced during systemic nitrite therapy, presumably as 
a consequence of the fall in PVR, and potentially due to its venodilator action (46). In 
contrast, the reduction in PCWP was somewhat less. This resulted in an increase in the 
estimated TSG despite a reduction in PCWP. The increase in TSG observed during nitrite 
therapy implies amelioration of this DVI with an increase in effective left ventricular preload 
and hence an increase in stroke volume via the Frank-Starling mechanism, implying 
amelioration of diastolic ventricular interaction (DVI) (359, 414). Furthermore, the increase 
in CO was significantly correlated with the change in TSG (R = 0.70 p=0.002) but not with 
the change in PCWP. A recent study undertaken in the Langendorff rat heart reported that 
nitrite had negative inotropic and lusitropic effects via e-NOS–independent NO generation 
(407). Although we did not measure contractile state directly, our findings do not support a 
substantial negative inotropic effect in either healthy subjects or in patients with heart failure, 
in contrast to the study in the Langendorff model.  
 
The substantial haemodynamic effects of sodium nitrite in patients with heart failure, albeit at 
a high dose were not replicated in healthy subjects as described in Chapter 2. This was the 
case even when subjects were administered i.v. nitrite under hypoxic conditions. NO 
resistance is well described in patients with heart failure in both platelets and blood vessels 
and in some patients may reduce the therapeutic effects of intravenous NO donors (414, 415). 
If nitrite bioactivity is predominantly mediated via reduction to NO as is commonly believed, 
then our study does not suggest marked NO resistance in these patients with heart failure 
(118). On the contrary, we have observed a much greater response in patients with heart 
failure compared to healthy controls.  
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Despite the favourable haemodynamic effects of short term administration of sodium nitrite 
at a dose of 50µg/kg/min in patients with heart failure, there would be substantial challenges 
to its use as a therapy for decompensated heart failure. Whilst we showed that sustained 
infusion of 10µg/kg/min sodium nitrite in both healthy volunteers and patients with heart 
failure only moderately increased methaemoglobin levels, this infusion rate did not cause a 
significant increase in cardiac output in heart failure patients during either short term or 
sustained infusion. Infusion of 60µg/kg/min in healthy subjects caused a substantial increase 
in methaemoglobin such that infusion was terminated in both subjects at 2 hours when 
methaemoglobin levels reached 10% (Chapter 2). Ingram and colleagues reported that 
infusion of sodium nitrite prevented hypoxia induced vasoconstriction in healthy subjects an 
hour after ceasing infusion at a time when plasma nitrite had returned to baseline (199). This 
may provide a rationale to investigate pulsed high dose sodium nitrite therapy in heart failure 
that may potentially have sustained favourable haemodynamic effects with only modest 
associated methaemogobinaemia.  
 
Plasma cGMP did not alter significantly in heart failure patients at a haemodynamically 
effective infusion rate. This could be suggestive of cGMP-independent vascular relaxation to 
NO which is purported to be seen mostly at high concentrations of NO donors (416). Baseline 
plasma cGMP levels were elevated in the heart failure patients compared to healthy 
volunteers, as well recognised by others (417).  
 
Plasma nitrite and nitrate increased in a dose dependent manner during the short-term 
infusions (figure 3.10). Despite similar increases within each group, there was a marked 
difference in haemodynamic effects between healthy volunteers (Chapter 2) and heart failure 
patients at peak nitrite infusion rate of 50µg/kg/min. Previously, Pinder et al. have 
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demonstrated, using rabbit aortic rings, that the effects of nitrite are not completely dependent 
upon nitrite reduction back to NO (418). Whether the effects observed in the heart failure 
patients could be explained by an NO-independent mechanism of nitrite –mediated vascular 
relaxation requires further exploration.  
 
Study limitations 
An important limitation of this study is the small number of patients studied. This may 
account for some of the perceived lack of benefit, particularly at the lower infusion rates of 
1µg/kg/min and 10µg/kg/min. A full dose ranging study would have helped to establish if 
these gains (PVR reduction and improved CO with modest SVR reduction) would be 
replicated at doses of nitrite which do not induce significant methaemoglobinaemia. The 
subjects consisted of heart failure patients with varying aetiologies, which reflects the patient 
group being assessed for cardiac transplantation at University Hospitals Birmingham NHS 
Trust. Furthermore, there was no placebo group, therefore we were unable to correct for any 
non-nitrite related effects on cardiovascular or peripheral haemodynamic measurements in 
particular. 
 
Conclusions 
Sodium nitrite infusion has favourable haemodynamic effects in patients with heart failure 
during short term administration but this is only observed with high doses, potentially at 
higher, clinically significant maethaemoglobin levels. Although, sustained infusion at a lower 
rate did not induce clinically important methaemoglobinemia, significant haemodynamic 
effects were not observed. This study provides important initial insight into the role of nitrite 
in heart failure patients and further, placebo-controlled trials are required to ascertain the 
efficacy and mechanisms of putative nitrite therapy in heart failure. Alternate dosing 
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strategies including pulsed therapy should be explored. Furthermore, the issue of nitrite 
tolerance was not explored in this acute study and would be an important issue to address in 
future studies.  
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Chapter 4: Effects of Glyceryl Trinitrate on Human Resistance 
Vessels during Normoxia and Hypoxia  
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4.1 Introduction  
Organic nitrates such as glyceryl trinitrate (nitroglycerin, GTN) have been in clinical use for 
approximately 130 years for the treatment of angina pectoris with the first literature report in 
the late 1800s (419). Notwithstanding modern pharmacological advances, they remain in 
widespread use for several cardiovascular conditions including acute coronary syndromes and 
heart failure. However, studies exploring the mechanisms of GTN bioactivity have only been 
conducted relatively recently. The discovery that endogenous NO production via GTN 
contributes to relaxation of vascular smooth muscle has only been made within the last 35 
years (5, 129, 420, 421). Since then much interest has focussed on the exact mechanisms of 
action of GTN-mediated vascular dilatation, which to date still remain to be fully determined.  
 
GTN is a pro-drug which is thought to exert its vascular effect through release of NO or a 
nitrosothiol intermediary. An earlier concept hypothesised that GTN is bioactivated non-
enzymatically through its interaction with thiols or sulfhydryl (-SH)-containing cellular 
receptors (129, 422). Reaction of GTN with thiol groups could result in formation of an S-
nitrosothiol intermediary and NO, with subsequent activation of soluble guanlyase cyclase 
(sGC) and vascular smooth muscle relaxation (129, 423). However, there is some controversy 
surrounding this notion as it has not been fully established whether the mechanistic processes 
seen in vitro result in GTN bioactivation in vivo (172).  
 
An alternative and more contemporary theory suggests that GTN bioactivation is catalysed 
via an enzymatic mechanism. Evidence to date suggests that the most likely candidate for this 
process is mitochondrial aldehyde dehydrogenase (ALDH2) (168). Firstly, Chen and 
colleagues demonstrated the biotransformation of GTN to 1,2-GDN and nitrite in vitro in 
mouse macrophages. They proposed the following stoichiometric reaction for this:- 
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GTN  +  Ered  → 1, 2 GDN  +  NO2-  +  Eox 
(Ered = reductase enzyme; Eox = oxidising enzyme) 
 
Secondly, there was an attenuation of GTN-mediated vascular relaxation in rat thoracic aorta 
following application of the ALDH inhibitors, cyanamide and chloral hydrate. Moreover, in 
anaesthetised rats receiving systemic infusions of i.v. GTN, administration of cyanamide and 
chloral hydrate attenuated the hypotensive effect of GTN, suggesting that nitrate tolerance 
may be caused by ALDH inhibition (largely the mitochondrial ALDH2 isoform) (168). 
Further work undertaken by the same group, confirmed these findings in ALDH2-knockout 
mice (170). Others have also confirmed the role of ALDH2 in the bio-activation of organic 
nitrates in subsequent in vitro and in vivo animal studies (169), (168, 170). Mackenzie and 
colleagues corroborated this by exploring forearm vascular responses to GTN (assessed via 
venous occlusion plethysmography) in healthy volunteers. They found that ALDH inhibition 
(either through oral disulfiram administration or through more specific intrinsic ALDH2 
inactivity in subjects lacking the glu504lys ALDH2 mutation) resulted in an attenuation of 
GTN-mediated forearm vasodilatation (171).  
 
Much of the clinical benefit conferred by GTN is attributed to its ability to dilate veins and 
large arteries at low doses, resulting in redistribution of blood flow to the venous capacitance 
bed (424-426). It is widely believed that in heart failure, this reduces preload and offloads a 
congested heart, allowing a modest improvement in cardiac output with a resulting 
improvement in clinical symptoms (427, 428). In support of this concept, administration of 
GTN has been shown to reduce right atrial pressure and left-ventricular end-diastolic pressure 
in studies (429-431). At high doses, GTN causes arteriolar dilatation resulting in reduced 
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afterload (432, 433). However, mechanistic studies directly comparing the arterial vs venous 
effects of GTN have reported variable results. Exposure of bovine intrapulmonary arteries 
and veins to GTN resulted in a greater vascular relaxation in veins compared to arteries (434). 
Similarly, in rabbit femoral and mesenteric vessels, veins were observed to be more sensitive 
to GTN than arteries at low concentrations of GTN (426). A related effect has been observed 
in human forearm resistance vessels compared to dorsal hand veins (435). In contrast, canine 
coronary arteries exhibited a much greater degree of GTN-mediated vasodilatation than 
mesenteric or saphenous veins (436). This greater arterial vasodilatation has been reported by 
others also (437, 438). A human study found GTN to be equipotent in the human forearm 
vasculature (439). These inconsistent reports may be attributable to differing protocols 
applied to a diverse range of blood vessels from a variety of animal species.  
 
Despite incomplete knowledge regarding the mechanisms of action of organic nitrates and 
lack of randomised controlled clinical trials with a proven mortality benefit, the medical 
experience with nitrates is long-standing and hence their use in clinical practice is well 
established (440). Nevertheless, alternatives are constantly being sought. Nitrite as a NO 
donor with its relative venoselectivity and attribute of specific hypoxic vasodilatation, could 
potentially offer an alternative therapy to the well-established organic nitrates. The data 
regarding enhanced vascular effects of nitrates during hypoxia is especially scanty. In 
experiments utilising ex vivo porcine coronary arteries, Fukuda and colleagues reported 
hypoxia-potentiated vascular relaxation following exposure to GTN (441). Agvald et al 
investigated the effect of reducing oxygen tension on NO release following administration of 
GTN. Using anaesthetised rabbits, they demonstrated an incremental increase in NO 
liberation following i.v. GTN administration as graded hypoxia was commenced. They 
reported a >300% increase in NO production during hypoxia. To eliminate the scavenging 
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effects of haemoglobin, they performed the experiments using isolated buffer-perfused lungs 
and observed similar results. They observed nitrite reduction to NO during hypoxia (but not 
normoxia), in the absence of haem proteins (442). 
 
In humans, greater peripheral haemodynamic effects have been observed following oral GTN 
administration in healthy subjects living at high altitude presumed to be due to moderate 
hypoxia, compared to those living at low altitude (443). With the paucity of data, it is 
unknown whether organic nitrates truly enhance vasodilatation during hypoxia or whether 
this phenomenon is unique to nitrite. Currently, the dosage and regimen of GTN treatment is 
similar for all patients regardless of underlying indication for vasodilator therapy and oxygen 
tension. This knowledge could yield important information for future studies investigating 
both nitrates and nitrite in cardiovascular disease as therapy could be tailored to patients with 
greater efficacy and improved clinical outcomes taking into consideration oxygen tension. 
Potentially, this may be important for subjects living at high altitude, critically ill patients 
with reduced oxygen saturations e.g. heart failure or those with myocardial infarction with 
associated cardiogenic shock.  
 
4.2 Objectives 
The objective of this study was to establish whether organic nitrates (GTN) exhibit hypoxia-
specific vasodilatation in humans, similar to that seen with nitrite. This was determined in the 
intact forearm vasculature of healthy volunteers, using venous occlusion plethysmography. 
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4.3 Methods 
4.3.1 Participants 
10 healthy volunteers were recruited into this study. Subjects were recruited from the 
University of Birmingham. The study was granted full ethical approval (South Birmingham 
Local Research Ethics Committee 08/H1207/283). The investigation conforms to the 
principles outlined in the Declaration of Helsinki. All of the subjects gave written, informed 
consent after satisfying the inclusion and exclusion criteria (see below). The study was 
performed at the University of Birmingham Clinical Research Block in a quiet vascular 
laboratory that was temperature-controlled at 22 - 24ºC. All subjects had a light breakfast and 
were requested to abstain from alcohol and caffeine-containing drinks and nitrite/nitrate rich 
food for 24 hours before the study (foods to avoid as part of nitrite/nitrate poor diet outlined 
in table 2.1).  
 
Inclusion criteria included age over 18 years, history of no-smoking and no regular 
medication (except the oral contraceptive pill). All subjects underwent a cardiovascular 
examination and had a normal electrocardiogram (ECG). Women of child-bearing potential 
or nursing mothers, people with BMI≥30kg/m2 and migraine sufferers were excluded from 
the study. 
 
4.3.2 Study protocol 
The study protocol is depicted in figure 4.1. 10 healthy volunteers attended on one occasion. 
Each subject received three 5-minute intra-arterial infusions of glyceryl trinitrate (GTN, 
Lipha Pharmaceuticals Ltd, UK) at escalating doses of 4, 8 and 16nmol/min using non-
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adsorptive tubing– once whilst breathing room air (normoxia) and once whilst breathing 12% 
oxygen (hypoxia), in random order. Forearm vasodilatation was assessed using venous 
occlusion plethysmography. Each series of infusions was separated by a 20-minute washout 
period to allow GTN-mediated vascular relaxation to return to baseline values. 
 
Subjects were placed in a semi-recumbent position enabling the administration of hypoxia 
to participants.  An intravenous cannula (20-gauge) was inserted into a vein in both 
antecubital fossae. Changes in blood flow, using mercury in-silastic strain gauges were 
recorded in both arms (DE Hokanson, Bellevue, Wash), as detailed in section 4.3.3. GTN 
was administered intra-arterially via a 27-gauge arterial needle (Coopers Engineering, UK) 
mounted onto a 16-gauge epidural catheter and sealed with dental wax, as depicted in figure 
4.2A. This was inserted aseptically into the brachial artery of the non- dominant arm under 
local anaesthesia (1% lidocaine) and was kept patent by intra-arterial (i.a) 0.9% saline 
infused at 1ml/min before initiation of GTN. Each subject underwent placement of a finger 
cuff for continuous blood pressure recording, an upper arm cuff for the oscillating blood 
pressure measurement, and chest electrodes for continuous electrocardiogram monitoring 
using the TaskForce Monitor® (CN Systems, Graz, Austria). Oxygen saturation levels were 
monitored continuously with pulse oximetry (Nellcor, Pleasanton, CA, USA). Measurement 
of forearm blood flow (FBF) is described in more detail in section 4.3.3. The experimental 
set-up is depicted in figure 4.2B. 
 
As depicted in figure 4.1, following 10 minutes of stabilisation, subjects received three 
doses of intra-arterial GTN (4, 8 and 16nmol/min for 5 minutes each; infusion rate 1ml/min 
using non-adsorptive tubing) as employed by Kharbanda et al. (444). GTN was infused into 
135 
 
the brachial artery of the non-dominant arm and FBF was measured in both arms after each 
dose, as detailed in section 4.3.3.  
 
6mL of venous blood was obtained from the infused arm cannula. 4mL was stored for later 
analysis of plasma nitrite/nitrates and 2mL was analysed immediately for plasma pH and 
lactate, as described in section 2.4.5. 
 
 
 
Figure 4.1: Study protocol. *One series of infusions was administered during normoxia and 
the other during hypoxia, in random order. 
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Figure 4.2: (A) Cooper’s needle for intra-arterial GTN infusion into the brachial artery; (B) 
Typical experimental set-up of subjects in the study.  
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The third infusion of intra-arterial GTN (16nmol/min) was followed by a 20 minute washout 
period, during which time intra-arterial 0.9% saline was infused to ensure patency of the 
Cooper’s needle. After 20minutes, the study then proceeded with three further 5minute 
infusions of intra-arterial GTN at 4, 8 and 16nmol/min, as described above. 
 
During one series of infusions, the subjects were rendered hypoxic by inspiring 12% oxygen 
via a Hudson facemask, as employed by Maher et al. (46). Target oxygen saturation as 
measured by pulse oximetry was 83-88%, as described in Chapter 2, section 2.3.3. Upon 
achieving target oxygen saturation a further 10minute stabilisation period was observed. 
Following steady state hypoxia, three 5minute infusions of intra-arterial GTN at 4, 8 and 
16nmol/min were administered, as described above. Oxygenation status was determined in 
random order.  
 
Heart rate (HR), mean arterial blood pressure (MABP) and arterial oxygen saturations were 
recorded at baseline and following each dose of GTN during normoxia and hypoxia.  
 
4.3.3 Measurement of forearm blood flow  
Forearm blood flow (FBF) is a well-established measure of vascular relaxation/dilatation, as 
described in the literature (445).  Mercury in-silastic strain gauges (DE Hokanson, Bellevue, 
Washington, USA) were placed on the widest part of the forearm and these allow detection 
of any changes to forearm circumference, as a result of variations in blood flow to the limb. 
A venous occlusion cuff was placed on the upper arm and one on the wrist, of each arm. 
During each recording, the wrist cuff was inflated to supra-systolic arterial blood pressure 
(200mmHg) to exclude the hand for the circulation. Blood flow in the hand is predominantly 
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through the skin and therefore fluctuates widely. This was followed by inflation of the upper 
arm cuff to 40mmHg to allow venous occlusion but without affecting arterial inflow. As 
blood flow into the limb increased, it caused the limb to swell at a rate proportional to the 
arterial inflow. Therefore the rate of swelling was used to measure the rate of arterial flow 
rate. The venous cuff was inflated for 10 seconds and then deflated for 5 seconds. This step 
was repeated three times for each recording in both arms simultaneously. FBF was calculated 
using LabChart 5 software (2006, AD Instruments, UK) in mL/100mL of tissue per minute 
and expressed as a ratio of change from baseline in FBF from infused:control arm (ΔFBF 
ratio). Figure 4.3 depicts a typical recording of FBF obtained from one of the study subjects. 
 
 
Figure 4.3: Typical FBF recording obtained during a recording. 
 
4.3.4 Blood sampling 
For analysis of plasma nitrite/nitrate, 4mL of blood was transferred into an EDTA collection 
tube (K3 EDTA, BD Vacutainers) pre-treated with N-ethylmaleimide (10mM; Merck, 
Germany). These samples were centrifuged at 2000rpm at 4ºC followed by immediate snap-
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freezing in liquid nitrogen and storage at -80ºC for later analysis of plasma nitrite/nitrates, as 
described in section 2.4.5. A further 2ml of venous blood was analysed immediately using a 
blood gas analyser (Bayer Rapidlab 865, Siemens, Tarrytown, NY) for measurement of pH 
and lactate.  
 
4.3.5 Statistical analysis 
Repeated measures ANOVA with consecutive Bonferroni post hoc was used to test for 
changes from baseline in all parameters during normoxia and hypoxia, with each subject 
acting as their own control. The data are expressed as mean ± standard error of mean 
(mean±SEM), unless otherwise stated. Probability values of <0.05 were considered 
statistically significant. Statistical analysis was undertaken using SPSS (version 21.0 SPSS 
Inc., Chicago, USA). 
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4.4 Results 
4.4.1 Baseline characteristics 
Table 4.1 outlines the subject characteristics. 
 
  
N=10 
 
Age, years (mean±SD) 
 
22±2 
Gender, m 5 
Body mass index (kg/m
2
, mean±SD) 21±2 
Forearm circumference (cm) 24±2 
HR (bpm) 64±3 
MABP (mmHg) 79±4 
HR, heart rate; MABP, mean arterial blood pressure. Data is expressed as mean±SEM unless 
stated otherwise. 
 
Table 4.1: Baseline characteristics of study participants. 
 
4.4.2 Effect of oxygenation on GTN-mediated vasodilatation 
There was a dose-dependent increase in FBF ratio with incremental infusions of intra-arterial 
GTN during normoxia and hypoxia (figure 4.4). During normoxia, there was a 3.5 fold 
increase in FBF ratio from baseline following peak GTN infusion rate (p<0.05, n=10). 
Absolute FBF ratio was not significantly different during normoxia or hypoxia, although 
there was a trend towards a lower FBF ratio in hypoxia. At baseline normoxia, FBF ratio was 
1.8±1.1 and at baseline in the hypoxia arm was 1.6±0.8 (p>0.05, n=10).  During hypoxia, a 
smaller increase in FBF ratio was observed. FBF ratio increased by 1.8 times from baseline 
following maximal GTN infusion rate (p<0.05, n=10). However, there was no statistically 
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significant difference between ΔFBF ratio between normoxia and hypoxia at any infusion 
rate of GTN (p>0.05, n=10).  
 
 
 
 
Figure 4.4: There was a dose-dependent increase in ΔFBF ratio during both normoxia and 
hypoxia. *p<0.05 compared to baseline, n=10. Data is expressed as mean±SD. 
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4.4.3 Haemodynamic data 
During normoxia, arterial oxygen saturations were 99.0±0.3% (at baseline and remained 
unchanged throughout the duration of the infusions (figure 4.5A, p>0.05, n=10). During 
hypoxia, baseline oxygen saturations of 86.0±0.5% were achieved and remain steady for the 
duration of the infusions (p>0.05, n=10). As expected, there was a significant difference 
between arterial oxygen saturations during normoxia and hypoxia at all infusion rates 
(p<0.05, n=10 for all infusion rates of GTN). 
 
During both normoxia and hypoxia, there was no significant change in HR from baseline 
(figure 4.5B). However, baseline HR differed significantly between normoxia and hypoxia 
and this difference remained constant throughout the duration of the GTN infusion. Baseline 
HR was 64±3bpm during normoxia and 71±3bpm during hypoxia (p<0.05, n=10).  
 
MABP remained constant (figure 4.5C) for the duration of the study, during both normoxia 
and hypoxia, with no difference being observed between the two oxygenation states.  
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Figure 4.5: (A): Arterial oxygen saturations were significantly different all time-points 
between normoxia and hypoxia (p<0.05, n=10); (B) HR was significantly different all time-
points between normoxia and hypoxia (p<0.05, n=10); (C) There was no significant change 
in MABP for the duration of the GTN infusions at any stage or with differing oxygenation 
conditions (p>0.05, n=10). *p<0.05 normoxia vs hypoxia for equivalent GTN dose. 
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4.4.4 Acid-base balance  
There was no evidence of significant acidosis with hypoxia. Whole blood venous pH or 
lactate did not alter at baseline (prior to onset of GTN infusion) or following completion of 
the GTN infusion (Table 4.2). 
 
 normoxia hypoxia 
 Pre-infusion Post-infusion Pre-infusion Post-infusion 
Arterial oxygen 
saturations (%) 
99.0±0.3 99.0±0.2 87±0.5* 87±0.9* 
pH 7.36±0.03 7.37±0.04 7.37±0.04 7.36±0.03 
Lactate (mmol/L) 1.4±0.5 1.4±0.5 1.5±0.6 1.4±0.3 
 
Table 4.2: pH and lactate values at baseline and following completion of intra-arterial GTN 
infusion. *p<0.05 normoxia vs hypoxia for equivalent GTN dose. 
 
 
4.4.5 Plasma nitrite and nitrate 
Plasma nitrite and nitrate levels were analysed. During normoxia, nitrite levels in the infused 
arm did not alter significantly for the duration of the GTN infusion (p>0.05 compared to 
baseline, n=7; figure 4.6A). Baseline nitrite concentration was 1.3±0.1µM and increased to 
1.5±0.2µM following 16nmol/min of intra-arterial GTN. During hypoxia, baseline nitrite 
concentration was significantly lower compared to hypoxia (1.3±0.1µM vs 0.5±0.1µM during 
normoxia vs hypoxia; p<0.05, n=7). There was a dose-dependent increase from baseline in 
nitrite levels following intra-arterial GTN during hypoxia (p<0.05 following 8 and 
16nmol/min of intra-arterial GTN, n=7). 
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During normoxia, nitrate levels did not alter for the duration of the GTN infusion (figure 
4.6B). During hypoxia there was a trend towards an increase in plasma nitrate levels with 
escalating doses of intra-arterial GTN however, this was not statistically significant. Baseline 
nitrate levels differed between normoxia and hypoxia (34.8±11.0µM vs 25.7±7.6µM, 
respectively) but this did not reach statistical significance (p>0.05, n=8).  
 
 
 
Figure 4.6: (A) Plasma nitrite levels following intra-arterial GTN infusion during normoxia 
and hypoxia (n=7); (B) Plasma nitrate levels following intra-arterial GTN infusion during 
normoxia and hypoxia (n=8). *p<0.05 compared to baseline; #p<0.05 normoxia vs hypoxia. 
146 
 
4.5 Discussion 
Acute hypoxia alone is well recognised to be associated with relaxation of forearm 
vasculature. Surprisingly, in our study there was a tendency to a lower FBF ratio (suggestive 
of attenuated vasodilatation) even at baseline, following stabilisation of target oxygen 
saturations (figure 4.4).  One study reported that in healthy subjects, hypoxia (target oxygen 
saturations of 85%) was associated with a 24% increase in FBF (446). Markwald’s findings 
corroborate those of several other groups previously (447-450). Therefore, the current study 
did not explore the effects of hypoxia alone on resistance vessels as it was decided that this 
has been well established. In view of the unanticipated findings above, it is recognised that a 
hypoxic control limb to the study would have provided useful insight to the forearm vascular 
response of the study subjects in our cohort. The aim of this study was to determine if GTN-
mediated vasorelaxation differed during normoxia and hypoxia. The data presented herein 
does not demonstrate an accentuated GTN-mediated vasodilatory effect during hypoxic 
conditions. The forearm vasculature tended to dilate to a lesser degree in response to intra-
arterial GTN during hypoxia as compared to normoxia. During hypoxia there was a smaller 
increase in FBF ratio (~1.8 fold during hypoxia compared to ~2.5 fold during normoxia) 
suggestive of attenuated forearm resistance vessel vasodilatation as compared to normoxia 
(figure 4.4). Augmentation of sympathetic vasoconstrictor activity is thought to diminish the 
degree of hypoxic vasodilatation seen, which in turn is believed to be due to a balance 
between sympathetic activity and local vasodilatory factors (such as NO) (180, 450, 451). In 
the current study, activation of sympathetic vasoconstrictor activity during hypoxia may 
explain the trend towards a lower baseline FBF ratio in the hypoxia limb of the study 
(1.5±0.2 and 1.8±0.4 during hypoxia and normoxia, respectively, p>0.05) and the diminished 
GTN-mediated vasodilatation seen, during hypoxia. Conversely, this inability of intra-arterial 
GTN to overwhelm possible sympathetic activity was not observed with nitrite. Intra-arterial 
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infusion of nitrite has been previously shown to cause an enhanced vasodilatory effect in the 
forearm vasculature (without blockade of sympathetic drive), presumably overcoming any 
sympathetic vasoconstrictor responses seen during hypoxia. Cosby et al demonstrated an 
increase in forearm blood flow with intra-arterial nitrite infusion, which was further enhanced 
during exercise and associated with nitrite reduction to NO via deoxyhaemoglobin (26). In a 
study by our group, intra-arterial nitrite was associated with greater venodilatation 
(presumably secondary to the lower oxygen tension in veins) during normoxia with no 
discernible effect on resistance vessels. During hypoxia, resistance vessels dilatation was 
observed also (46). 
 
A Russian study found accentuated peripheral vasodilatory effects following sublingual GTN 
administration in humans living at high altitude (compared to those living at low altitude), 
presumably secondary to moderate hypoxia (443). Our contradictory findings may be due to 
differences in GTN vasodilatory effects during chronic hypobaric hypoxia (where adaptations 
have occurred) compared to acute normobaric hypoxia (as delivered in the current study). 
Erzurum and colleagues found accentuated forearm blood flow in Tibetan residents living at 
altitude, compared to subjects living at sea-level. This was associated with 10-fold greater 
concentrations of bioactive NO products (nitrate and nitrite) within the plasma of Tibetans 
(452). In our study, despite greater forearm vasodilatory responses during normoxia 
compared to hypoxia following administration of intra-arterial GTN, plasma nitrite and 
nitrate levels did not change significantly from baseline during normoxia (figure 4.6). Nitrite 
levels in the infused arm were higher during normoxia (with a greater FBF ratio response) 
and remained elevated above hypoxic levels for all corresponding GTN infusion rates (figure 
4.6A). This may support Chen and colleagues’ report that GTN-mediated vasodilatation 
occurs via conversion to 1,2GDN and nitrite (168) and is consistent with findings by others 
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(453). Moreover, baseline nitrite concentration was significantly lower during hypoxia 
compared to normoxia, which may reflect nitrite consumption during hypoxia. Despite the 
lower baseline nitrite concentration during hypoxia, the increase from baseline was greater 
during hypoxia compared to normoxia (15% vs 160%, respectively), again suggestive of 
enhanced nitrite bioavailability following GTN administration. Physiological plasma nitrite 
concentrations are between 150-1000nM (26). We observed supra-physiological levels (up to 
~1500nM during normoxia at maximal GTN infusion rate). Lack of correlation between 
vasodilatory response and plasma nitrite concentration has been reported previously by 
Ingram and colleagues, following administration of nitrite in healthy volunteers and may be 
suggestive of the existence of further, unknown mechanisms contributing to nitrite-mediated 
hypoxic vasodilatation (199).  
 
MABP remain constant during both normoxia and hypoxia with no significant change 
between oxygenation states or with intra-arterial GTN infusion (figure 4.5). However, HR 
was significantly higher in the hypoxia group and remained so for the duration of hypoxia. 
This finding is in keeping with the effect of acute hypoxia and has been observed by others 
(449, 450).  
 
Study limitations 
The aim of this study was to directly compare GTN-mediated vasodilatation during normoxia 
and hypoxia, therefore a hypoxia-only group was not studied. Although, the effects of acute 
hypoxia on forearm vasculature have been described by others, it would have been useful to 
investigate the effect on our cohort due to the surprising findings of attenuated dilatation 
during hypoxia (446, 449, 450). Furthermore, we did not utilise sympathetic blockade to 
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diminish the sympathetic vasoconstrictor effect of hypoxia, which may account for the 
differing changes in GTN-mediated vasodilatation during normoxia and hypoxia. 
 
Conclusions  
GTN does not appear to display an accentuated vasodilatory effect during hypoxia, as 
reported with nitrite. Indeed, differing vasodilatory effects of NO-donors may be detected 
between species, degrees of hypoxia and different vascular beds within species. These 
findings provide important insight into the pharmacodynamic effect of GTN in vivo in man, 
and supports further research into nitrite as a putative NO donor for use in cardiovascular 
conditions.  
  
150 
 
 
 
 
Chapter 5: Nitrite-mediated Cardioprotection in Patients 
undergoing Coronary Artery Bypass Grafting Surgery  
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5.1 Introduction 
Ischaemia-reperfusion injury (IRI) is a well-recognised paradox of reperfusion following a 
period of ischaemia, undoing some of the benefit gained by restoration of blood flow (94). 
Several examples of IRI exist in cardiovascular medicine, for example acute myocardial 
infarction (AMI) with thrombolysis/percutaneous coronary intervention (PCI), during cardiac 
surgery with cardio-pulmonary bypass, following organ transplantation and following cardiac 
arrest. These clinical conditions are commonly encountered and remain a significant health 
problem. Despite reductions in cardiovascular mortality, cardiovascular disease is still the 
largest killer in the UK (454). Approximately 100,000 people suffer an acute myocardial 
infarction in the UK every year. A significant proportion of patients with cardiovascular 
disease undergo cardiac surgery. Coronary artery bypass grafting (CABG) surgery usually 
with cardiopulmonary bypass and cardioplegic arrest is a common surgical procedure. 
Greater than 16,000 isolated, first-time elective CABG operations were performed in the UK 
in 2010-11 (455). The risk profile of patients undergoing cardiac surgery has increased over 
time due to more elderly patients having surgery along with a rise in the complexity of 
operations being undertaken (455). Approximately 60,000 people in the UK suffer an out-of-
hospital cardiac arrest with the majority presumed to be cardiac in origin (456, 457). 
Irrespective of advances in modern medicine, survival rates, particularly from out-of-
hospitals cardiac arrest remain poor, variable and largely unchanged over the years (458). 
Consequently, due to the potential for methods to protect against IRI to improve clinical 
outcomes in these commonly encountered circumstances, the impetus to find ways to reduce 
the lethal effects of IRI has been the ‘holy grail’ of countless research studies and has formed 
the basis of numerous literature reviews on the subject (209-211, 459, 460).  
The role of nitrite in cardioprotection is being increasingly recognised with several 
experimental studies proposing that nitrite may protect the myocardium against IRI. A 
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number of in vitro studies have demonstrated that nitrite is cardio-protective and some of 
these have been reviewed in Chapter 1 (27, 97, 329, 331-333, 461). In vivo animal studies 
have corroborated these findings by demonstrating a reduction in myocardial injury in several 
animal models (334, 335). In particular, Gonzalez and colleagues explored the role of low-
dose nitrite infusion administered to dogs during myocardial ischaemia and reported an up to 
50% reduction in myocardial infarct size following intravenous nitrite administered during 
the ischaemic period (336). Additionally, Doganci and colleagues recently administered intra-
coronary nitrite (0.5µg/kg) immediately prior to ischaemia in a pig model of AMI (462). The 
authors reported favourable haemodynamic recovery following restoration of blood flow with 
an associated reduction in biochemical markers of oxidative stress and myocardial injury. In a 
further murine cardiac arrest model, a single bolus dose of i.v. nitrite (bolus dose of 
0.13mg/kg) during ischaemia improved cardiac function, survival and neurological outcomes 
(339).  
 
These promising findings led to some recent translational studies in man to investigate the 
role of nitrite-mediated protection.  Administration of dietary nitrate in the form of beetroot 
juice (with a resultant increase in plasma nitrite) to 10 healthy subjects was associated with 
diminution of ischaemia-induced endothelial dysfunction in a forearm resistance vessel 
model of IRI (338). This finding was later corroborated by Ingram and colleagues with the 
similar reduction in ischaemia-induced endothelial dysfunction in the brachial artery of 
healthy volunteers, when nitrite is administered pre-ischaemia. Preliminary data from an on-
going Phase I human trial of intravenous nitrite therapy in human cardiac arrest survivors 
exploring the safety of tolerability of intravenous nitrite administration, has suggested that 
nitrite is safe to administer to humans in doses that confer cardio-protection in animals (340). 
The majority of studies have investigated nitrite peri- or post-conditioning, whereas data 
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exists that nitrite may confer myocardial protection when delivered up to hours before the 
ischaemic insult also (332, 333, 335, 463).  
 
Despite an increasing number of studies detailing nitrite-mediated protection against IRI, 
there is a relative paucity of data outlining the exact mechanisms of this protection, 
particularly in humans. There is some evidence to suggest that NO-independent nitrite-
mediated protective activity may occur via modulation of mitochondrial function (333). The 
importance of mitochondria as the final target for protective signaling cascades such as the 
‘Reperfusion Injury Salvage Kinase’ (RISK) pathway, (as described in section 1.7.2.4) is well 
established (295). The RISK pathway (figure 1.4) comprises a series of pro-survival kinases 
which include phosphatidylinositol-3-OH kinase (P13K–Akt), extra-cellular signal-regulated 
kinases (Erk 1/2) and endothelial nitric oxide synthase (eNOS) (102, 296). Several 
experimental studies report up-regulation of eNOS phosphorylation associated with 
myocardial conditioning, downstream of Akt activation (464-467). A recent study 
demonstrated that nitrite may confer protection against vascular injury through mitochondrial 
biogenesis, independent of an NO-mediated pathway (341). Furthermore, Perlman and 
colleagues provided some important insights into the role of nitrite in cardioprotection. The 
authors demonstrated that nitrite exhibits a dose-response relationship in affording cardio-
protection in the Langendorff rat heart. Low (0.1mg/kg) and high (10mg/kg) doses of nitrite 
were cardio-protective whereas intermediate (1.0mg/kg) doses had no effect. Additionally, 
directly and through NO-release, nitrite alters tissue redox status, alters transcription factor 
signaling, protein expression and cardiac metabolism (176). Dezfulian’s study, although 
investigating mechanisms of neuro-protection, have again demonstrated nitrite-mediated 
protection via modulation of mitochondrial function, and S-nitrosation independent of sGC-
signaling pathways (340). To date, there is extremely limited data on mechanisms of 
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protection against IRI in the human myocardium, with no studies investigating the 
mechanisms of nitrite-mediated cardio-protection specifically. Furthermore, the optimal dose 
and optimal timing (i.e early vs late window of pre-conditioning) of nitrite-mediated 
cardioprotection in humans remains unknown. This requires further investigation and forms 
the basis of the work presented in this chapter.  
 
An important setting of IRI in the clinical environment is that of ‘on-pump’ cardiac surgery 
with cardiopulmonary bypass (CPB) and cardioplegic arrest. Overall 30-day cardiac mortality 
in patients undergoing CABG surgery is low at 1-3% (455, 468, 469). Nonetheless, 
depression of myocardial function with post-operative myocardial stunning and peri-
operative myocardial necrosis remains commonplace with up to 50% of peri-operative deaths 
attributed to a cardiac cause (470, 471). In one large study involving approximately 2500 
patients undergoing CABG surgery, myocardial stunning with low cardiac output syndrome 
requiring inotropes or mechanical circulatory support, was observed in 9.2% of patients, and 
in this group mortality was 16% (472). Peri-operative myocardial necrosis, as evidence by 
elevated troponins or creatinine kinase is associated with a poor prognosis over the months to 
years after the operation (473-477). Therefore, the impetus to discover methods of protection 
during CABG surgery remains strong.  
 
CPB requires cannulation of the right atrium and the ascending aorta, with re-direction of 
blood from the right atrium, via a cardio-pulmonary bypass machine into the ascending aorta, 
thus bypassing the myocardium. The aorta is cross-clamped with subsequent disruption of 
blood flow and oxygen transport to the myocardium leading to myocardial ischaemia, 
resulting in a degree of myocardial damage further compounded by IRI (478, 479). Studies 
investigating mechanisms of IRI have consistently demonstrated that oxidative stress plays an 
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important role in myocardial IRI in patients undergoing cardiac surgery with CPB and 
cardioplegic arrest, as evidenced in some studies by elevated levels of plasma 8-isoprostane 
(a well recognised marker of oxidative stress) (479-482). However, limited data exists on the 
exact mechanisms of myocardial protection in patients undergoing cardiac surgery. One 
human study proposed that post conditioning in human atria (in patients undergoing coronary 
artery bypass grafting surgery) occurs via the RISK pathway (483). In a recent study, 
Cappellano et al observed up-regulation of RISK-pathway associated proteins (extracellular 
signal-regulated kinases 1 and 2, Erk 1/2) in patients undergoing valvular cardiac surgery 
(484). During cardiac surgery, the timing of ischaemia is known in advance, allowing 
investigation of pre-conditioning agents to be undertaken. Hence, the setting of CABG 
surgery lends itself well to investigate the possible mechanisms by which nitrite exerts its 
cytoprotective effects. Additionally, there is no data to date outlining the role of the RISK 
pathway in nitrite-mediated cardioprotection specifically and thus the current study attempts 
to elucidate this further.  
 
5.2 Objectives 
The aim of this double-blind, ‘proof of principle’ study was to determine the molecular 
mechanisms that might lead to cardioprotection by nitrite in humans, in the setting of CABG 
surgery. The objectives of this study are as follows:- 
 
1. To determine if nitrite confers cardioprotection through reduction of intra-operative 
myocardial injury (troponin) and reduction of intra-operative oxidative stress. 
2. To determine the time-scale of nitrite-mediated cardioprotection against IRI e.g. early 
window and late window. 
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3. To determine the optimal dose of nitrite required for cardioprotection. 
4. To determine whether the RISK pathway is involved in nitrie-mediated 
cardioprotection. Tissue and blood samples obtained at the time of surgery will help 
elucidate the molecular and metabolic mechanisms which play a role in the 
conditioning pathways involved in ischaemia-reperfusion injury.  
 
5.3 Methods 
5.3.1 Participants 
The study was granted full ethical approval (South Birmingham Local Research Ethics 
Committee 09/H1207/7) and was registered with the UK Clinical Research Network (No. 
9329; www.ukcrn.org.uk). The investigation conforms to the principles outlined in the 
Declaration of Helsinki. Patients, undergoing isolated coronary artery bypass grafting surgery 
were recruited from pre-admission clinics or cardiology/cardiac surgery wards at the Queen 
Elizabeth Hospital Birmingham NHS Trust. All of the subjects gave written, informed 
consent after satisfying the inclusion and exclusion criteria (table 5.1). All subjects were 
admitted onto the cardiac surgery/cardiology ward the day before surgery and were fasted 
from midnight prior to their surgery, as part of their surgical management. The study was 
conducted on the ward (pre-surgery nitrite infusion) and in dedicated cardiac theatres at the 
University Hospital Birmingham NHS Trust. All subjects were requested to adhere to the 
following advice prior to their surgery:- 
 
1. Omit nitrate medication 72 hours prior to surgery. 
2. To follow a nitrate/nitrite-poor diet for 2 days prior to surgery (table 5.2). 
3. To abstain from alcohol and caffeine-containing drinks for 24 hours prior to surgery. 
157 
 
Table 5.1: Inclusion/exclusion criteria for recruitment into study. 
 
 
Table 5.2: List of food items subjects were asked to abstain from, as part of a nitrate/nitrite 
poor diet. 
Leafy vegetables e.g. Cured meat Pickled vegetables 
Lettuce Cured fish Pickled meat 
Beetroot  Pickled fish 
Celery   
Radish   
Rhubarb   
Turnip   
Spinach   
 
Inclusion criteria 
 Patients undergoing isolated first time multi-vessel CABG 
 Aged 18 years or over 
 
 
Exclusion criteria 
 Significant psychiatric /neurological impairment that might prevent 
adherence to the requirements of the protocol or the ability to give informed 
consent 
 Redo operation 
 Age >80 years 
 Pregnancy 
 Renal Impairment requiring pre-operative renal support 
 Diabetes Mellitus 
 Intended heart valve or additional surgery 
 Episodes of angina or ischaemia within 48hours prior to the procedure 
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5.3.2 Study protocol 
44 patients, who were undergoing isolated CABG surgery for multi-vessel coronary artery 
disease (elective and urgent), were recruited and underwent evaluation of myocardial 
protection afforded by systemic nitrite infusions, administered 24 hours prior to onset of 
ischaemia (late window) or immediately before onset of ischaemia (early window). Figure 
5.1 outlines the flow of patients through the study. Figure 5.2 outlines the study protocol. 
The study drug was administered in a double-blind manner and assigned randomly on a 1:4 
basis. Randomisation was undertaken via a computer-generated randomisation schedule, 
undertaken by a person independent of the study. The schedule generated was placed in 
sequentially numbered sealed envelopes. 
 
(1) Day before Surgery 
Following admission to the hospital ward (the day prior to surgery), all subjects received a 30 
minute infusion of i.v. sodium nitrite or placebo (0.9% saline, Infusion 1). Subjects rested in a 
semi-recumbent position on a hospital bed and an intravenous cannula (Venflon, 20 Gauge) 
was placed in each antecubital fossa. One intravenous cannula was used to administer the 
infusion, with blood obtained from the non-infused arm cannula. A blood pressure cuff and 
an oxygen saturation probe were placed on the infusion arm. After 5 minutes of rest, heart 
rate (HR) and blood pressure (BP) was recorded. 10ml of venous blood was extracted. 2mL 
was analysed immediately for metHb and 8mL stored for later analysis of plasma 
nitrite/nitrates and plasma 8-isoprostane, as described in section 5.3.3. Thereafter, a 30minute 
infusion of the study drug (nitrite/placebo) was initiated. After 30 minutes, peripheral 
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haemodynamic parameters were re-measured and a further 10ml of venous blood was 
obtained and analysed as described in section 5.3.3.  
 
 
 
 
Figure 5.1: Flowchart depicting study design. Infusion 1: 30minute i.v. infusion of sodium 
nitrite (1µg/kg/min or 10µg/kg/min) or placebo (0.9% saline) at infusion rate of 1mL/min the 
day before surgery. Infusion 2: 30minute i.v. infusion of sodium nitrite (1µg/kg/min or 
10µg/kg/min) or placebo (0.9% saline) at infusion rate of 1mL/min intra-operatively. 
160 
 
 
 
Figure 5.2: Study protocol. AXC, aortic cross-clamp; CPB, cardiopulmonary bypass; LV, left ventricle.  
Infusion 1 and Infusion 2 = i.v. sodium nitrite (1 or 10µg/kg/min) or placebo (0.9% saline) for 30minutes at infusion rate of 1mL/min.  
*Peripheral venous blood sampling and **peripheral arterial blood sampling. 
#
Coronary sinus blood sampling and 
$
arterial blood sampling (via 
cardiopulmonary circuit).  
LV biopsy 1, pre-AXC (pre-ischaemia); LV biopsy 2, pre-reperfusion; LV biopsy 3, 10minutes post-reperfusion. 
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(2) Day of Surgery 
On the day of surgery, subjects underwent general anaesthesia as per a standardised clinical 
protocol (appendix 1). Briefly, anaesthesia was induced with etomidate, fentanyl, and 
rocuronium with the use of propofol and alfentanil for maintenance, supplemented on cardio-
pulmonary bypass by isoflurane. Following induction of anaesthesia, all subjects underwent 
placement of a 4French right internal jugular central venous line, a 7.5French, quadruple-
lumen Swanz-Ganz catheter via the right internal jugular vein (Edwards Lifesciences, 
California, USA , a 20Gauge cannula (Becton Dickinson UK Ltd) into the right radial artery 
and a trans-oesophageal echocardiogram (TOE) probe (Philips CX50, USA). These 
procedures were performed by a Clinician (independent of the study) and positioning of the 
central venous and radial arterial catheters was confirmed by pressure waveform monitoring.  
The position of venous lines remained unchanged for the duration of the study and placement 
of the Swan-Ganz catheter allowed invasive cardiac measurements, as described in section 
5.3.5.  
 
Following transfer to the operating table, CABG surgery was commenced as per a 
standardised protocol (appendix 1). Briefly, a membrane oxygenator at 34°C was utilised to 
undertake CPB. Standard, clinical myocardial protection was undertaken using intermittent 
antegrade cold blood cardioplegia (St Thomas cardioplegia, Martindale Pharmaceuticals, 
Essex, United Kingdom) with an initial dose of 12 mL/kg followed by maintenance 
administration every 20 minutes. All anastomoses were made using a single cross-clamp 
technique. Discontinuation of CPB was undertaken when the patient’s temperature reached 
36°C (as measured by a nasopharyngeal temperature probe). All subjects underwent 
placement of epicardial wires for atrial or dual-chamber pacing, with a target heart rate of 
162 
 
90bpm. During surgery, if inotropic support was required, dopamine (3 to 10µg/kg/min), was 
commenced if the cardiac index (CI) was ≤2.2 L/min/m2 in the presence of a central venous 
pressure (CVP) of 12 mmHg, pulmonary capillary wedge pressure (PCWP) of 14 mmHg, and 
heart rate (HR) of 90bpm. Escalation of inotrope therapy with epinephrine or norepinephrine 
or intra-aortic balloon pump (IABP) insertion was allowed at the clinician’s discretion. 
Introduction of support was also permitted if the operating surgeon identified poor 
contractility at separation of CPB. Intraoperative boluses of phenylephrine were used to 
maintain a mean arterial blood pressure (MABP) of ≥55 mmHg during CPB and ≥65 mmHg 
after discontinuation of CPB and with associated low systemic vascular resistance (SVR). As 
part of the study protocol, during surgery a retrograde cardioplegia cannula was inserted into 
the coronary sinus (CS) for blood sampling only and placement confirmed by trans-
oesophageal echocardiography. 
 
Prior to sternotomy, cardiac and peripheral haemodynamic measurements were undertaken as 
detailed in section 5.3.5. A 12mL sample of venous blood (from the distal port of the Swanz-
Ganz catheter) and a further 10mL sample of arterial blood (from the radial arterial cannula) 
were obtained. These samples were analysed immediately for methaemoglobin, pH and 
lactate using a blood gas analyser, and some stored for later analysis (section 5.3.3). 
Thereafter, a 30minute infusion of the study drug (nitrite/placebo, Infusion 2) was 
commenced via the right internal jugular central venous catheter, with the aim of completing 
this infusion within 30minutes of onset of ischaemia. Following completion of the study 
drug, repeat cardiac and peripheral haemodynamic measurements were recorded and venous 
and arterial blood samples obtained, as described above.  
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As the operation proceeded, biopsy and further blood samples were obtained at the time-
points indicated in figure 5.2 and outlined below:-  
 
i. Pre-ischaemia - prior to placement of aortic cross-clamp (pre AXC), a left ventricular 
(LV) biopsy was obtained, as described below (LV 1). 12mL of coronary sinus 
venous blood and 10mL of arterial blood was obtained.  
ii. Pre-reperfusion– prior to reperfusion (removal of AXC) – a further LV biopsy was 
obtained (LV 2). 
iii. Reperfusion 10minutes - blood (coronary sinus and arterial via CPB pump) was 
obtained at 10minutes post-removal of aortic cross-clamp. A further LV biopsy (LV 
3) was obtained at 10minutes post-reperfusion. 
iv. 5 minutes post CPB – 5minutes after discontinuation of CPB, further blood samples 
(coronary sinus and peripheral arterial) were taken. 
 
During the surgery, cardiac and peripheral haemodynamic measurements (section 5.3.5) were 
undertaken at the following time-points:- 
i. Pre-administration of intra-operative study drug.  
ii. Post-administration of intra-operative study drug. 
iii. Pre-CPB. 
iv. 5minutes post discontinuation of CPB. 
 
5.3.3 Blood sample analysis 
Blood samples obtained intra-operatively were analysed for the following:- 
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1. Plasma nitrite/nitrate in venous and arterial (pre and post infusion 2) and CS and 
arterial blood, pre AXC, at 10minutes post-reperfusion (Rep 10) and 5minutes after 
discontinuation of CPB (Off CPB).  
2. Plasma 8-isoprostane in CS and arterial blood obtained pre AXC, at 10minutes post-
reperfusion and 5minutes after discontinuation of CPB. 
3. Plasma troponin in coronary sinus blood, obtained pre AXC and 5minutes after 
discontinuation of CPB. 
4. Immediate blood gas analysis for pH, lactate and metHb in venous/CS and arterial 
blood before and after infusion 2 and pre AXC, at 10minutes post-reperfusion and 
5minutes after discontinuation of CPB. 
 
(1) Plasma nitrite/nitrate analysis 
For analysis of plasma nitrite/nitrate, 4mL of blood was transferred into an EDTA collection 
tube (K3 EDTA, BD Vacutainers) pre-treated with N-ethylmaleimide (10mM; Merck, 
Germany). These samples were centrifuged at 2000rpm at 4ºC followed by immediate snap-
freezing in liquid nitrogen and storage at -80ºC for later analysis of plasma nitrite/nitrates, as 
described in Chapter 2, section 2.4.5. 
 
(2) Plasma analysis of 8-isoprostane 
To investigate the effect of nitrite on oxidative stress, plasma 8-epi-prostaglandin F2α (8-epi-
PGF 2α) was measured. 8-epi-PGF 2α is a well recognised marker of oxidative stress (485). 
4mL of blood was added to a second EDTA tube.  These samples were centrifuged at 
2000rpm at 4ºC. 2mL of plasma for measurement of 8-epi-prostaglandin F2α (8-epi-PGF 2α) 
was aliquoted to tubes, each containing 20µL of 0.005% butylated hydroxytoluene (BHT; a 
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free radical scavenger), snap-frozen in liquid nitrogen and stored at -80ºC for later analysis. 
The samples were purified and analysed for 8-epi-PGF 2α using a commercially available 
affinity sorbent and enzyme immunoassay kit as per the manufacturer’s instruction (Cayman 
Chemical, Ann Arbor, MI, USA). Briefly, the plasma samples were thawed and centrifuged 
at 2000rpm at 4ºC for 5minutes to remove particles and diluted 1:5 with 0.1M phosphate 
buffered solution, (PBS/column buffer; pH 7.4). The affinity sorbent was washed twice with 
PBS. 1mL of plasma was added to 100μL of affinity sorbent and gently agitated for 
60minutes, followed by centrifugation at 2000rpm for 5minutes. The sorbent was separated 
from the supernatant be pipetting/decanting, and washed with 1mL of PBS (0.1M, pH 7.4), 
centrifuged for a further 5minutes at 2000rpm followed by removal of excess supernatant. 
Following a further washing step with 1mL of ultra pure water, the 8-isoprostane was eluted 
from the affinity sorbent using 0.5mL of eluting solution (95% ethanol/5% ultra pure water). 
This solution was centrifuged at 2000rpm for 5minutes.  The eluting solution containing the 
8-isoprostane was transferred to a clean tube, with a further 0.5mL of eluting solution added 
and centrifuged again. The samples were evaporated to dryness under vacuum centrifugation 
and reconstituted in methanol. 50μL aliquots of sample per well were added to a 96-well 
plate in triplicate, containing 50μL 8-isoprostane AChE tracer and 50μL of 8-isoprostane 
antiserum. The plates were covered with plastic film and incubated at 4ºC for 18 hours. After 
rinsing the wells five times with wash buffer, 200μL of Ellman’s reagent was added to each 
well and the plate contents were gently mixed in the dark (at room temperature) for 2 hours. 
A spectrophotometric microplate reader (410nm) was used to measure the absorbance of each 
well.  
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(3) Blood gas analysis  
Lactate, pH and metHb quantification was performed immediately with 2ml of blood using a 
blood gas analyser (Bayer Rapidlab 865, Siemens, Tarrytown, NY). 
 
(4) Troponin analysis  
2mL of blood for troponin T (TnT) was transferred into a Lithium heparin bottle and sent to 
the Biochemistry laboratory (at University Hospitals Birmingham) for immediate analysis. 
This was undertaken using a commercially available assay (Elecsys 170, Roche Diagnostics, 
United Kingdom).   
 
5.3.4 Western blot analysis for phosphorylation of eNOS and AkT in LV cardiac 
biopsies  
LV biopsies were obtained at three time points – pre-ischaemia (LV 1), pre-reperfusion (LV 
2) and 10minutes post-reperfusion (LV 3). These were immediately snap-frozen in liquid 
nitrogen and stored at -80ºC until used Western blot analysis of endothelial nitric oxide 
synthase (eNOS) and protein kinase B (Akt). 
 
At the time of the Western blot analysis, the samples were homogenized under liquid 
nitrogen conditions with lysis buffer (pH 7.4) containing 2mM sodium orthovanadate, 5mM 
sodium fluoride, 1 x complete protease inhibitor tablet (Roche Applied Sciences, Upper 
Bavaria Germany). The samples were placed immediately back into liquid nitrogen, followed 
by two times freeze-thawing procedure. Once samples were thawed the cardiac lysate was 
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centrifuged at 13,000 rpm for 15 minutes at 4°C. The supernatant was transferred into a new 
eppendorff tube and placed on ice for protein content analysis. 
 
Protein content was quantified using the BCA protein assay kit (Thermo Scientific, Waltham 
MA, USA). Briefly, assay reagents A and B supplied were mixed in a ratio of 20:1. Bovine 
serum albumin at concentrations of 0 -1.0µg/µL was used to create a standard curve. 5uL of 
each sample of homogenate was diluted in 10uL of lysis buffer. 5uL of cardiac lysate was 
added to the 96-well plate for triplicate analysis. 25ul of reagent A was added to each of the 
wells, followed by 200uL of reagent B. The plate was incubated for 15 min with foil. After 
15mins, the absorbance was read at 750nm. The sample was compared against the standard 
curve and the samples were normalised to 25ug protein with 1 x Laemmli Buffer (Bio-rad, 
Hercules, CA, USA) with 5% mercaptoethanol and stored at -80ºC for Western blot analysis. 
 
Western blotting protocol  
Samples were allowed to thaw in ice, followed by boiling at 95°C for 5 min. The samples 
were centrifuged at room temperature at 1200 rpm for 10 min). 40uL of sample was loaded 
onto a SDS polyacrylamide gel electrophoresis (SDS-page) to separate the proteins based on 
molecular weight. The gels were run on at 180V for approximately 60 minutes or until the 
protein marker was seen to have run off the gel. Once completed, gels were removed from the 
tank and placed into cooled wet transfer tank (4ºC; Wet transfer buffer: 3g Tris Base, 14.4g 
Glycine, 200ml methanol, made up to 1L with ddH20).The transfer stacks were formed with 
a layer of fibre pad and pre-cut blotting paper (both soaked in transfer buffer) as the base for 
the gel. A polyvinylidene difluoride (PVDF) membrane (activated by soaking in 100% 
methanol for 10 minutes prior to rinsing in transfer buffer) was placed on top of the gel and 
the stack was completed with further layers of blotting paper and fibre pad, prior to rolling to 
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remove air bubbles. Transfers were conducted for 1.5 hrs at 30V with constant stirring using 
a magnetic flea.  
 
After transfer, PVDF membrane were placed in blocking buffer containing 5% non-fat 
milk/0.05% PBS Tween*20 detergent for 2 hours at room temperature on the shaker. After 2 
hours blocking, the PVDF membranes was incubated with the primary antibody (phospho-
eNOSser1177 (1:500/1% non-fat milk and PBS/Tween; Cell Signalling Tech, Danvers, MA, 
USA); total eNOS (1:200; BD Bioscience, Franklin Lakes, New Jersey, USA); phospho-AKT 
ser473(1:1000; Cell Signalling Tech, Danvers, MA, USA) or total AKT (1:2000; Santa Cruz 
Biotech, Dallas, TX, USA). Primary antibody was incubated overnight on shaker at 4ºC.  
 
The next day, primary antibody was removed and washed four times for 15 minutess each 
with PBS/Tween. After washing, the membrane was incubated on the shaker for 1 hour 
(room temperature) with the secondary antibody (horseradish peroxidase–conjugated donkey 
anti-rabbit immunoglobulin G (1:1000 in 5% milk/PBS Tween; GE healthcare, Amersham, 
UK).  After 1 hour, the membrane was then washed with PBS/Tween 4 times for 15 minutes 
each.  
 
ECL detection reagent (GE Healthcare, Amersham, UK) was mixed in a 1:1 ratio and pipette 
onto the membrane for 5 minutes at room temperature. The resulting chemiluminescence was 
detected using ECL film (GE Healthcare, Amersham, UK). Western blots were scanned and 
quantified using Gel-Pro analyser software. To determine equal loading of samples, 
glyceraldehyde-3-phosphate dehydrogenase (GADPH; 1:1000; Abcam, Cambridge, UK) was 
also conducted. 
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5.3.5 Cardiac and Peripheral Haemodynamic measurements 
The following peripheral and cardiac haemodynamic parameters were recorded at the time 
points specified previously:- 
i. Heart rate (HR) 
ii. Mean arterial blood pressure (MABP) 
iii. Pulmonary artery pressure (PAP)  
iv. Pulmonary capillary wedge pressure (PCWP)  
v. Systemic vascular resistance (SVR) 
vi. Central venous pressure (CVP) 
vii. CO (Thermodilution method) 
 
5.3.6 Study drug 
1µg/kg/min or 10 µg/kg/min sodium nitrite or 0.9% saline was infused at a rate of 1mL/min 
over 30minutes. Sodium nitrite was purchased from Martindale Pharmaceuticals (Brentwood, 
UK). 0.9% sodium chloride (Baxter Healthcare, USA) was used for the placebo infusion. The 
study drug was prepared by a member of clinical staff (nurse or theatre practitioner 
independent of the study) with the researcher blinded to this process. 
 
5.3.7 Statistical analysis 
The data were analysed using SPSS version 21.0 software (SPSS Inc., Chicago, USA). The 
data are expressed as mean ± standard error of mean (mean±SEM) or median (upper quartile 
ranges), unless otherwise stated. Probability values of <0.05 were considered statistically 
significant. Continuous data were analysed using repeated measures ANOVA with 
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consecutive Bonferroni post-hoc tests for serial measurements between subjects or paired t-
test. Categorical data were compared suing Chi-Square test and ordinal data with Kendall-tau 
b. Due to a change in assay part way through the study (without informing the research team), 
later samples (from 20 subjects) were analysed for high sensitivity troponin (hsTnT) instead 
of troponin T. To allow for this, analysis of samples undertaken from a separate group of 
patients undergoing CABG for both troponin and hsTnT were used to construct a regression 
model (using Pearson’s correlation) and this was used to predict TnT levels from the hsTnT 
values obtained.  
 
5.4 Results 
5.4.1 Patient characteristics 
The characteristics of the patient’s taking part in the study are outlined in table 5.3. All 
subjects underwent a standardised anaesthetic and surgical operation, as outlined previously 
The subjects were split into 5 groups: ‘Placebo’ (0.9% saline), ‘Late_1’ (sodium nitrite 
1µg/kg/min the day before surgery, ‘Early_1’ (sodium nitrite 1µg/kg/min during surgery), 
‘Late_10’ (sodium nitrite 10µg/kg/min the day before surgery) and ‘Early_10’ (sodium 
nitrite 10µg/kg/min during surgery). Nitrite infusion was well tolerated in all patients with no 
adverse effects reported. 
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Table 5.3 Placebo Late_1 
 
Early_1 
 
Late_10 
 
Early_10 
 
P value 
Age, yrs (mean±SD) 68±9 61±2 66±3 61±3 63±3 ns 
Male, n (%) 7(88) 7(78) 7(78) 8(89) 9(100) ns 
BMI (kg/m
2
) 26±1 30±2 29±3 26±1 28±1 ns 
Elective, n (%) 7(88) 6(67) 7(78) 5(56) 6(67) ns 
Angina CCS class 2(1 – 2) 2(2 – 2) 2(2 – 2) 2(2 – 2) 2(1 – 2) ns 
NYHA class 1(1 – 1) 1(1 – 1) 1(1 – 1) 1(1 – 2) 2(1 – 2) ns 
Preserved LV function, n (%) 7(88) 7(78) 9(100) 7(78) 6(67) ns 
Logisitic Euroscore 0.8 
(0.7 – 1.0) 
1.2 
(1.0 – 1.6) 
1.9 
(1.2 – 2.4) 
1.5  
(1.2 – 2.8) 
1.5 
(1.0 – 3.1) 
ns 
Standard Euroscore 4(2 – 4) 1(1 - 2) 3(1 – 3) 2 (1 – 4) 2(1 – 4) ns 
Comorbidities       
Recent AMI, n(%) 3(38) 4(44) 4(44) 5(56) 5(56) ns 
Hypertension, n(%) 5(63) 5(56) 7(78) 4(44) 3(33) ns 
Hypercholesterolaemia, n(%) 5(63) 3(33) 5(56) 2(22) 3(33) ns 
Previous TIA/CVA, n(%) 1(13) 0(0) 0(0) 1(11) 0(0) ns 
Smokers, n(%) 5(63) 7(78) 4(44) 4(44) 4(44) ns 
Pre-operative bloods       
Hb (g/dL) 13.7±0.4 14.0±1.0 14.0±1.0 14.0±0.5 14.0±0.4 ns 
Fasting glucose (mmol/L) 5.2±0.2 5.9±0.3 5.9±0.2 5.9±0.3 6.0±0.2 ns 
Creatinine (µmol/L) 87±9 88±8 89±3 95±10 88±12 ns 
Pre-operative medication       
Aspirin, n(%) 8(100) 9(100) 9(100) 7(78) 8(89) ns 
Statin, n(%) 8(100) 9(100) 8(89) 9(100) 9(100) ns 
Β-blockers, n(%) 8(100) 8(89) 6(67) 7(78) 7(78) ns 
ACEI/ATII blockers, n(%) 7(88) 5(56) 8(89) 7(78) 7(78) ns 
Ca-channel blockers, n(%) 2(25) 1(11) 2(22) 2(22) 3(33) ns 
Diuretics, n(%) 3(38) 0(0) 1(11) 1(11) 2(22) ns 
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Table 5.3 (previous page): Patient characteristics. There was no significant difference in 
baseline characteristics between patients in different groups. N=8-9, ns=p>0.05. Data is 
expressed as mean±SEM or median (inter-quartile ranges).  
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Pre-operative oral nitrate use was present in a minority of patients in each group. In the 
placebo group, 3(38%) of subjects were prescribed oral nitrate and this was discontinued 7(5 
– 10) days prior to surgery. In the Late_1 group, 1(11%) subject received oral nitrates and 
this was discontinued 3(3 - 3) days before the day of surgery. Similarly oral nitrates were 
prescribed to 1(11%), 3(33%) and 1(11%) of subjects and these were discontinued 4(4 – 4) 
days, 4(1 – 3) days and 4(4 – 4) days in the three further groups Early_1, Late_10 and 
Early_10, respectively. 
 
Time between study drug infusion and pre-ischaemia are outlined in table 5.4.  
 
 Placebo 
N=8 
Late_1 
N=9 
Early_1 
N=9 
Late_10 
N=9 
Early_10 
N=9 
P value 
No. of grafts 4(3 – 4) 4(4 – 5) 4(3 – 4) 3(3 – 4) 3(3 – 4) ns 
CPB time (min) 121±9 138±8 125±12 107±7 103±8 ns 
AXC time (min) 73±3 80±6 77±9 70±5 71±6 ns 
Time from Inf 1 to AXC (hrs) 19.7±0.8 17.9±1.0 18.2±0.7 17.4±1.1 17.4±0.5 ns 
Time from Inf 2 to AXC (min) 54±6 61±8 52±5 59±7 43±6 ns 
 
Table 5.4 (above): Intra-operative details. There was no difference in ischaemia time or ‘time 
of study infusions to ischaemia’ between groups. Data is expressed as mean±SEM or median 
(inter-quartile ranges), ns=p>0.05. 
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5.4.2 Effect of nitrite infusion on heart rate and blood pressure  
Figure 5.3 depicts the HR and MABP before and after infusion 1 and infusion 2. 
Administration of 1µg/kg/min and 10µg/kg/min of i.v. sodium nitrite did not result in 
alteration of either HR or MABP after 30minutes. 
 
 
 
 
Figure 5.3: A) HR during infusion 1; B) HR during infusion 2; C) MABP during infusion 2; 
D) MABP during infusion 2. N=8-9, p>0.05. Data is expressed as mean±SEM. 
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5.4.3 Effect of nitrite infusion on intra-operative haemodynamic parameters 
Intra-operative cardiac and peripheral haemodynamic variables, measured before 
commencement of and 5 minutes after discontinuation of cardio-pulmonary bypass (CPB) are 
shown in figure 5.4.  
 
Intra-operative CO increased significantly from pre-CPB measurements to following 
discontinuation of cardiopulmonary bypass (post-CPB) , in the placebo group and the two 
groups that received nitrite the day before surgery (figure 5.4 A). Pre-CPB cardiac output 
increased from 4.2±0.4L/min to 5.3±2.3L/min, 4.3±0.4L/min to 5.2±2.1L/min and 
4.2±0.4L/min 5.4±2.1L/min in the Placebo, Late_1 and Late_10 groups, respectively (p<0.01 
for all, n=8 each group). There appeared to be an attenuation of CO increase in subjects 
receiving nitrite intra-operatively. CI exhibited a similar pattern to CO (figure 5.4B).  
 
Although, there was a general reduction in mPAP pre and post CPB, this only reached 
significance in patients receiving 10µg/kg/min of nitrite intra-operatively (figure 5.4C). 
mPAP in the Early_10 group decreased from 22±2mmHg pre-CPB to 17±2mmHg post CPB 
(p<0.05, n=8 each group). There was a reduction in mPCWP within all groups (figure 5.4D). 
Pre-CPB, mPCWP was 14±1mmHg, 14±1mmHg, 16±1mmHg, 11±1mmHg and 14±1mmHg 
and fell to 9±1mmHg, 8±1mmHg, 8±1mmHg, 8±1mmHg and 9±1mmHg in the Placebo, 
Late_1, Early_1, Late_10 and early_10 groups, respectively (p<0.05 for all, n=8 each group). 
 
SVR fell significantly pre and post CPB in all groups except those receiving intra-operative 
10µg/kg/min of nitrite (figure 5.4E). Pre-CPB SVR measurements were 1268±240, 
1279±132, 1248±137 and 1413±131 dyne*s/cm
^5
 and deceased to 1082±122, 958±114, 
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989±115and 971±115 dyne*s/cm
^5
 in the Placebo, Late 1, Early_1 and Late_10 groups, 
respectively (p<0.05, n=8 each group). There was no significant change in MABP pre and 
post CPB in any group (figure 5.4F).  
 
Despite changes within groups between pre and post CPB measurements, as outlined above, 
there was no significant between-groups difference in any of the parameters, as measured by 
2-way ANOVA (p>0.05, n=8 in each group). 
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Figure 5.4: A) CO, B) CI, C) mean PAP, D) mean PCWP, E) SVR and F)MABP. *p<0.05, 
**p<0.01, ***p<0.001 comparing pre and post CPB measurements. N=8, Data is expressed 
as Data is expressed as mean±SEM. 
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5.4.4 Venous methaemoglobinaemia associated with nitrite infusion 
Venous methHb increased significantly from baseline with i.v. infusion of 10µg/kg/min of 
sodium nitrite during both ‘late’ and ‘early’ infusions (figure 5.5, A and B). Following 
administration of 10µg/kg/min of sodium nitrite the day before surgery, venous metHb rose 
from 0.64±0.06% at baseline to 0.88±0.08 (p<0.01, n=8-9). Similarly, following intra-
operative administration of 10µg/kg/min of sodium nitrite, baseline venous metHb was 
0.63±0.06% and increased to 0.98±0.07% after 30minutes (p<0.05, n=8-9).  
 
There was a small, statistically significant decrease in venous lactate levels during the 
placebo infusion administered the day before surgery. Initial lactate levels were 
1.4±0.14mmol/L and decreased to 1.17±0.12mmol/L after 30minutes of i.v. 0.9% saline 
(p<0.05, n=8, figure 5.5 C and D). There was no significant change in acid-base balance 
(figure 5.5 E and F) or lactate levels associated with nitrite infusion, either the day before 
surgery or intra-operatively.  
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Figure 5.5: A) Venous metHb infusion 1; B) Venous metHb infusion 2; C) Lactate infusion 
1; D) Lactate infusion 2; E) pH infusion 1; F) pH infusion 2. *p<0.05 and **p<0.01 
comparing pre and post infusion values. N=8-9, data is expressed as mean±SEM.  
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5.4.5 Changes in intra-operative acid-base balance 
During surgery, there was no change in pH between groups or within each group at any time-
point (figure 5.6 A and B). Overall lactate levels were higher prior to onset of ischaemia (pre 
AXC) and fell following onset of reperfusion (figure 5.6 C and D, p<0.001 compared to 
placebo group for both arterial and coronary sinus samples). Pooled mean lactate levels prior 
to onset of ischaemia were 4.34±0.17mmol/L and 4.15±0.12mmol/L in arterial and coronary 
sinus blood, respectively. Following onset of reperfusion, lactate levels fell to 
2.66±0.12mmol/L and 3.05±0.13mmol/L in arterial and coronary sinus blood, respectively 
(p<0.001, n=44). Thereafter, lactate levels did not alter significantly. Between groups 
analysis did not demonstrate any difference in change in lactate levels between the five 
groups at any timepoint.  
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Figure 5.6: A) Intra-operative pH in arterial blood; B) Intra-operative pH in CS blood; C) 
Intra-operative lactate in arterial blood; D) Intra-operative lactate in CS blood. N=8-9, 
*p<0.01 compared to pre-ischaemia (preAXC levels). Rep 1min, 5min and 10min = 1minute, 
5minutes and 10minutes post onset of reperfusion, respectively. Off CPB = 5 minutes after 
discontinuation of cardiopulmonary bypass. Data is expressed as mean±SEM. 
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5.4.6 Plasma nitrite and nitrate levels 
Following administration of i.v. sodium nitrite, plasma nitrite and nitrate levels increased in a 
dose-dependent manner (figure 5.7 A and C). Administration of 1µg/kg/min of nitrite 
resulted in an increase in venous plasma nitrite from 1.1±0.4µM to 1.8±0.6µM the day before 
surgery (figure 5.7A) and 1.2±0.1µM to 2.0±0.4µM intra-operatively (*p<0.05 comparing 
pre and post infusion values, figure 5.7C). Administration of 10µg/kg/min of nitrite was 
associated with a greater increase in venous plasma nitrite levels from 1.3±0.2µM to 
5.2±2.0µM (**p<0.01 comparing pre and post infusion values, figure 5.7A) the day before 
surgery and, 1.2±0.1µM to 6.1±0.3µM during surgery (***p<0.001 comparing pre and post 
infusion values, figure 5.7C). Peripheral arterial blood was also sampled intra-operatively. 
Following administration of 1µg/kg/min, arterial plasma nitrite increased from 1.7±0.4µM to 
3.0±2.0µM (**p<0.01 comparing pre and post infusion values) with a greater increase seen 
following 10µg/kg/min of nitrite from 2.4±0.4µM to 10.5±0.2µM (***p<0.001 comparing 
pre and post infusion values). Baseline nitrite levels were higher in arterial plasma compared 
to venous plasma (
#
p<0.05).  
 
Following nitrite infusion administered the day before surgery, there was a small dose-
dependent increase in venous plasma nitrate levels following 1µg/kg/min of i.v. sodium 
nitrite from 31.3±4.2µM to 34.5±4.9µM (*p<0.05 comparing pre and post, figure 5.7B). 
10µg/kg/min i.v. sodium nitrite was associated with an increase in venous plasma nitrate 
from 27.3±3.5µM to 37.2±3.6µM (**p<0.01 comparing pre and post). In contrast, intra-
operative nitrite infusion did not yield any significant change in plasma nitrate levels (figure 
5.7D). In subjects receiving 1µg/kg/min of i.v. sodium nitrite, pre-infusion nitrate 
concentration was 19.2±3.4µM and post-infusion nitrate concentration was 18.2±2.4µM 
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(p>0.05). Intra-operative 10µg/kg/min i.v. sodium nitrite was associated with a non-
significant increase in nitrate concentration from 20.3±3.2µM to 25.8±2.3µM (p>0.05).   In 
arterial blood, nitrate concentration exhibited a similar pattern of change to that in venous 
plasma. 1µg/kg/min of i.v. sodium nitrite was not associated with a change in arterial plasma 
nitrate concentration and 10µg/kg/min of i.v. sodium nitrite was accompanied by a small, 
non-significant increase in arterial plasma nitrate concentration.  Baseline plasma nitrate 
concentration was higher in arterial blood compared to venous blood (
#
p<0.05).   
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Figure 5.7: A and B) Venous plasma nitrate and nitrate levels Infusion 1; C and D) Venous 
and arterial plasma nitrate and nitrate levels Infusion 2. *p<0.05, **p<0.01 and **p<0.001 
comparing pre and post infusion values. 
#
p<0.05 comparing pre-infusion venous vs pre-
infusion arterial levels. N=8-9, Data is expressed as mean±SEM. 
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Intra-operative plasma nitrite and nitrate concentration were also measured in coronary sinus 
and arterial blood, prior to onset of ischaemia (Pre AXC), 10 minutes after start of 
reperfusion (Rep 10) and 5 minutes after discontinuation of cardio-pulmonary bypass (Off 
CPB), as depicted in figure 5.8. Administration of 10µg/kg/min of i.v. sodium nitrite intra-
operatively (Early_10 group) was associated with an higher pre-ischaemia nitrite 
concentration in both coronary sinus (CS) and arterial compared to the placebo group (***p< 
0.001, figure 5.8 A and B). Following onset of reperfusion, nitrite concentration fell to 
placebo levels (
$
p<0.001 compared to pre-ischaemia, figure 5.8 A and B) and remained at 
that level after discontinuation of CPB. 1µg/kg/min of i.v. sodium nitrite was not associated 
with a noticeably different pre-ischaemia nitrite concentration in CS or arterial plasma 
compared to the placebo group. Overall, pre-ischaemia nitrite concentration (both CS and 
arterial) was higher compared to 10 minutes post-reperfusion and after CPB discontinuation 
(
#
p<0.01, figure 5.8 A and B). Both CS and arterial plasma nitrate levels exhibited a similar 
pattern with non-significantly higher nitrate concentration in both the Placebo and the 
Early_10 groups at all time-points (p>0.05, figure 5.8 C and D). Overall, nitrate 
concentration were higher at all time-points in arterial plasma compared to CS plasma 
(
§
p<0.001 CS vs arterial, figure 5.8 C and D).          
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Figure 5.8: Intra-operative plasma nitrite and nitrate concentrations. A) CS nitrite, B) 
Arterial nitrite, C) CS nitrate and D) Arterial nitrate. Pre AXC, pre-ischaemia, Rep 10, 
10minutes after onset of reperfusion and off CPB, 5 minutes after discontinuation of CPB. 
***p<0.001 compared to Placebo group, #p<0.02 compared to pre-ischaemia, 
$
p<0.001 
compared to pre-ischaemia and 
§
p<0.001 CS vs arterial. N=8-9, data is expressed as 
mean±SEM. 
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5.4.7 Intra-operative myocardial injury  
Plasma troponin levels were measured intra-operatively prior to ischaemia (pre AXC) and 5 
minutes after discontinuation of CPB (off CPB). As described previously, due to a change in 
troponin assay to hsTnT partway through the study, a regression model (figure 5.9A) was 
constructed and used to calculate troponin from hsTnT values obtained for the later 20 
subjects.  
 
TnT results are depicted in figure 5.9B. Following reperfusion, TnT concentration had 
increased significantly from pre-ischaemia levels (**p<0.01 and ***p<0.0001, compared to 
pre-ischaemia levels. Pre-ischaemia troponin levels were 0.06±0.04ng/mL (Placebo), 
0.10±0.02ng/mL (Late_1), 0.05±0.02ng/mL (Early_1), 0.04±0.03ng/mL (Late_10) and 
0.06±0.02ng/mL (Early_10).  After discontinuation of CPB, troponin levels were 
1.10±0.34ng/mL (Placebo), 0.93±0.18ng/mL (Late_1), 0.77±0.18ng/mL (Early_1), 
0.49±0.24ng/mL (Late_10) and 0.48±0.19ng/mL (Early_10). Although, the degree of 
increase appeared to be attenuated with increasing dose of i.v. sodium nitrite, this difference 
did not reach statistical significance.  
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Figure 5.9: A) Regression model used for calculating TnT from hsTnT, n=18; B) Intra-
operative troponin T levels. **p<0.01 and ***p<0.0001 comparing pre AXC with post CPB 
levels. N=5-9, Data is expressed as mean±SEM.   
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5.4.8 Plasma 8-isoprostane levels  
Plasma 8-isoprostane levels were measured in the placebo group and in those subjects 
receiving 10µg/kg/min of nitrite the day before surgery or intra-operatively.  In the Placebo 
group and the Late_10 group there was a significant increase in plasma 8-isoprostane 
concentration from pre-ischemia levels to after discontinuation of CPB (figure 2.10). Pre-
ischaemia 8-isoprostane were 33.1±3.0pg/mL at baseline and increased to 45.6±7.1pg/mL 
after discontinuation of CPB, in the Placebo group (*p<0.05, n=7). A similar increase was 
noted in those subjects receiving nitrite the day before surgery from 34.2±3.0pg/mL to 
51.5±7.1pg/mL pre-ischaemia to post-CPB levels, respectively (*p<0.05, n=7). In the 
Early_10 group, no significant increase in plasma isoprostane concentration was observed.  
 
 
Figure 2.10: Intra-operative plasma isoprostane. Data is expressed as mean±SEM. *p<0.05 
compared to pre AXC; n=7. 
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5.4.9 Myocardial expression of eNOS and Akt  
 
Figures 5.11 and 5.12 depict myocardial expression of eNOS phosphorylation at ser1177 (p-
eNOS) and pAKT phosphorylation at ser473 (p-Akt)and total Akt and eNOS expression, at 
three time-points – pre-ischaemia (LV1), pre-reperfusion (LV2) and 10minutes after onset of 
reperfusion (LV3).  
 
Nitrite treatment did not enhance Akt phosphorylation in human myocardial cells compared 
to placebo, during ischaemia or 10-minutes after onset of reperfusion (figure 5.11 B, 
p>0.05). Although there was a trend towards increased eNOS phosphorylation with nitrite, 
particularly immediately prior to ischaemia and before onset of reperfusion that appeared to 
reduce after onset of reperfusion, this was not significant (figure 5.11 C, p>0.05).    
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Figure 5.11: A) Western blots showing p-Akt(ser473), p-eNOS(ser1177) and GAPDH protein bands in human myocardial tissue from patients 
undergoing CABG surgery, following i.v. administration of sodium nitrite to patients; B) p-Akt protein expression in subjects receiving placebo 
or nitrite; C) p-eNOS protein expression in subjects receiving placebo or nitrite. Data is expressed as mean±SEM; n=4-8 in each group.  
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Figure 5.12: A) Western blots showing total Akt, total eNOS and GAPDH protein bands in human myocardial tissue from patients undergoing 
CABG surgery, following i.v. administration of sodium nitrite to patients; B) Total Akt protein expression in subjects receiving placebo or 
nitrite; C) Total eNOS protein expression in subjects receiving placebo or nitrite. Data is expressed as mean±SEM; n=4-8 in each group.  
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5.5 Discussion 
To the best of our knowledge this is the first human study investigating the role of nitrite-
mediated cardioprotection in humans in the setting of CABG surgery. Administration of 
10µg/kg/min of i.v. sodium nitrite immediately prior to ischaemia, attenuated oxidative stress 
and myocardial injury. Oxidative stress following cardiac surgery and CPB is well recognised 
(479-481). During CABG, there is an increase in markers of oxidative stress which remain 
elevated for several hours after discontinuation of CPB and positively correlates with 
ischaemia time (482, 486). As anticipated, our findings in the Placebo group reproduce the 
intra-operative plasma 8-isoprostane profile observed by others (486). 10µg/kg/min sodium 
nitrite administered immediately prior to ischaemia significantly attenuated the increase in 
plasma isoprostane, suggesting that nitrite may abrogate oxidative stress in patients 
undergoing CABG (figure 5.10). Intra-operative myocardial injury, as assessed by an 
increase in troponin, demonstrated a trend towards attenuation with increasing nitrite dose 
(figure 5.9). Greater troponin release following cardiac surgery is associated with a worse 
clinical prognosis in several studies (473, 474, 476). The lack of statistical significance in this 
study may be explained in part due to change in the troponin assay partway through the study 
and therefore requirement of a regression model to calculate the troponin values for the latter 
20 subjects and/or due to under-powering of the study for this end-point. Nonetheless, these 
findings are encouraging and favour a role of nitrite in cardio-protection.  
 
Despite mounting evidence postulating a role for nitrite in affording protection against 
myocardial IRI, the exact mechanisms of nitrite-mediated cardioprotection remain to be fully 
elucidated. Cardioprotection is thought to be mediated via several molecular signalling 
cascades, including the RISK pathway (102, 296). Herein, the importance of the RISK 
194 
 
pathway in nitrite-mediated cardioprotection was explored. Whether administered the day 
before surgery or within 30minutes of ischaemia onset, nitrite did not induce phosphorylation 
of Akt (figure 5.11). However, phosphorylation of eNOS (which occurs downstream to Akt 
activation in the RISK pathway) demonstrated a non-significant trend towards accentuated 
protein levels with nitrite. eNOS uncoupling has been implicated in reducing NO 
bioavailability and augmenting oxidative stress, thereby facilitating IRI (487, 488). Greater 
phosphorylation of eNOS with nitrite may be a consequence of reduced oxidative stress seen 
with the larger nitrite infusion rate, and whether this was associated with abrogation of eNOS 
uncoupling and/or tetrahydrobiopterin (BH4) depletion was not explored in this study. 
Numerous upstream activators of eNOS exist, and include protein kinase A (PKA), AMP-
activated protein kinase (AMPK) and protein kinase G (PKG), particularly in endothelial 
cells (489). A recent in vitro study in culture rat cardiomyocytes and the intact rat heart 
demonstrated nitrite-mediated cytoprotection mediated through activation of PKA with 
consequent alteration in mitochondrion structure and function resulting in generation of 
reactive oxygen species (ROS) (490). In the intact heart, nitrite-associated protection 
occurred through up-regulation of AMPK (a downstream target of mitochondrial ROS). This 
protection was afforded with nitrite delivery up to 6 hours prior to ischaemia and 
demonstrated a bi-phasic response, similar to that with ischaemic preconditioning. With the 
complexity of mechanisms involved in conditioning, the observed trend towards eNOS 
activation with nitrite may be associated with a non-RISK signalling pathway and requires 
further exploration.  
 
CPB is associated with elevated lactate levels and persistent hyperlactatemia  on admission to 
the intensive care unit following cardiac surgery is thought to be associated with poorer 
clinical outcomes (491-493). In the present study, lactate levels pre-ischaemia were high as 
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expected and decreased significantly immediately following onset of reperfusion in all groups 
(figure 5.6). Nitrite administration did not appear to have a significant effect on alterations in 
lactate levels at any time-point.  
 
As anticipated, nitrite concentration increased in a dose–dependent manner with i.v. nitrite 
infusion (figure 5.7). We observed a significant arterio-venous difference in plasma nitrite 
concentration with higher arterial concentrations as compared to venous levels, pre and intra-
operatively. This is consistent with findings by others where a significant baseline arterio-
venous gradient of nitrite was detected in the human forearm vasculature (194). Following 
nitrite infusion, peak nitrite concentrations were higher with both nitrite infusion rates in 
arterial blood compared to peripheral venous blood. A similar pattern of higher arterial nitrite 
concentration was found in CS and arterial blood, intra-operatively. This observation 
supports occurrence of greater nitrite bioactivity at lower oxygen tension, as reported by 
others (46, 194).  
 
Nitrite infusion per se did not cause any alteration in HR or MABP (figure 5.4). Observed 
differences in intra-operative cardiac and peripheral haemodynamic parameters could not be 
solely attributed to nitrite infusion. This study was not designed to assess such clinical 
variables, but has demonstrated that no major adverse effects were noted in patients receiving 
nitrite compared to placebo, providing further support for the safety of nitrite use in humans 
at the present doses for a short period of time. Furthermore, venous peak venous metHb 
levels achieved with the higher nitrite infusion of 10µg/kg/min was 0.98±0.07% suggestive 
of clinically insignificant metHb accumulation with exogenous nitrite administration at 
potentially protective infusion rates.  
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Study limitations 
A significant limitation of this study is underpowering. A scientifically improved approach 
would have been to simplify the study design to include less limbs e.g. comparison of one 
study dose rather than two, investigation of early or late window not both or comparison of 
two nitrite doses without assessment of time window of protection, or alternatively to 
perform an adequately powered study which would have required a greater number of 
subjects to be recruited. Although cardiac surgery lends itself well to investigating ischaemic 
pre-conditioning agents, several potential confounders do exists in these groups of patients 
which may not allow further conditioning to take place such as volatile anaesthetic agents 
(494). A standardised anaesthetic and surgical protocol was adhered to but this cannot take 
account of the differing needs of individual patients in terms of dosages/quantities of 
anaesthetic agents, inotropes, and/or fluid volume requirements. This study focussed on 
limited mechanistic/molecular outcomes, whereas several potential pathways of myocardial 
protection exist (as summarised in Chapter 1, section 1.7.2.4). The importance of the RISK 
pathway compared to these others remains to be fully elucidated. Moreover, whether the 
current cardio-protection is afforded through release of NO was not explored in this study.  
 
Conclusion  
The importance of nitrite in cytoprotection is being increasingly recognised. Despite probable 
underpowering, this study provides important mechanistic insights into myocardial protection 
afforded by nitrite in patients undergoing cardiac surgery at doses that are safe to administer 
in humans. We have demonstrated that nitrite at 10µg/kg/min reduces oxidative stress and 
may attenuate myocardial injury. This protection does not appear to be elicited through 
activation of Akt and may be elicited through eNOS up-regulation, suggesting that the RISK 
pathway may not be implicated in nitrite-mediated ischaemic pre-conditioning. Numerous 
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intra-cellular signalling processes have been implicated in protection against IRI. The 
importance of these pathways in nitrite-mediated cytoprotection remains to be fully 
determined. However, these data support larger placebo-controlled clinical trials of nitrite in 
patients undergoing cardiac surgery. There are currently on-going trials to investigate the 
clinical effect of nitrite-mediated cardioprotection in humans and these will provide further 
useful insight into the potential clinical role of nitrite in man (495, 496).  
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Chapter 6: The Role of ALDH2 in Nitrite-mediated Vascular 
Relaxation 
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6.1 Introduction 
Nitrite reduction to NO under conditions of hypoxia and/or acidosis is well established (117). 
Numerous potential mechanisms of nitrite conversion to NO have been explored in a variety 
of experimental conditions from in vitro to in vivo animal and some human models, as 
detailed in section 1.6. One of the first mechanisms of nitrite reduction to be discovered was 
acid disproportionation, which occurs under profound hypoxia and/or acidosis (124). In less 
extreme conditions, nitrite reduction to NO has been observed with several endogenous 
substances. These include haemoglobin (26, 139, 497), myoglobin (141, 146, 147), 
neuroglobin (149), cytoglobin (151), XOR (160) and eNOS (160, 166). Thus far, it remains 
unclear which, if any one of these mechanism(s) is predominantly responsible for bio-
activation of nitrite, particularly in humans.  
 
A further important potential nitrite reductase enzyme is mitochondrial aldehyde 
dehydrogenase (ALDH2). ALDH2 is closely linked to alcohol dehydrogenase, which is a 
cytoplasmic protein that is found in the stomach and liver and breaksdowns ethanol to 
acetylaldehyde, which in turn is further metabolized by ALDH2 (mostly found within 
mitochondria of hepatic cells) to form an acetic acid radical and H
+
. Both this enzymes are 
important in alcohol metabolism (498). 50% of the Far East Asian population is thought to 
lack intrinsic ALDH2 activity due to a genetic mutation of the ALDH2*2 gene (499). This 
commonly manifests as facial flushing following administration of alcohol, as ALDH2 is 
crucial for alcohol metabolism. 
 
ALDH2 was identified by Chen and colleagues as an important enzyme involved in the 
bioconversion of GTN to 1,2-GDN within mitochondria (67). Firstly, in vitro experiments 
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using mouse macrophages, demonstrated the biotransformation of GTN to 1,2-GDN and 
nitrite (NO
2-
). They proposed the following stoichiometric reaction for this:- 
 
GTN  +  Ered  → 1, 2 GDN  +  NO
2-
  +  Eox 
(Ered = reductase enzyme; Eox = oxidising enzyme) 
 
Secondly, there was an attenuation of GTN-mediated vascular relaxation in rat thoracic aorta 
following delivery of the ALDH inhibitors cyanamide and chloral hydrate. Moreover, in 
anaesthetised rats receiving systemic infusions of i.v. GTN, administration of cyanamide and 
chloral hydrate attenuated the hypotensive effect of GTN, suggesting that nitrate tolerance 
may be caused by ALDH inhibition (predominantly the mitochondrial ALDH2 isoform). 
Further work undertaken by the same group, confirmed these findings in ALDH2-knockout 
mice (170). Others have also confirmed the role of ALDH2 in the bio-activation of organic 
nitrates in subsequent in vitro and in vivo animal studies (168-170). In humans, Mackenzie 
and colleagues verified these findings in the forearm vasculature of healthy volunteers. They 
found that ALDH inhibition (through administration of oral disulfiram or through more 
specific intrinsic ALDH2 inactivity in subjects with the glu504lys ALDH2 polymorphism) 
resulted in decreased GTN-mediated forearm vasodilatation (171). This study was 
particularly pertinent as up to 50% of the Far East Asian population is thought to lack 
intrinsic ALDH2 activity due to a genetic mutation of the ALDH2*2 gene (499).  
 
It has been established that mitochondria may provide an important platform for the reduction 
of nitrite to NO (173, 174). As described above, nitrite is a major product of GTN bio-
activation. Recently, Perlman and colleagues demonstrated that nitrite-mediated 
cardioprotection was associated with phosphorylation of ALDH2 in the rat myocardium 
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(176). Thus, ALDH may potentially be an important source of nitrite-derived NO. As nitrite 
has been discovered to be an important source of NO during hypoxia and/or ischaemia, 
ALDH may be an important nitrite reductase during these conditions. However, the exact role 
of ALDH2 as a nitrite reductase and its importance in nitrite-mediated vasodilatation remains 
unknown. Therefore, this mechanism and how this translates into physiological effects 
requires further investigation. 
 
An additional important finding highlighted by Chen and colleagues was that prolonged 
exposure to low dose GTN diminished ALDH activity (168, 170). Other investigators have 
proposed that ALDH inactivation (primarily the mitochondrial ALDH2 isoform) is the 
principal mechanism responsible for the development of nitrate tolerance (169, 500, 501). 
These experimental studies have been performed in animal models. In contrast, in a human 
study in patients undergoing coronary artery bypass grafting surgery, Philpot and colleagues 
demonstrated abrogation of vascular ALDH activity with GTN administration (502). They 
administered low dose i.v. GTN to subjects for 18 hours prior to surgery. In vascular rings 
harvested from these subjects they found that there was no attenuation of vascular 
responsiveness with GTN (suggesting lack of tolerance) but there was significant inactivation 
of vascular ALDH activity. Chen and colleagues confirmed this ex vivo in rodent 
myocardium, where administration of GTN attenuated ALDH activity (503). Recently, 
D’Souza et al. demonstrated discrepancy between the onset/offset of ALDH inactivation by 
GTN and the time course of GTN tolerance (504). This pattern of activity potentially permits 
the utilisation of GTN pre-exposure as an ALDH-inactivating manoeuvre, without the 
induction of GTN tolerance. 
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6.1.1 Preliminary data  
The study presented herein was based on preliminary in vitro experiments undertaken by Dr 
Melanie Madhani, utilising rat thoracic aortae, exploring (1) the effect of ALDH inhibition on 
nitrite-mediated vascular relaxation during normoxic and hypoxic conditions; (2) 
determination of the effect of GTN on nitrite responsiveness (presumably via inactivation of 
ALDH) and (3) determination of the effects of nitrite treatment in the presence or absence of 
GTN on ALDH2 expression and on the phosphorylation status of vasodilator-stimulated 
phosphoprotein (VASP) (Madhani M, unpublished data). Therefore, the findings from these 
in vitro experiments are summarised herein:- 
 
(1) Using the technique of wire myography, vasorelaxation in rat thoracic aorta was 
observed following administration of sodium nitrite during normoxic and hypoxic 
conditions, with and without cyanamide (ALDH inhibitor). As shown in figure 6.1, 
no statistically significant difference was observed between the degree of nitrite-
induced relaxation in the absence and presence of cyanamide during normoxic 
conditions. Hypoxia enhanced nitrite-induced vasorelaxation, as expected. However, 
following ALDH inhibition, there was a significant rightward shift of the 
concentration-response to nitrite, suggesting that nitrite responsiveness is attenuated 
with ALDH inhibition  
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Figure 6.1: Concentration response curves to sodium nitrite in rat aortic thoracic rings in the 
absence and presence of ALDH inhibitor, cyanamide during (A) normoxia and (B) hypoxia, 
respectively. Relaxation is expressed as mean±SEM % reversal of phenylephrine -induced 
tone. NS=not significant; *P<0.05, control versus cyanamide for nitrite only (n=3-4). 
 
(2) To determine whether GTN pre-exposure leads to attenuation of nitrite response 
(presumably via inactivation of ALDH), rat thoracic aortae were exposed to hypoxic 
conditions and then incubated in the presence or absence of 30 µM or 100 µM of 
GTN for a period of 60 minutes. A concentration response curve to sodium nitrite was 
then constructed under hypoxic conditions. Pre-treatment with 30 µM or 100 µM 
GTN significantly attenuated the response to sodium nitrite compared to controls 
during hypoxia (P<0.01 for 30µM GTN and P<0.001 for 100µM GTN; figure 6.2). 
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Figure 6.2: Concentration-response curve to sodium nitrite in isolated rat aortas in the 
absence or presence of GTN (30 or 100μM) during hypoxic conditions. Relaxation is 
expressed as mean ± SEM percentage reversal of phenylephrine-induced tone (n=12); 
*p<0.05, ***P< 0.001 versus control. 
 
(3) To determine the effects of nitrite treatment in the presence or absence of GTN on 
ALDH2 expression and on the phosphorylation status of vasodilator-stimulated 
phosphoprotein, VASP-ser
239
 (a specific PKG substrate to determine whether ALDH-
induced activation of nitrite involved the NO-sGC-cGMP-PKG-VASP pathway.), rat 
thoracic aortic vessels from the above myograph experiments were immediately snap 
frozen at the end of the defined protocol. Using Western Blot analysis, it was 
demonstrated that ALDH2 expression was significantly attenuated following pre-
treatment with 100μM GTN and nitrite (p<0.05 when comparing to controls; figure 
6.3A). In contrast, nitrite treatment significantly enhanced the phosphorylation of 
VASP ser
239
 (P<0.05; 2.6 fold over control; figure 6.3B). Following pre-treatment 
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with GTN (100 μM, but not 30μM), the effects of nitrite in stimulating VASPser239 
phosphorylation was attenuated when compared to nitrite alone (figure 6.3B). 
 
 
Figure 6.3: The effect of sodium nitrite in the presence or of GTN (30 or 100µM) during 
hypoxic conditions on (A) ALDH2 expression and (B) phosphorylation VASP ser239 in 
thoracic aorta. Bars represent mean ± SEM from n=6-9 animals. *p<0.05 versus control . 
 
These findings in rat thoracic aortae demonstrate an attenuation of nitrite-mediated 
vasorelaxation following pre-treatment with GTN during hypoxic conditions. This 
attenuation in vascular response is associated with reduced ALDH2 expression. Furthermore, 
phosphorylation of VASP at ser
239
 site (a reliable biochemical biomarker of vascular PKG 
activity) demonstrates that nitrite significantly phosphorylates VASP-ser
239
 during hypoxia, 
thereby supporting the concept that nitrite mediates vasorelaxation through the NO-sGC-
cGMP-PKG-VASP pathway. Additionally, nitrite-mediated vasorelaxation following pre-
treatment with GTN treatment (100μM) is associated with decrease in VASP ser239 
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phosphorylation. Thus, demonstrating that nitrite-mediated vasorelaxation involves both 
ALDH2 and VASP-ser
239
. 
 
6.2 Objectives 
The aim of this study is to explore the putative role of ALDH as a contributor to nitrite-
mediated vasorelaxation in humans, during normoxia and hypoxia. Both ex vivo vascular ring 
studies (wire myography) and in vivo forearm vasodilatory experiments (venous occlusion 
plethysmography) were performed.  
 
Work detailed in chapter 3 (Systemic Nitrite in Heart failure) and further work undertaken by 
our group has demonstrated that patients with chronic heart failure (HF), exhibit accentuated 
vascular responses to nitrite and that nitrite should be investigated further in patients with 
heart failure (505). Given the potential therapeutic implications in heart failure, we felt it 
important to understand the role of ALDH2 in nitrite bioactivation in this disorder. Therefore, 
this study was undertaken in patients with HF rather than healthy volunteers.  
 
The objectives of the study were as follows:- 
(1) To determine the role of ALDH in nitrite mediated vasorelaxation during normoxia 
and hypoxia, using isolated resistance vessels from patients with HF. 
(2) To determine whether ALDH activity is decreased in patients with heart failure, 
following GTN exposure, prior to development of nitrate tolerance, using isolated 
resistance vessels from patients with HF. 
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(3) To determine the role of ALDH in nitrite mediated vasorelaxation during normoxia 
and hypoxia, in intact human vasculature in patients with HF. 
 
6.3 Power calculation 
Based on the study by Maher et al (46) in healthy volunteers, during hypoxia FBF was 
2.37±0.40 (mean±SD) at the 7.84micromol/min dose. To detect a 20% difference in nitrite-
mediated vasorelaxation (as assessed by venous occlusion plethysmography) with 1-β of 0.8 
and α of 0.05, 14 patients were recruited for the GTN group of the study. A further 8 patients 
were recruited for the saline group and 23 patients for the Biopsy only group. Therefore a 
total of 45 patients were required to accommodate this study. 
 
6.4 Methods 
The study was approved by the South Birmingham Research Ethics Committee, 
10/H1207/50 and conforms to the principles outlined in the Declaration of Helsinki. All 
subjects gave written, informed consent.  
 
6.4.1 Participants  
Subjects were recruited from outpatient clinics at the University Hospitals Birmingham NHS 
Foundation Trust. The inclusion criteria included patients with systolic heart failure (left 
ventricular ejection fraction ≤ 40%) of any cause, aged between 40-80 years with no active 
history of smoking. Patients treated with long-acting nitrates, or with past histories of adverse 
reactions to organic nitrates, hypotension (systolic BP<110mmHg), concomitant 
warfarin/clopidrogel therapy or with bleeding diathesis were excluded from the study. 
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Because of the use of hypoxia in the in vivo arm of the study, patients with a BMI >30kg/m
2
 
and those with obstructive sleep apnoea, were excluded from this limb of the study. All 
subjects had a light breakfast and were requested to abstain from alcohol and caffeine-
containing drinks and follow a low nitrate/nitrite diet (table 2.1) for 24 hours for before the 
study.  
 
6.4.2 Study protocol  
Figure 6.4 depicts the study protocol. The patients were grouped as follows: (1) Biopsy 
group (patients who participated in the ex vivo myography experiments only; n=22), (2) 
Saline group plethysmography study (n=8) and (3) GTN group plethysmography study 
(n=13).  
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Figure 6.4: Study protocol 
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(1) Biopsy-only Group 
To determine the impact of ALDH inhibition on nitrite bioactivity in resistance vessels, these 
vessels were obtained from a group of HF patients who were nitrite/nitrate free. A sample of 
subcutaneous gluteal fat (approximately 2cm x 2 cm x 2cm; figure 6.5A) was obtained under 
local anaesthetic (2% lidocaine). The harvested tissue was placed immediately in ice-cold 
Krebs-Hensleleit buffer solution (composition in mM: NaCl 119; KCl 4.7, KH2PO4 1.18; 
NaHCO3 25; MgSO4 1.2; Glucose 11; CaCL2 2.5). Subcutaneous small arteries (~250µM 
internal diameter and 2mm segment length) were dissected from the adipose tissue, cleaned 
of adherent fat and connective tissue, and mounted onto an automated tension wire myograph 
(AD Instruments, Denmark). In most cases, two vessels from each biopsy were studied. 
Vessels were processed using a well-described technique (506). Firstly, they were maintained 
in Krebs-Hensleleit buffer kept at 37°C under normoxic conditions with a 95% O2/5% CO2 
gas mixture. After an equilibration period of 45minutes (with regular replacement of Krebs-
Hensleleit buffer after every 15 minutes), vessels were normalised to obtain an internal 
circumference with a transmural pressure of 100mHg (13.3kPa). This allowed the vessels to 
be standardised prior to subsequent comparisons. Furthermore, the internal circumference 
that allows maximal response (both constriction and dilatation) is defined as the 
circumference when the transmural pressure is at 100mmHg (507). Following normalisation, 
each vessel was primed with potassium chloride solution (KCl; 4.8 x 10
-2
M) to assess 
viability (KCl depolarises and therefore activates the vascular smooth muscle, thus causing 
vasoconstriction in an endothelium-dependent manner). This was proceeded by the addition 
of supra-maximal concentration of phenylephrine (PE; 10
-6
M) to pre-constrict the vessels. 
Once this response had stabilised, acetylcholine (ACh; 10
-6
M) was added to the bath to assess 
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the integrity of the vascular endothelium. If the constrictor responses to PE were not 
maintained, or relaxations greater than 50% of the PE-induced tone to ACh were not 
observed, the vascular rings were discarded. The vascular rings were then washed for 30 
minutes (by addition of fresh Krebs-Hensleleit buffer at 15 minute intervals) after which 
cumulative concentrations of PE (10
-9
, 3x10
-9
, 10
-8
, 3x10
-8
, 10
-7
, 3x10
-7
, 10
-6
, 3x10
-6
 and 10
-
5
M) were added to the organ bath to constrict the vessels. Each subsequent concentration was 
added after the response to the present PE concentration had reached a plateau. 80% of the 
maximal contraction (EC80) of each vessel was calculated using the log dose-response curve. 
The vessels were then washed over 60 minutes to restore basal tone before contracting to 
EC80 of the PE-induced response. Once a stable response to PE was achieved, a cumulative 
concentration response curve to sodium nitrite was constructed (10
-9
, 3x10
-9
, 10
-8
, 3x10
-8
, 10
-
7
, 3x10
-7
, 10
-6
, 3x10
-6
 and 10
-5
 and 3x10
-5
M) under normoxic conditions (95% O2/5% CO2). 
For the vessels tested under hypoxic conditions (95% N2/5% CO2; resulting in ≈1% organ 
bath O2), the tissue was first incubated for 30 minutes before exposure to EC80 PE (to 
achieve similar tension observed at 95% O2) before administration of sodium nitrite.  
 
To investigate whether attenuation of nitrite efficacy during hypoxia was caused by the 
effects of ALDH inhibition on downstream signalling in the NO cascade, concentration 
response curves to the NO donor, spermine-NONOate (SPNO) were constructed in the 
absence and presence of the ALDH inhibitor, cyanamide, under hypoxic conditions. 
 
(2) In vivo Plethysmography Group 
To determine the effect of ALDH inactivation by GTN on arteriolar responsiveness in 
patients with HF, forearm vascular responsiveness was assessed using the technique of 
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venous occlusion (strain-gauge) plethysmography. The study was performed at the University 
of Birmingham, in a quiet and temperature controlled (22 - 24°C) laboratory. All subjects 
were placed in a semi-recumbent position enabling the administration of hypoxia to 
participants. Intravenous cannulae (20-gauge) were inserted into a vein in each antecubital 
fossa. This technique is described in detail in Chapter 4, section 4.3.3. Briefly, changes in 
blood flow, using mercury in-silastic strain gauges were recorded in both arms (DE 
Hokanson, Bellevue, Wash). Sodium nitrite was administered intra-arterially via a 27-gauge 
arterial needle (Coopers Engineering, UK) mounted onto a 16-gauge epidural catheter and 
sealed with dental wax, as depicted in figure 6.5B. This was inserted aseptically into the 
brachial artery of the non- dominant arm under local anaesthesia (1% lidocaine) and was kept 
patent by intra-arterial (i.a) 0.9% saline infused at 1ml/min before initiation of sodium nitrite. 
Each subject underwent placement of a finger cuff for continuous blood pressure recording, 
an upper arm cuff for the oscillating blood pressure measurement, and chest electrodes for 
continuous electrocardiogram monitoring using the TaskForce Monitor® (CN Systems, Graz, 
Austria). Oxygen saturation levels were monitored continuously with pulse oximetry 
(Nellcor, Pleasanton, CA, USA). Measurement of forearm blood flow (FBF) is described in 
more detail in Chapter 4 section 4.3.3. FBF was calculated in mL/100mL of tissue per minute 
and expressed as a ratio of FBF from infused:control arm (FBF_R). The experimental set-up 
is depicted in figure 6.5. 
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Figure 6.5: (A): Picture of typical gluteal fat biopsy obtained from participants,  
(B) Coopers’s needle in situ, for administration of intra-arterial sodium nitrite;  
(C) Typical experimental set-up with administration of hypoxia.  
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As depicted in Figure 6.4B, following 10 minutes of stabilisation, CHF patients 
received two doses of intra-arterial sodium nitrite (784nmol/min then 7.84µmol/min for 
20 min; infusion rate 1ml/min) as employed by Maher et al (46). Nitrite was infused into 
the brachial artery of the non-dominant arm and FBF was measured in both arms. 
Following the second dose of intra-arterial sodium nitrite (7.84µmol/min), the patients 
were rendered hypoxic by inspiring 12% oxygen via a Hudson facemask. Target oxygen 
saturation as measured by pulse oximetry was 83-88% (as described in Chapter 2, 
section 2.4.3). Upon achieving target oxygen saturation the study proceeded with the 
7.84µmol/min infusion for a further 10 minutes. Thereafter, patients were randomised (in 
a double-blind fashion) to receive either an intravenous (i.v.) infusion of low-dose 
(10µg/min) GTN (to decrease ALDH activity) or 0.9% saline for 4 hours,  at a rate of 
15ml/hour. This was followed by a 30 minute washout period (i.v. 0.9% saline at 
1ml/min). During the 4-hour intravenous saline/GTN infusion, the arterial needle was 
removed for subject comfort and re-inserted during the 30-minute washout period. 
Repeat infusions of sodium nitrite (i.a) were administered during normoxia and hypoxia, 
as described above. Heart rate (HR), mean arterial blood pressure (MABP) and arterial 
oxygen saturations were recorded at baseline and following each dose of nitrite during 
normoxia and following the administration of hypoxia.  
 
Upon completion of the plethysmography protocol, the intra-arterial needle was removed. 
Participants were allowed to rest for 10 minutes following which a subcutaneous fat biopsy 
was obtained, as described above. The resistance vessels obtained were used to determine 
whether infusion of GTN had induced significant nitrate tolerance. GTN vasodilator 
concentration response curves were compared in resistance vessels obtained from 
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patients with and without prior GTN infusion using the technique of wire myography. As 
described above, the vascular rings were assessed for endothelial integrity and then 
contracted sub-maximally with phenylephrine (EC80) and cumulative concentration 
response curves were obtained for GTN (10
-9
, 3x10
-9
, 10
-8
, 3x10
-8
, 10
-7
, 3x10
-7
 and 10
-6
M). 
 
6.4.3 Study medication 
Sodium nitrite for the human studies was purchased from Martindale Pharmaceuticals 
(Brentwood, UK). 0.9% sodium chloride (Baxter Healthcare, USA) was used for the 
placebo (saline) infusion. GTN was purchased from Lipha Pharmacuticals Ltd, UK. 
 
6.4.4 Blood sampling 
Venous blood samples were obtained at eight time points during the in vivo 
plethysmography study, as depicted in figure 6.4B. These samples were analysed for the 
following:- 
 
(1) Methaemoglobin and pH: Venous whole blood was analysed immediately using a 
blood gas analyser for methaemoglobin, lactate and pH levels (Bayer Rapidlab 865, 
Siemens, Tarrytown, USA). 
(2) Assessment of total 8-iso Prostaglandin F2α: Total plasma 8-iso Prostaglandin F2α 
(8-isoprostane) was measured by using an 8-Isoprostane EIA assay kit protocol 
(Cayman Chemical, Ann Arbor, MI) as a marker of oxidative stress. 
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6.3.5 Statistical analysis 
For the myography analysis, relaxations are expressed as percent reversal of PE-
induced tone (mean±SEM). Curves were fitted to all the data using a nonlinear 
regression and the –log [M] of each drug giving a half maximal response (pEC50) were 
used to compare potency. Concentration response curves were analysed using 2-way 
ANOVA. For the in vivo FBF analysis, 1-way ANOVA repeated measures coupled with 
a Bonferroni post hoc test was used to compare the change from baseline in FBF_R in 
each of the saline and GTN groups. An unpaired two- tailed Student t test was used to 
compare FBF_R following hypoxia between GTN and saline group. Data are given as 
mean ± SEM, and significance was accepted with P<0.05. Statistical analysis was 
undertaken using SPSS software (version 21.0). 
 
6.5 Results 
6.5.1 Baseline characteristics 
Patient demographics are depicted in table 6.1. A total of 45 patients were recruited into 
the study. Following recruitment, one patient was excluded from the in vivo 
plethysmography GTN Group due to an episode of hypotension associated with pre-
syncope after onset of the first infusion of sodium nitrite (784nmol/min). This subject was 
withdrawn from the study at that time point with no acquisition of data. One subject was 
excluded from data analysis from the Biopsy-only Group as no vessels were found in the 
gluteal fat excised from this subject. 
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The subjects were well matched between the groups. The major difference was between 
the body mass index between the Biopsy-only group (31±8kg/m
2
, n=22) compared to the 
plethysmography study groups (25±2kg/m
2
 in the Saline group and 27±8kg/m
2
 in the GTN 
group). This difference was statistically significant (p<0.05).  
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 Ex vivo analysis In vivo analysis 
 Biopsy only Group 
(n=22) 
SALINE group 
(n=8) 
GTN group 
(n=13) 
Age, years (mean ±SD) 64±13 62±11 66±12 
Male gender, n (%) 16 (80) 7(88) 12(92) 
Mean weight (kg) 86±5 75±3 82±3 
Body mass index (kg/m2) 31±2 25±2 27±1 
Ejection fraction (%) 25±2 25±3 29±2 
NYHA class, n (%)    
I 2 1 1 
II 6 4 10 
III 14 3 2 
    
HR (bpm) 72±2 62±4 62±2 
MABP (mmHg) 97±34 89±3 88±2 
Aetiology, n (%)    
Dilated cardiomyopathy 13 (59) 5 (62) 3 (38) 
Ischaemic cardiomyopathy 7 (32) 3 (38) 6 (46) 
Other 2 (9) 0 (0) 1 (8) 
Medication, n (%)    
ACEI/ARB antagonists 20 (91) 8 (100) 12 (92) 
Beta-blockers 14 (64) 5 (63) 10 (77) 
Spironolactone/eplerenone 12 (55) 3 (38) 3 (23) 
Loop diuretic 15 (68) 4 (50) 8 (62) 
           Aspirin 15 (68) 4 (50) 10 (77) 
Statin 17 (77) 5 (63) 9 (69) 
 
Table 6.1: Baseline characteristics of study subjects. Data are expressed as mean±SEM, 
unless otherwise stated. NYHA, New York Heart Association class; ACEI, angiotensin-
converting enzyme inhibitors; AT2, angiotensin 2 receptor blockers. 
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6.5.2 Effect of ALDH inhibition on nitrite-induced vasorelaxtion in resistance 
vessels from heart failure patients 
Under both normoxic and hypoxic conditions, sodium nitrite caused concentration- 
dependent relaxation of resistance vessels obtained from HF patients (figures 6.6A and 
6 . 6 B). During normoxic conditions, pre-treatment with cyanamide tended to shift the 
nitrite concentration response curve to the right but this was not significant (n=7; figure 
6.6A). However under hypoxic conditions, cyanamide potently inhibited nitrite-induced 
relaxation in a concentration-dependent manner. There was a significant difference 
between cyanamide and control; P<0.01 between 3-10 μM and at 100 μM; P<0.05 30 
μM; figure 6.6B; n=9). To assess whether this effect was nitrite-specific, concentration-
response curves to the NO donor SPNO, were constructed in the presence or absence of 
cyanamide. Cyanamide had no inhibitory activity on the vasorelaxant responses to SPNO 
in isolated resistance vessels from HF patients under hypoxic conditions (P>0.05; n=6-10; 
figure 6.6C). 
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Figure 6.6: Concentration-response curve to sodium nitrite in resistance vessels obtained 
from HF subjects in the presence and absence of ALDH2 inhibitor, cyanamide (1mM) 
during (A) normoxia and (B) hypoxia. (C) Concentration-response curve to NO donor, 
SPNO, in the absence and presence of cyanamide during hypoxic conditions, resepectively 
Relaxation is expressed as mean±s.e.m. percentage reversal of PE-induced tone. *P< 0.05 
and **P<0.01 control versus cyanamide (n=6-10). 
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6.5.3 Effect of ALDH inactivation by GTN on intact forearm vasculature 
Forearm vasodilator response increased dose-dependently with nitrite in both the saline 
and GTN groups (figure 6.7A and B). FBF_R increased from 1.0±0.1 at baseline pre-
saline infusion to 1.8±0.2 (p<0.05) during normoxia and 2.3±0.3 (p<0.05) during hypoxia. 
Post-saline infusion, FBF_R increased from 1.1±0.1 at baseline to 2.1±0.2 (p<0.05) during 
normoxia and 1.8±0.1 (p<0.01) during hypoxia.  Similarly, prior to administration of i.v. 
GTN, FBF_R increased from 1.2±0.1 at baseline to 2.3±0.4 (p<0.05) during normoxia and 
2.4±0.4 (p<0.05) during hypoxia. FBF_R increased from 1.2±0.1 at baseline post-GTN 
infusion to 2.0±0.2 (p<0.01) during normoxia and 1.7±0.1 (p<0.05) following hypoxia. 
Likewise, rendering subjects hypoxic did not result in a significant attenuation of vascular 
response (figure 6.8) following exposure to low=dose i.v. GTN treatment compared to 
saline (FBF_R is 1.8±0.1 post-saline and 1.7±0.1 post-GTN, p=NS).  
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Figure 6.7: Dose-response forearm blood flow (expressed as FBF_R) in subjects receiving 
incremental doses of sodium nitrite either (A) pre- and post- i.v. saline (n=8) or (B) pre- 
and post i.v. GTN (n=13). Data is expressed as mean±SEM. *p=<0.05 and #p<0.01 
compared to baseline. 
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Figure 6.8: Forearm blood flow (expressed as FBF_R) following 7.84µmol/min of intra-
arterial sodium nitrite during hypoxic conditions post saline/GTN infusion. Data is 
expressed as mean±SEM. N=6 in the saline group and n=11 in the GTN group. 
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PRE-SALINE/GTN 
 Baseline 7.84nmol/min 7.84µmol/min Hypoxia + 
7.84µmol/min 
SALINE group (n=8) 
HR (bpm) 59±5 60±5 60±4 63±4 
MABP (mmHg) 87±4 89±5 83±2 77±3 
Arterial 02 sats (%) 97.0±0.6 97.0±0.5 96.0±0.6 87.0±1.9** 
GTN group (n=13) 
HR (bpm) 60±2 59±1 60±2 62±2 
MABP (mmHg) 80±3 78±2 85±2 88±3* 
Arterial 02 sats (%) 98.0±0.4 98.0±0.7 98.0±0.4 86.0±0.6** 
POST-SALINE/GTN 
 Baseline 7.84nmol/min 7.84µmol/min Hypoxia + 
7.84µmol/min 
SALINE group (n=8) 
HR (bpm) 61±3 64±3 64±3 64±4 
MABP (mmHg) 80±6 79±5 79±5 86±5 
Arterial 02 sats (%) 97.0±0.6 97.0±0.3 97.0±0.6 86.0±0.8** 
GTN group (n=13) 
HR (bpm) 60±2 60±2 60±2 64±42 
MABP (mmHg) 85±4 84±4 82±2 863±3 
Arterial 02 sats (%) 98.0±0.4 98.0±0.3 98.0±0.4 87.0±0.6** 
 
Table 6.2: Haemodynamic data from HF subjects in the in vivo plethysmography study. 
Data is expressed as mean±SEM, *p<0.05 and **p≤0.001 compared to baseline. 
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6.5.4 Effect of nitrite on haemodynamic parameters before and after saline/GTN 
infusion 
As shown in table 6.2, HR and MABP did not alter significantly from baseline following 
administration of sodium nitrite in the saline and GTN groups, both before and after the 4-
hour i.v. saline/GTN infusions. Furthermore, there was no significant difference in baseline 
haemodynamic parameters before and after the saline/GTN infusions. Arterial oxygen 
saturations remained stable throughout the normoxia period in the saline group, but fell 
significantly following administration of 12% oxygen. Mean oxygen saturations were 
significantly lower than baseline following administration of hypoxia (from 97±0.5% to 
87±1.1%, baseline and hypoxia 7.84µmol/min nitrite, respectively. n=8; p<0.001). 
Similarly, the arterial oxygen saturations in the GTN group remained stable throughout the 
normoxia period, and fell significantly following administration of 12% oxygen (from 
97±0.3 to 87±0.6, baseline and hypoxia 7.84µmol/min nitrite, respectively; n= 12; 
P<0.001).  
 
6.5.5 Effect of nitrite on venous pH, isoprostanes and methaemoglobin before and 
after saline/ GTN infusion 
As shown in table 6.3, There was no significant change in venous pH in the control arm at 
any nitrite dose both pre and post i.v. 0.9% saline infusion. However, venous pH increased 
significantly from baseline following administration of hypoxia in the infused arms from 
7.37±0.01 to 7.41±0.01 prior to the 4-hour saline infusion (n=7, p<0.05) and from 
7.38±0.01 to 7.42±0.01 after the 4-hour saline infusion (p<0.0001, n=7). 
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In the GTN Group, venous pH remained unchanged in the control arm prior to the 4-hour 
i.v. GTN infusion. There was a significant increase from baseline with escalating nitrite 
dose post 4-hour i.v. GTN infusion in the control arm, from 7.38±0.01 to 7.40±0.01 
following 784µmol/min during hypoxia (p<0.01, n=13). In the infused arm there was a 
significant change from baseline in venous pH in both limbs, both pre- and post- 4-hour 
i.v. GTN infusion. Prior to GTN infusion, venous pH increased from 7.37±0.01 at baseline 
to 7.40±0.01 (normoxia) and 7.41±0.01 (hypoxia) following peak nitrite dose (p<0.001, 
n=13, respectively). A similar change in pH was noted in the infused arm post-GTN 
infusion from7.37±0.01 at baseline to 7.40±0.01 (784µmol/min nitrite, normoxia; p<0.001, 
n=13) and 7.43±0.01 (784µmol/min nitrite, hypoxia; p<0.001, n=13). There was no 
significant change in pH at any stage between at peak nitrite dose between normoxia and 
hypoxia.  
 
No change in plasma 8-isoprostane levels (saline group n=6; GTN group n=11; P>0.05) or 
lactate levels was detected (saline group n=7; GTN group n=13; P>0.05) in both the saline 
and GTN groups following nitrite infusions (table 6.3). 
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Table 6.3: Venous blood data from HF subjects in the in vivo plethysmography study. 
 PRE-SALINE/GTN 
 BL 784nM 7.84µM Hypoxia + 7.84µM 
 CON INF CON INF CON INF CON INF 
SALINE group (n=7) 
pH 7.38±0.13 7.37±0.01 7.38±0.11 7.40.±0.01 7.39±0.11 7.40±0.01 7.40±0.16 7.41±0.01
* 
lactate 
(mmol/L) 
1.55±0.07 1.59±0.08 1.60±0.07 1.54±0.06** 1.42±0.05 1.52±0.04 1.53±0.05 1.51±0.05* 
 K+ 
(mmol/L) 
4.37±0.10 4.28±0.12 4.36±0.11 4.24±0.11 4.29±0.16 4.30±0.13 4.51±0.15 4.43±0.13 
Isoprostane 
(ng/L) 
10.8±1.6 6.0±1.0 6.8±1.6 6.8±0.9 7.7±1.0 13.1±4.7 11.0±2.8 4.7±1.8 
 GTN group (n=13) 
pH 7.38±0.01 7.37±0.01 7.38±0.01 7.39±0.01 7.39±0.01 7.40±0.01*** 7.39±0.01 7.41±0.01
*** 
lactate 
(mmol/L) 
1.43±0.07 1.38±0.07 1.40±0.08 1.40±0.09 1.42±0.07 1.31±0.06 1.50±0.08 1.38±0.05 
K+ 
(mmol/L) 
4.69±0.13 4.60±0.14 4.63±0.12 4.57±0.13 4.64±0.10 4.57±0.11*** 4.56±0.09*** 4.53±0.10*** 
Isoprostane 
(ng/L) 
8.7±1.4 11.0±2.4 6.6±0.9 8.6±1.9 7.4±1.1 10.1±1.5 8.7±0.8 13.5±3.7 
 
POST SALINE/GTN 
 BL 784nM 7.84µM Hypoxia + 7.84µM 
 CON INF CON INF CON INF CON INF 
SALINE group (n=7) 
pH 7.38±0.01 7.38±0.01 7.39±0.01 7.40±0.01 7.40±0.01 7.42±0.01 7.40±0.01 7.42±0.01*** 
lactate 
(mmol/L) 
1.59±0.08 1.58±0.06 1.54±0.06 1.32±0.04 1.52±0.04 1.60±0.06 1.51±0.05 1.50±0.02 
 K+ 
(mmol/L) 
4.74±0.14 4.77±0.10 4.85±0.12 4.53±0.10 4.78±0.11 4.58±0.07 4.74±0.07 4.49±0.08 
Isoprostane 
(ng/L) 
7.8±0.8 6.0±0.3 8.8±1.2 7.5±3.4 5.6±4.0 10.2±2.0 5.0±1.1 7.3±0.8 
GTN group (n=13) 
pH 7.38±0.01 7.37±0.01 7.37±0.01 7.39±0.01** 7.37±0.01 7.40±0.01** 7.40±0.01** 7.43±0.01
*** 
lactate 
(mmol/L) 
1.70±0.08 1.70±0.12 1.42±0.08 1.48±0.09^ 1.43±0.07 1.43±0.07 1.51±0.08 1.44±0.06* 
 K+ 
(mmol/L) 
4.79±0.09 4.84±0.16 4.70±0.14 4.64±0.12 5.01±0.19 4.59±0.12** 4.62±0.13*** 4.60±0.16*** 
Isoprostane 
(ng/L) 
7.6±1.8 7.7±0.9 5.2±1.7 8.6±1.6 6.5±0.8 7.3±0.7 7.7±0.9 12.1±3.5 
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CON, control arm bloods, INF, infused arm bloods. For plasma isoprostane measurements, 
n=6 in the SALINE group and n=9 in the GTN group. Data are expressed as mean±SEM. 
*p<0.05, **p≤0.01 and ***p≤0.001 compared to baseline in the same limb. 
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Whole blood venous methaemoglobin (metHb) levels (table 6.3) increased significantly 
with escalating nitrite dose infusions in both the saline and GTN groups, in both control 
and infused arms. The greatest increases, as expected were observed in the infused arms as 
compared to the control arms. In the pre-saline group, metHb levels increased from 
0.36±0.02% (baseline) to 1.31±0.18% (7.84µmol/min nitrite, normoxia; p<0.001, n=7) and 
1.79±0.10% (7.84µmol/min nitrite, hypoxia; p<0.001, n=7) in the infused arm. Post-saline 
there was an increase from 0.19±0.04 (baseline) to 1.54±0.18 (7.84µmol/min nitrite, 
hypoxia; p<0.001, n=7). 
 
In the GTN group, a similar trend was observed as metHb levels increased from 
0.39±0.05% to 1.49±0.10% (baseline and 7.84µmol/min normoxia nitrite, respectively; 
p<0.001, n=13) with the highest levels of metHb (1.58±0.09%; P<0.001; n=13) reached 
following 7.84µmol/min nitrite infusion during hypoxic conditions, prior to i.v. GTN 
infusion. Post-GTN infusion a similar trend was observed in the infused arm. Venous 
metHb increased from 0.37±0.04 (baseline) to 1.54±0.17 (7.84µmol/min nitrite, normoxia; 
p<0.001, n=13) and 1.55±0.11 (7.84µmol/min nitrite, hypoxia; p<0.001, n=13). 
 
6.5.6 GTN - induced tolerance in human resistance vessels  
Vascular response of isolated resistance vessels (obtained at the end of the 
plethysmography protocol) to GTN was determined. There was no significant attenuation 
of GTN response relative to those in the control vessels (Saline group) and the GTN group 
(pEC50: 7.94 ± 0.14 and 8.72 ± 0.25 in the saline group (n=7) and GTN group (n=11), 
respectively; P=0>0.05; figure 6.9). 
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Figure 6.9: Concentration-response curve to GTN in isolated resistance vessels from CHF 
patients who were subjected to saline (n=7) or GTN (n=11) infusion. 
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6.6 Discussion 
It has been previously observed that intra-arterial nitrite causes forearm vasodilatation in 
both healthy subjects and in patients with heart failure, with greater potency in the latter 
(505). However, the mechanisms underlying these effects remain to be fully established 
Numerous nitrite-reductases have been identified, including eNOS, XOR, haem proteins 
which can bio-activate nitrite under hypoxia (508). However, whilst all of these agents 
alone and/or in combination convert nitrite to NO, their e x a c t  physiological role remains 
incompletely understood. Additionally, inhibition of eNOS or XOR does not attenuate 
nitrite-induced vasodilatation in healthy volunteers, implying either that these mechanisms 
are unimportant in man or that there is considerable redundancy (26, 161). Despite data 
suggesting that ALDH may be an important nitrite reductase, the effects of ALDH 
inhibition during normoxia and hypoxia remain unknown (176). 
 
Preliminary animal data from in vitro studies demonstrated that ALDH inhibition (by 
inhibitors/inactivators and tolerance-independent inactivation of ALDH by GTN), 
abrogated the vascular response to nitrite in isolated rat thoracic aortae (Madhani M, 
unpublished data). These in vitro experiments demonstrated that administration of an ALDH 
inhibitor (cyanamide) and substrate (propionaldehyde) reduced vascular relaxation to 
sodium nitrite significantly under hypoxic conditions when compared to normoxia (figure 
6.1). These data indicated the potential for ALDH to be involved in nitrite-mediated 
hypoxic vasodilatation.  
 
In this study, the ex vivo vascular rings studies confirmed that ALDH inhibition substantially 
attenuated nitrite-mediated vasorelaxation during hypoxia and further supported the results 
obtained from the rat thoracic aortae experiments (figure 6.6). Cyanamide did not alter the 
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potency of the NO donor SPNO, which ruled out non-specific effects on NO bioactivity. 
These observations are in keeping with functional data obtained by Huellner and co-
workers, where pharmacological inhibition of ALDH did not alter the potency to the NO 
donor diethylamine NONOate in isolated human veins (509).  
 
In vivo, GTN pre-treatment tended to decrease the forearm resistance vascular dilatation to 
nitrite infusion in HF patients, but this was not significant (figure 6.7). This was in 
contrast to the animal data from rat thoracic aortae and the response of the resistance 
vessels to sodium nitrite ex vivo. It may be that ALDH does plays a role in nitrite-
mediated vasorelaxation although, this effect was less marked in vivo. This could be due 
to the presence of multiple in vivo mechanisms which are easier to elicit in isolation in the 
laboratory where the confounding effect of other nitrite reductases is absent.  
 
Previous studies have reported that prior GTN exposure induces nitrate tolerance in 
association with attenuated ALDH activity in the vasculature (500, 504, 509). The 
preliminary studies by Madhani (Madhani M, unpublished data) utilised a well described 
model of nitrate tolerance in the isolated rat aortae, as described previously (510, 511). In 
these experiments there was reduction of nitrite-mediated vasorelaxation following pre-
treatment with GTN during hypoxia (figure 6.2). Therefore, attenuation in vascular response 
associated with reduced ALDH2 expression was demonstrated, to confirm the role of ALDH 
as an important effector of nitrite-mediated vascular dilatation (figure 6.3). Furthermore, to 
establish whether ALDH-induced stimulation of nitrite involved the NO-sGC-cGMP-PKG-
VASP pathway, expression of VASP-ser
239
 site (a reliable biochemical biomarker of 
vascular PKG activity) was evaluated, as described previously (512, 513). These results 
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demonstrated that nitrite substantially increases VASP-ser
239
 phosphorylation during 
hypoxia, thereby supporting the theory that nitrite mediates vasorelaxation via the NO-sGC-
cGMP-PKG-VASP pathway. Moreover, it was shown that a reduction in nitrite-mediated 
vasorelaxation following GTN pre-treatment (100µM) is associated with reduction in 
VASP-ser
239
 phosphorylation. This demonstrates that nitrite-mediated vasorelaxation 
comprises both ALDH2 and VASP-ser
239
. Therefore, in the current study low dose GTN 
infusion was used to inactivate ALDH. 10µg/min of i.v. GTN over 4 hours (as employed 
in the current study) has previously been utilised by Philpott and co-workers who have 
reported that it rapidly inactivates vascular ALDH. They reported that this inactivation 
occurs before significant nitrate tolerance develops and before impairment of GTN 
bioconversion is detected (502). In human clinical studies, disulfiram is commonly used as 
the ALDH inhibitor of choice however, its use in patients with heart failure is contra-
indicated and it was therefore not employed in the current study (514).  
 
Endothelial dysfunction and NO resistance are well established in HF (515). In this study, 
sufficient vascular activity in response to nitrite was observed. During normoxia, a doubling 
of forearm vasodilatory response was seen, following 7.84µmol/min of sodium nitrite in both 
the saline and GTN group when comparing to their baseline responses (figure 6.7). However, 
during hypoxia, the inhibition of ALDH with GTN marginally inhibited forearm vasodilatory 
response when compared to the saline group (figure 6.8). Nonetheless, to establish whether 
the trend to decreased forearm vasodilataion to nitrite was associated with GTN tolerance, 
resistance vessels were obtained from HF patients (both saline and GTN groups) at the end of 
the in vivo study protocol. These resistance vessels were then used to assess the vascular 
response to GTN. There was no significant difference in vascular response between the saline 
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and GTN groups, suggesting the observed trend to attenuation of FBF observed from the 
GTN group was not due to GTN tolerance, but potentially due to inactivation of ALDH 
(figure 6.9). 
 
Study limitations 
Despite strict inclusion/exclusion criteria to standardise experimental procedures, a degree of 
heterogeneity will exist in the population studied in terms of cause and severity of HF. 
Although, the majority of baseline characteristics were similar there was a discrepancy in the 
body mass index of subjects within the biopsy group (31±8kg/m
2
, n=22) compared to the in 
vivo plethysmography study group (25±2kg/m
2
 in the saline group and 27±8kg/m
2
 in the 
GTN group) which was statistically significant (p<0.05). This could be a possible confounder 
for the vascular responses seen, as described previously (516). Limited options exist for 
clinical ALDH inhibition in humans; we were unable to use Disulfiram (ALDH inhibitor in 
clinical studies), as it is contra-indicated in patients with cardiovascular disease, as 
described above. Furthermore, plasma levels of nitrite/nitrate were not measured as the 
results are likely to have been affected greatly by the metabolism of GTN to nitrite/nitrate, 
thus masking any changes to endogenous nitrite/nitrate levels. Finally, we were unable to 
confirm in our in vivo studies whether ALDH activity was actually attenuated by GTN. 
 
Conclusions 
The major finding of this study is that ALDH is involved in nitrite-mediated vasorelaxation 
during hypoxia, as demonstrated in human resistance vessels from patients with HF. The in 
vivo results demonstrate a (non significant) trend towards attenuation of intact forearm 
vasodilatory response to nitrite following GTN treatment, which may be due to a 
reduction in ALDH activity. However, no firm conclusion can be made about this effect 
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in vivo. The non-significance of this effect may reflect the presence of multiple in vivo 
mechanisms of nitrite –mediated vasorelaxation. Therefore, the relative contribution to the 
hypoxic vasodilatory effect of the various nitrite reductases in vivo remains unsolved. 
Furthermore, these observations in the present study suggest that pre-treatment with GTN 
(even without inducing tolerance) might abrogate nitrite-mediated hypoxic vasodilatation. 
Further studies to elucidate the extent to which ALDH is involved in nitrite reduction to 
NO in vivo in man may be required. 
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Chapter 7: General Discussion 
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In recent years, there has been an explosion of studies investigating the role of nitrite in both 
physiological and pathological states. The work presented herein provides important new 
insights into this re-emergence of nitrite through both physiological and 
molecular/mechanistic studies.  
 
Firstly the role of nitrite in healthy volunteers was explored. Our group had previously 
evaluated the role of nitrite in the human forearm vasculature under both normoxic and 
hypoxic conditions, reporting hypoxic augmentation of vascular effects during intra-arterial 
administration of nitrite (46). Others have corroborated these findings in humans with greater 
observed vasodilatation in the hypoxic pulmonary vasculature (199). In contrast to these 
findings, we observed that in healthy volunteers (Chapter 2 – the role of systemic nitrite in 
healthy volunteers) systemic nitrite administration did not reproduce enhanced 
vasodilatation during hypoxia, in respect relative to normoxia, despite substantial increase in 
plasma nitrite concentration. Importantly, this study established the safety profile of sodium 
nitrite at doses of up to 50µg/kg/min in humans. Therefore, nitrite may not have an enhanced 
hypoxic vasodilatory effect in hypoxia that could be potentially utilised in disease states such 
as heart failure or pulmonary artrterial hypertension. Furthermore, the safety issue of 
methaemoglobin accumulation with nitrite therapy has been addressed. The findings indicate 
that sustained infusions at rates higher than 10µg/kg/min, would require close monitoring of 
methaemoglobin and is likely to provide a limitation to continuous nitrite therapy in patients. 
Peak methaemoglobinaemia following a 5minute infusion of 50µg/kg/min was approximately 
1%. Data from the preliminary healthy volunteer study (figure 2.3) showed that 60µg/kg/min 
i.v. nitrite was associated with a methaemoglobinaemia of 10% after 2.5 hours. 
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Furthermore, the pre-clinical and earlier human studies as mentioned above are reasonably 
convincing in demonstrating nitrite-mediated hypoxic vasodilatation. Therefore, further 
studies to assess reproducibility of our data with a longer period of hypoxia stabilisation may 
prove useful prior to labelling nitrite as an ineffective hypoxic vasodilator when administered 
intravenously. Particularly as more marked effects were seen in the HF group in Chapter 3 – 
the effects of systemic nitrite in heart failure. In HF, i.v.sodium nitrite was associated with 
a favourable haemodynamic profile during short term administration, with an increase in 
cardiac output in these patients, albeit at the peak infusion rate of 50µg/kg/min only. There 
was a substantial reduction in PVR (30%) but only a modest reduction in SVR (11%) at this 
dose. Since CO increased and SVR fell only modestly, the fall in blood pressure was very 
small. Despite the differing haemodynamic effects, plasma nitrite increased to a similar 
degree in heart failure patients as compared to the healthy volunteers. Likewise, in keeping 
with the findings in healthy subjects, sustained infusion of 10µg/kg/min of i.v. sodium nitrite 
in heart failure patients did not demonstrate any significant effect on cardiac or peripheral 
haemodynamic measurements.  
 
Despite providing important mechanistic insights into nitrite infusion in heart failure (i.e. 
relief of diastolic ventricular interaction), the vasodilatory effect of nitrite may not be as 
beneficial as previously suggested, particularly at doses deemed to be safe and tolerable in 
humans. Nitrite therapy was deemed to be potentially attractive in patients with congestive 
heart failure due to its relative venoselectivity, however continuous therapy at efficacious 
doses may be limited by clinically significant methaemoglobinaemia. Ingram and colleagues 
reported that infusion of sodium nitrite prevented hypoxia induced vasoconstriction in 
healthy subjects an hour after ceasing infusion at a time when plasma nitrite had returned to 
baseline (199). These findings support the exploration of an alternative nitrite administration 
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regimen, such as pulsed therapy (i.e. interrupted infusions of nitrite rather than a continuous 
infusion) prior to complete rejection of nitrite as a potential therapeutic option in heart 
failure. A placebo-controlled trial with greater number of patients may provide more insight 
into the haemodynamic effects of nitrite in this patients group. 
 
Alternatively, this study does not rule out the potential for nitrite therapy in subjects with 
pulmonary hypertension, without left ventricular systolic dysfunction. Current treats for 
pulmonary arterial hypertension include selective pulmonary vasodilators such as 
phosphodiesterase V inhibitors (which inhibit breakdown of cGMP and therefore increase 
NO bioavailability, endothelin antagonists and prostacyclins (517).  Nitrite, particularly if 
targeted to the pulmonary vasculature e.g. inhaled preparations, could be used to enhance NO 
bioavailability in the relatively hypoxic pulmonary vasculature, without significant clinical 
methaemoglobinaemia. Future studies in this patient group may provide favourable results to 
a greater degree than that seen in our heart failure patients. Animal models of pulmonary 
hypertension (e.g. monocrotaline model of pulmonary hypertension in rats) could also be 
utilised to investigate whether nitrite has the potential to reverse adverse vascular remodeling 
seen in pulmonary hypertension, through enhanced NO generation or directly through other 
unspecified mechanisms.   
 
Alternatively, the well-established organic nitrates are in widespread clinical use for 
treatment of heart failure. Whether GTN exhibits hypoxia-specific vasodilatation is unknown, 
and was investigated in Chapter 4 (Effects of glyceryl trinitrate on human resistance 
vessels during normoxia and hypoxia). This may be of importance as patients presenting in 
acute, decompensated heart failure often are hypoxic due to acute pulmonary oedema, and 
there is no data to guide differing nitrate therapy in these patients, in respect to those with 
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chronic congestive heart failure. GTN did not display an accentuated vasodilatory response 
during hypoxia, suggesting that GTN vasodilatation is independent of ambient oxygen 
tension. Interestingly, the forearm vasculature tended to dilate to a lesser degree in response 
to intra-arterial GTN during hypoxia as compared to normoxia, likely through activation of 
sympathetic vasoconstrictor activity during hypoxia (140, 450, 451). Future studies of GTN 
vs nitrite in heart failure subjects may provide further insight into the comparative efficacy of 
these agents. These studies could initially be conducted in the forearm vasculature of HF 
subjects to determine the relative potency of GTN vs nitrite, with further studies involving 
systemic infusions of GTN vs nitrite in a larger number of heart failure subjects.  
 
Protection against ischaemia-reperfusion injury (IRI) has been proposed as a further potential 
application of nitrite in clinical practice. Numerous in vitro and animal studies exist to 
support this notion, with limited human data (as reviewed in Chapter 5 - Mechanisms of 
nitrite-mediated cardioprotection in patients undergoing cardiac surgery). We sought to 
explore this further in patients undergoing cardiac surgery, a clinical model of IRI with an 
associated mortality and morbidity. Nitrite appears to abrogate myocardial injury and 
oxidative stress associated with cardio-pulmonary bypass. This appears to be mediated via 
eNOS conceivably through a RISK-independent pathway, which requires further 
investigation. The nitrite administration regimen required for cardioprotection is not 
associated with clinically significant methaemoglobinaemia. These promising findings lend 
further support to exploration of nitrite in human models of IRI. One of the major limitations 
of this study was the likely underpowering for the multiple arms of this study i.e. early vs late 
window and two differeng nitrite doses. A simpler study would have been more likely to 
determine the role of nitrite-mediated cardioprotection, for the given number of recruited 
patients.   Therefore clinical trials powered to end-points of myocardial injury e.g. troponin, 
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myocardial area at risk on cardiac magnetic resonance imaging and low cardiac output 
syndromes will provide useful insight into this expanding field. Furthermore, larger-scale 
trials in cardiac surgery patients will provide a larger bank of human myocardial tissue which 
could be utilised to investigate other (several) mechanisms of nitrite-mediated 
cardioprotection, as depicted in figure 1.4. Moreover, the downstream effects of nitrite on the 
mitochondrial transition permeability pore could be explored, although this requires ‘fresh’ 
tissue samples which need to be analysed immediately. The results of two on-going trials 
investigating nitrite in the setting of acute myocardial infarction are eagerly awaited and 
should help determine the clinical utility of nitrite in cardioprotection (196, 518).  
 
Despite some controversy, nitrite-mediated biological actions are thought to be largely 
mediated through NO (117). Several reported mechanisms of nitrite reduction to NO exist 
e.g. haem proteins, xanthine oxireductase, aldehyde oxidase, mitochondrial aldehyde 
dehydrogenase and acid disproportionation. Numerous experimental studies imply the 
significance of individual mechanisms in generating nitrite-derived NO. However, the 
relative importance of these mechanisms in vivo remains to be fully determined. In 
experiments presented herein, isolation of molecular mechanisms in rat thoracic aortae and 
human resistance vessels demonstrated that ALDH causes significant reduction in nitrite-
mediated vasorelaxation, particularly during hypoxia (Chapter 6 – the role of ALDH2 in 
nitrite-mediated vascular relaxation during normoxia and hypoxia). However, these 
findings were not reproduced in the intact forearm vasculature of patients with heart failure. 
This is likely to be representative of the importance of an array of complex mechanisms 
which underly this process in vivo with no one mechanism predominating. Nonetheless, no 
firm conclusion can be drawn about the role of ALDH in nitrite bioactivity in vivo. 
Pharmacological methods of ALDH inhibition e.g. disulfiram or GTN, utilised for research 
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purposes tend to provide non-specific ALDH inactivation. Future human studies should 
recruit subjects with the Glu504Lys mutation, as they specifically lack ALDH2 function. This 
population is likely to possess reliable and consistent ALDH2 inactivity which can be utilised 
to explore the role of ALDH2 in nitrite-mediated bioactivity.  
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